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ABSTRACT 
The ocean is a major source of structurally unique natural products that are mainly 
found in marine organisms. Numerous compounds already isolated from these marine 
organisms have been shown to possess anti-inflammatory activities. The objective of 
this work was to examine a range of marine organisms in order to identify compounds 
that had anti-inflammatory potential and also to elucidate the mechanism of their 
actions. Inflammatory diseases account for significant ill health and morbidity 
worldwide and are typically associated with dysregulated T cell responses, which are 
activated by dendritic cells (DC). Therefore, novel strategies that modulate the 
activation of DCs may have therapeutic potential. We screened a number of marine 
species by examining their effects on DC function and from this focussed on 
candidate marine extracts for further assessment. These were then fractionated and 
further purified until we had a single compound sample (INV013). This purified 
compound was then used to determine the intracellular target of INV013.   
 
DCs were exposed to marine extract INV013 and then activated with a panel of TLR 
ligands (TLR2/1, TLR2/6, TLR3, TLR4, TLR5, TLR7 and TLR9). INV013 
specifically suppressed the IL-12 family of cytokines (IL-12p40, IL-12p70 and IL-
23), IL-1β, IL-6 but not TNF-α, and enhanced IL-10 production following activation 
only with TLR4 or TLR2 ligands. The marine compounds also suppressed DC 
migration in response to TLR4 and inhibited production of chemokines.  INV013 had 
no effect on DCs stimulated with ligands to the other TLRs. While there are some 
common pathways downstream of TLR activation TLR2 and TLR4 use an adaptor 
protein called MyD88 adaptor-like molecule (Mal), which is not used by the other 
TLRs. 
 
Examination of the TLR downstream signalling pathways revealed that INV013 
selectively inhibited NF-κB activation but had no effect on IRF3 activation. 
Furthermore, INV013 was also able to block Mal-driven activation of NFκB. These 
findings demonstrate that marine extract INV013 has specific effects on DCs and 
indicates that it exerts these effects by targeting Mal. This suggests that INV013 has 
the potential to be developed as a therapeutic for treatment of inflammatory disease.  
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CHAPTER 1 
GENERAL  
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.0 THE IMMUNE SYSTEM 
 
 
The immune system is an extremely complex system of lymphoid organs, cells, 
humoral factors and cytokines. An effective immune response is provided by means 
of innate ‘early’ and adaptive ‘delayed’ immunity. Although considered independent, 
there is a high level of interaction and collaboration between the two. 
1.1  OVERVIEW OF INNATE IMMUNITY 
The innate immune system comprises the first line of defence to the body in a non-
specific manner. Most organisms exist with only innate mechanisms however 
vertebrates have alternative systems for pathogen recognition and elimination, 
collectively known as adaptive immunity (Kimbrell and Beutler 2001) The principal 
components of innate immunity include physical, chemical and anti-microbial barriers 
to infection (Beutler 2004). Innate immunity is mostly dependant on phagocytosis, a 
process which engulfs and destroys invading pathogens. Phagocytic cells 
(macrophages, neutrophils) also produce a wide range of inflammatory mediators, 
including cytokines and chemokines, which simultaneously direct other host 
responses. Macrophages are found throughout the body (e.g. heart, lung, brain and 
liver), and upon breach of the epithelial barrier are the first cells to encounter invading 
microbes (Beutler 2004). The majority of neutrophils are found circulating in the 
blood and have a short life span. They are attracted to the site of infection by activated 
macrophages and upon activation they release cytokines and chemokines which in 
turn amplify inflammatory reactions by several other cell types (Janeway et al. 2008) 
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1.2  MACROPHAGE FUNCTION AND ACTIVATION 
Macrophages (MØ) are key effector innate immune cells that play a fundamental role 
in tissue homeostasis, pathogen clearance, wound healing and resolution of 
inflammation. MØ have been a continuous source of investigation for immunologists 
since their discovery by Elie Metchnikoff in 1905 (HIRSCH 1959). MØ are 
prodigious phagocytic immune cells that perform several different functions 
throughout the innate and adaptive immune response. They are present in lymphoid 
and non-lymphoid tissues and their primary role is to recognise, engulf and kill 
invading pathogens. MØ express numerous pattern recognition receptors (PRRs) such 
as toll-like receptors (TLRs) which enable them to recognise pattern associated 
molecular patterns (PAMPs) resulting in phagocytosis and the initiation of 
intracellular signalling pathways, leading to the production of inflammatory mediators 
such as cytokines and chemokines (Gordon 2007). In addition MØ are capable of 
initiating an adaptive immune response by presenting antigen to CD4+ T cells via 
major histocompatibility class (MHC) II molecules. Phagocytosis is a fundamental 
process that is involved in the clearance of cellular debris from tissue remodelling and 
apoptosis and without this process the host would not survive (Janeway et al. 2008). 
The receptors that are involved in this homeostatic clearance include scavenger 
receptors (SRs), phosphatidyl serine receptors, integrins and complement receptors 
(Erwig and Henson 2007). MØ activation is dependant on the type of pathogen 
encountered or the environment in which the macrophage resides. Currently MØ can 
be classified into three different subsets classically activated (M1 or host defence), 
alternatively activated (M2 or wound healing) and regulatory MØ (Fairweather and 
Cihakova 2009, Gordon and Martinez 2010) [see figure 1.1]. However they are not 
permanently differentiated but have plasticity and are capable of moving from 
 4 
classically activated to alternatively activated and back again depending on the local 
environment (Stout and Suttles 2004)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Diagrammatic representation of cytokines produced by immune cells and their 
effect on macrophage physiology.  
 
1.2.1  CLASSICAL AND ALTERNATIVE ACTIVATION   
MØ that are produced during cell-mediated immune responses are termed ‘classically 
activated.’ Classically activated MØ are generated following stimulation with pro-
inflammatory cytokines IFN-γ and TNF-α or LPS. Cells of both the innate and 
adaptive immune system are involved in the production of IFN-γ whereas TNF-α is 
produced by the ligation of a TLR to its respective ligand, activating the MyD88-
dependant signalling pathway (O'Shea and Murray 2008, Ma, et al. 2003). IFN-γ 
primes MØ to secrete pro-inflammatory cytokines such as TNF-α, IL-1β, IL-12, and 
the chemokines MIP-1α/CCL3, IP-10/CXCL10 and MCP-1 (Fairweather and 
Cihakova 2009). In addition, classical activation is associated with increased 
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expression of the antigen presentation receptor, MHCII and also the co-stimulatory 
marker, CD86 (Martinez, Helming and Gordon 2009). Although these MØ are vital 
components of host defence there activation must be firmly controlled as over-
production of pro-inflammatory cytokines can lead to host-tissue damage resulting in 
autoimmune diseases such as rheumatoid arthritis (RA) and inflammatory bowel 
disease (IBD) (Szekanecz and Koch 2007, Zhang and Mosser 2008).  
 
Contrastingly, alternative activation of macrophages is induced by IL-4 and IL-13, 
cytokines that are secreted in a Th2 response particularly in allergic, cellular and 
humoral responses to parasitic and extracellular pathogens (Martinez, Helming and 
Gordon 2009). Similar to classically activated macrophages they can develop in 
response to innate and adaptive signals. Innate immune cells including basophils, mast 
cells and granulocytes are fundamental early sources of IL-4 secretion following 
tissue injury (Louis, et al. 1999, Brombacher, et al. 2009). Similar to classically 
activated macrophages, these MØ can be detrimental to the host when their matrix-
enhancing activity is dysregulated leading to autoimmune diseases such as RA. In 
addition alternatively activated macrophages are more susceptible to intracellular 
infections for example M.tuberculosis (Gordon and Martinez 2010). 
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1.3 OVERVIEW OF ADAPTIVE IMMUNITY 
In addition to innate immunity, vertebrates have evolved an adaptive immune system, 
utilizing antigen-specific receptors on T and B cells to direct effector responses. T and 
B lymphocytes are the recognized cellular pillars of adaptive immunity. T 
lymphocytes are chiefly responsible for cellular immunity and B lymphocytes for 
humoral immunity but they work together with other cell types to mediate an effective 
adaptive immune response (Pancer and Cooper 2006). T and B lymphocytes originate 
in the bone marrow from progenitor cells. T cells migrate and mature in the thymus 
while B cells remain in the bone marrow undertaking further development. The 
antigen recognition of T cells is attributed to the T cell receptor (TCR) while B cell 
specificity is due to membrane bound antibody (Janeway et al. 2008). Specificity of 
both T and B cells for TCR and antibody is a result of random reorganization of genes 
encoding them, thus resulting in the expression of a vast repertoire of receptors 
(Nemazee 2006). Naïve lymphocytes migrate to peripheral lymphoid organs including 
lymph nodes, spleen and the mucosa associated lymphoid tissues such as Peyer’s 
patches (PP) in the gut.  It is in these particular locations where the majority of the 
immune responses occur. Both lymphocytes display surface receptors for a single 
specific antigen but due to a high level of specificity, only a reasonably small number 
of lymphocytes are able to recognize any given antigen. Lymphocytes are constantly 
circulating between the blood and the peripheral lymphoid tissues in order to increase 
their chances of encountering their specific antigen. When the lymphocytes recognize 
their specific antigen which is coupled to the MHC receptor on the surface of an 
antigen presenting cell, it ceases to migrate. For several days it proliferates, 
undergoing clonal expansion and differentiation eventually giving rise to effector T 
cells of identical antigen specificity. The effector T cells then re-enter the bloodstream 
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and migrate to the sites of infection (Janeway et al. 2008). Upon re-exposure to a 
particular antigen, memory T and B lymphocytes initiate an important and effective 
immune response a process often referred to as ‘immunological memory’(Gourley, et 
al. 2004). 
1.3.1 LINKING INNATE AND ADAPTIVE IMMUNITY 
 
The co-ordination of innate and adaptive responses is assisted by signalling among 
different PRRs (Reise Sousa 2004).While innate immunity is essential as the first line 
of defence against infection, adaptive immunity provides specific targeted response to 
the invading pathogen. Furthermore adaptive immunity provides long-lasting 
protection against pathogens (Janeway et al. 2008). Dendritic cells which are the main 
antigen presenting cells of the immune system play a key role in linking innate and 
adaptive immunity (Gottenberg and Chiocchia 2007). Figure 1.1a illustrates various 
cells of the immune system and the differentiation from stem cells.  
 
                          
Figure 1.1a: Diagrammatic representation of the differentiation of immune cells from a 
myeloid stem cells (Geissmann, et al. 2010) 
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1.4 DENDRITIC CELLS (DC) 
 
Dendritic cells (DC) are a heterogeneous family of cells that are present in low 
quantities in those tissues which are in contact with the environment e.g. the skin 
(where they are often called Langerhans cells). They are considered the most 
influential antigen presenting cells (APC) in the body because they are capable of 
internalizing, processing endogenous or exogenous antigen and their unique ability to 
present antigen-MHC complexes to the peptide specific T cells thereby initiating 
adaptive immunity (Banchereau, et al. 2000). DC have a plethora of other functions 
which include, induction of tolerance, control of T cell polarization and recruitment of 
T cells to the site of infection. They start out as immature DCs where they are 
constantly patrolling for pathogens such as viruses and bacteria (Knight, Burke and 
Bedford 2002). Once a DC detects a pathogen, the initial interaction is between a 
specific PAMP found on the pathogen and its relevant receptor such a toll-like 
receptor (TLR) on the surface of the DC (Beutler 2009). TLRs are essential 
transmembrane proteins that detect pathogens and alert the immune system to the 
presence of invading microbes (Goldstein 2004). TLR ligation leads to the activation 
of DCs and the instantaneous production of pro-inflammatory cytokines such as IL-
12, TNF-α and IL-1β that facilitate the enhancement of innate and adaptive immune 
responses. Throughout DC maturation there is an  increase in the levels of MHC 
molecules bearing pathogen-derived antigen on the surface of DCs which engages 
with naïve pathogen-specific T cells (signal  1), in addition to an up-regulation in co-
stimulatory molecules (CD40, CD80, CD86), greatly enhancing their ability to 
activate naïve T cells (signal 2). Finally, DC maturation also results in inflammatory 
mediators (i.e. cytokines, co-stimulatory molecules) that can act on naïve T cells to 
promote their differentiation into effector T cells such as Th1, Th2, Th17 or 
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regulatory T cells (signal 3), summarised in figure 1.2 (Joffre, et al. 2009). DCs play a 
central role in the controlling immunity and are thus targets for clinical research 
examining T –cell mediated events e.g. transplantation, allergy and autoimmune 
diseases (Banchereau and Steinman 1998b). 
 
Immature DCs capture antigens by phagocytosis, macropinocytosis or via interaction 
with a variety of cells surface receptors and endocytosis. The most prevalent antigen 
receptors expressed by DCs include members of the C-type lectin family, such as 
mannose receptor, DEC-205 and Fcγ receptors (Banchereau, et al. 2000). These 
receptors allow efficient capture of IgG immune complexes and opsonised particles 
(Cella, Sallusto and Lanzavecchia 1997). Internalization of foreign antigens by these 
receptors eventually leads to DC activation. Once DCs become activated the 
maturation process commences, DCs gain the ability to migrate to the lymph nodes 
where they stimulate naïve T cells. 
1.4.1 DENDRITIC CELL MATURATION 
 
The process of DC maturation coordinates a series of significant changes resulting in 
the loss of endocytic/phagocytic activity, up-regulation of adhesion and co-
stimulatory molecules (CD40, CD80, CD86), redistribution of MHC II molecules and 
a change in morphology (Banchereau and Steinman 1998a). The interaction of co-
stimulatory molecules will be discussed later in chapter 3. The maturation process 
also results in changes in the expression of chemokine receptors on the surface of 
DCs. Immature DCs express high levels of chemokine receptors including CCR1, 
CCR2, and CCR5 which are essential in assisting the migration of DC to T cell areas. 
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Once DCs reach the lymph node area they lose their migratory capacity and produce 
T and B cell stimulatory cytokines such as Interferons (IFN), IL-12 and IL-6. When 
DCs have acquired the ability to activate T cells they have completed their core 
function and thus commit suicide by apoptosis (Matsue, et al. 1999). 
1.4.2 ANTIGEN PROCESSING AND PRESENTATION 
 
Antigen processing and presentation is an intriguing combination of cellular functions 
and specialized processes. DCs are capable of processing and presenting peptides in 
the context of either MHC I or II. Two generally distinct pathways are used by MHC I 
and II molecules in order for the presentation of antigens to T cells. If the antigen is 
found endogenously i.e. within the cell, it is complexed to MHC I through an 
intracellular processing pathway. On the other hand exogenous antigens taken up by 
APCs (macrophages, DC, B cells) through endocytosis are processed onto MHC II 
and then expressed on the surface of the cell. DC-LAMP, a lysosomal glycoprotein, is 
specifically expressed in the lysosomal MHC II compartment and aids in the 
processing of exogenous antigen or in assisting transport of antigen-loaded MHC II 
complexes to the cell surface (Banchereau, et al. 2000). Immature DCs synthesize 
high levels of MHC II but instead of being expressed on the surface of APC they are 
expressed in the endosomal compartments where they have a short life. When 
immature DCs are activated by inflammatory stimuli, such as lipopolysacharide 
(LPS), the antigen is degraded within the MHC II endosomal compartment, coupled 
to MHC II molecules and then transported to the surface of the APC where it remains 
stably complexed to peptide for days and available for CD4+ T cells (Steinman, et al. 
1999). 
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1.4.3 ACTIVATION OF T CELLS 
 
T cells express a specific antigen receptor termed TCR which interacts with DCs. This 
interaction is fundamental for initiating cell mediated adaptive immune responses. 
However, full activation of T cells critically depends on three signals. The TCR is 
composed of a α- and β-chain that form the TCR heterodimer which is responsible for 
ligand recognition. These α- and β-chains are non-covalently associated with a 
complex of low molecular weight transmembrane proteins, referred to as the CD3 
complex (Schmitz and Krappmann 2006). The first signal is initiated upon binding of 
the TCR with antigenic peptides complexed to MHC molecules. The TCR-CD3 
complex interaction plays an essential role in mediating cell recognition and inducing 
signal transduction into the nucleus, activating genes involved in T cell proliferation. 
Signal 2 is provided by the co-stimulatory molecules CD80 and CD86 which engage 
with the accessory molecule, CD28 on the T cell. Co-stimulatory molecules are only 
present on activated DCs ensuring that T-cell immunity is not activated unnecessarily 
(Smith-Garvin, Koretzky and Jordan 2009). These co-receptors are essential to 
enhance a productive immune response, which leads to the secretion of cytokines and 
increased survival and clonal expansion of T cells. However, in the absence of these 
costimulatory signals, the T cells will either become anergic or die by apoptosis, 
thereby promoting T cell tolerance. Anergy can occur in two distinct ways, one being 
if the TCR is engaged by a non-professional APC lacking costimulatory molecules on 
its surface (Macian, et al. 2004, Schwartz 2003); the second is if TCR ligation is 
followed by the binding of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) 
with CD28 on the T cell (Inobe and Schwartz 2004). 
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 Signal 3, relies on the ligation of a polarizing cytokine to its corresponding receptor 
on the T cell allowing naïve T cells to finally become effector T cells (Corthay 2006). 
Naïve T cells require stimulation for at least 20 hrs in order to be committed to 
proliferate whereas memory/effector cells are able to respond within 0.5-2hrs. 
Following engagement with antigen, the TCR is internalised and degraded and the 
differentiated cells lose their lymph-node homing receptors and acquire receptors that 
control their migration to inflamed tissues where they execute their effector functions 
(Sallusto and Lanzavecchia 2002). In contrast, T cells that receive a short stimulation 
proliferate, but fail to differentiate to effector cells and maintain the lymph node 
homing characteristics of naïve T cells. Division and clonal expansion of each T cell 
results in up to 1000 progeny, most of which are armed effector cells (Parkin and 
Cohen 2001a).  
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1.5 T CELLS 
T cells are a subset of lymphocytes that arise from the bone marrow and undergo a 
cascade of events in the thymus including, differentiation and proliferation before 
returning to the circulation as mature T cells. They are found throughout the body, 
they often reside in the secondary lymphoid organs (the lymph nodes and spleen) as 
sites where activation occurs, but they are also found in other tissues of the body, 
most conspicuously the liver, lung, blood, and intestinal and reproductive tracts 
(Bousso 2008). T cells can be divided into two major subsets that are functionally and 
phenotypically different; T-helper cells (Th) and cytotoxic T-cells (CTLs) 
characterised by the expression of CD4 and CD8 respectively on their cell surface 
[see table 1.1]. T cells are able to recognise antigen bound to MHC molecules. CD4+ 
T cells recognise antigen complexed to MHCII molecules whereas CD8+ T cells 
recognise antigen complexed to MHCI molecules (Parkin and Cohen 2001a). As 
mentioned in section 1.4 these T cells are only activated if accessory molecules on the 
T cell are ligated to costimulatory molecules on the APC. 
 
CD8+ T cells exhibit cytotoxic activity, which is fundamental in directly killing 
certain tumour cells, viral-infected cells, any cells displaying foreign antigen coupled 
to MHCI and occasionally parasites. The CD8+ T cells are also essential in down-
regulation of immune responses (Foulds, et al. 2002). CD4+ T cells are important in 
directing the immune response. CD4+ T lymphocytes differentiate into distinct 
effector cell subsets characterised by their function and cytokine production profile. 
Defects in the appropriate regulation of CD4+ T cell function have been implicated in 
the exacerbation of numerous autoimmune diseases such as RA and IBD (Egwuagu 
2009, Palmer and Weaver 2010). Until recently the general agreement was that there 
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were only 2 types of T helper lineages; Th1 and Th2, however new lineages of T cells 
are emerging including Th17, Th9 and Th22.  Figure 1.2 below depicts the processes 
involved in the polarisation of Th1 and Th2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 T-cell activation and TH1/TH2-cell differentiation require three dendritic 
cell-derived signals; Signal 1 is the recognition and ligation of the TCR receptor to 
MHC peptide complexes. Signal 2 is the co-stimulatory signal, mainly mediated by 
ligation of CD28 by CD80 and CD86 on APC and, signal 3 secretion of cytokines by 
APC that bind to cytokine receptors on the surface.  
 
1.5.1 TH1 AND TH2 CELL DEVELOPMENT 
 
Numerous factors are involved in the polarisation of naïve T cells into a Th1 or a Th2 
phenotype. The cytokines IL-12, IL-27, IFN-γ and the transcription factors, signal 
transducer and activator of transcription- (STAT)-1, STAT4, the adhesion molecule, 
ICAM-1 (intracellular adhesion molecule-1) and T-bet promote the development of 
Th1 cells, where as the differentiation of Th2 is largely dependant on the cytokine IL-
4 in combination with the transcription factors STAT6 and GATA3 (Murphy and 
Reiner 2002, Callard 2007).  
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The conventional definition of Th1 and Th2 cells depends firmly on the cytokines that 
they produce. Th1 cells produce IL-2, IL-15, TNF-β, and IFN-γ which activate 
macrophages, NK cells, and CTLs. The primary role of Th1 cells is regulating 
protective immune responses against infection with intracellular pathogens (Murphy 
and Reiner 2002). In addition, they are principal effectors of cell-mediated immunity 
and delayed type hypersensitivity (DTH) (Agnello, et al. 2003). Conversely, Th2 cells 
secrete IL-4, IL-5 and IL-13, which promote humoral immunity, allergic responses 
and constrain cell mediated immunity and inflammation. During Th2 responses, IL-4 
and IL-13 stimulate B cells to produce IgE, in contrast IL-5 is the main eosinophil-
activating cytokine (Trinchieri 2003b). Extracellular pathogens, such as helminthic 
worms, tend to induce differentiation along the Th2 pathway (see table 1.1). IFN-γ 
and IL-4 act in regulatory feedback loops promoting further differentiation of Th1 and 
Th2 cells, respectively, in an anticrine manner (Murphy and Reiner 2002). One vital 
characteristic of the Th1/Th2 paradigm is that they can antagonise each other, Thl-
type cytokines, especially IFN-γ, inhibit the differentiation of Th2 cells, while Th2-
type cytokines, especially IL-4, inhibit the differentiation of Thl cells (Ho and 
Glimcher 2002).  
 
Several diseases have been associated with the dysregulated function of Th1 and Th2 
cells. For example, Th1 cells have been implicated in the development and 
pathogenesis of autoimmune diseases such as multiple sclerosis (MS) while Th2 cells 
contribute atopic diseases such as allergy and asthma (Deenick and Tangye 2007). 
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1.5.2 TH17 CELL DEVELOPMENT  
 
Recently a subset of Th cells have been identified, termed Th17 cells (Bettelli, Korn 
and Kuchroo 2007, McGeachy and Cua 2008). In the same way as Th1 and Th2 cells, 
Th17 cells require specific cytokines and transcription factors for their differentiation. 
Th17 cells are characterised by the secretion of a distinct cytokine profile, including 
IL-17A, IL-17F, IL-21 and IL-22 (see table 1.1). IL-17 has emerged as a key pro-
inflammatory cytokine and is known to induce the production of IL-1, TNF-α, and 
GMCSF.  Differentiation of this subset is controlled by transforming growth factor- 
(TGF)-β and IL-6 (Smith-Garvin, Koretzky and Jordan 2009). These cytokines act in 
a STAT3-dependant manner to induce the expression of the orphan nuclear receptor-
RORγt which subsequently upregulates the production of IL-17 and the IL-23R 
(Deenick and Tangye 2007). In addition, the production of IL-21 by Th17 cells 
together with TGF-β and in the absence of IL-6 are able to initiate Th17 
differentiation, therefore IL-21 may be a positive feedback loop to amplify the 
precursor frequency of Th17 cells (McGeachy and Cua 2008).  The differentiation of 
this subset was shown to be inhibited by IL-4 and IFN-γ as naïve T cells cultured with 
TGF-β and IL-6, in the absence of IFN-γ and IL-4 were found to differentiate into 
Th17 cells (Kikly, et al. 2006). Development of Th17 cells can also be suppressed by 
the presence of IL-27, a member of the IL-12 family of cytokine, as mice lacking the 
IL-27 receptor are highly susceptible to EAE because of increased production of IL-
17 (Batten, et al. 2006). 
 
Initially IL-23, a member of the IL-12 family, was thought to be involved in the 
development of Th17, however later studies showed that IL-23 acts on previously 
differentiated Th17 cells to induce expansion and s
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(Kikly, et al. 2007). Th17 cells are fundamental cells in host defence against certain 
pathogens such as Candida albicans and specific extracellular bacteria and fungi and 
have been implicated as being responsible for many inflammatory disorders 
previously attributed to Th1 cells, including RA and EAE (Himer, et al. 2010, 
Lubberts 2010, Segal 2010, Furuzawa-Carballeda, Vargas-Rojas and Cabral 2007). 
1.5.3 TH9 CELL DEVELOPMENT  
 
The complexity of Th cells increased further with the identification of a new subset of 
Th cells, termed Th9 cells (Veldhoen, et al. 2008). The combination of TGF-β and IL-
4 induced the differentiation of naïve CD4+ T cell into a Th9 subset which are 
characterised by the secretion of a distinct cytokine profile including IL-9 and IL-10. 
The generation of these cells requires the expression of the transcription factor, PU.1 
and secretion of IL-9 is upregulated by IL-25 (Lloyd and Hessel 2010). Both human 
and murine Th9 cells do not co-express the characteristics of other Th subsets such as 
IFN-γ produced by Th1 cells. IFN-γ and/or IL-27 impeded the generation of Th9 
cells. Th9 cells have been demonstrated to be involved in promoting inflammation 
and allergic reaction, mostly by recruiting macrophages, mast cells and eosinophils. 
Conversely, IL-9 modulates virus initiated inflammation and enhances the 
immunosuppressive activity of natural T regulatory cells. However, Vijay Kuchroo 
and workers have demonstrated that Th9 may elicit inflammation, particularly 
following re-stimulation (Jager, et al. 2009).  
1.5.4 T REGULATORY CELL DEVELOPMENT  
 
T regulatory cells or Tregs play a fundamental role in suppressing T cell responses to 
foreign and self antigens, preventing autoimmune diseases and limiting chronic 
inflammatory diseases (Mills 2004).  
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In general, Tregs can directly suppress the activation of effector T cells, compete with 
pathogenic T cells for access to APCs, or directly target APCs (Rutella and Lemoli 
2004). Treg cells can be divided into two subsets based on the expression of cell 
surface markers, production of cytokines and mechanism of action; CD4+CD25+ 
Tregs that are developmentally programmed and suppress the activation of other self 
reactive T cells, and those that secrete abundant amounts of IL-10 and TGF-β which 
have shown to be essential for the prevention of colitis in mouse models of IBD 
(Izcue and Powrie 2008, Iwasaki and Medzhitov 2004).  
 
T-Helper 
cell 
subsets 
Differentiated 
by 
Cytokines 
produced 
Inhibited 
by 
Protective 
activity 
Th1 
IL-12 
ICAM-1 
IL-27 
IFN-γ 
IL-2 
TNF-α/β 
IL-4 
I L-17 
Cell-mediated 
immunity against 
intracellular bacteria 
& some viruses 
Th2 
IL-10 
OX40L 
IL-4 
IL-4 
IL-5 
IL-6 
IL-13 
IFN-γ 
IL-12 
Humoral responses 
against helminth 
infections & 
multicellular 
organisms 
Th17 
IL-23 
IL-1β, IL-6 
TNF-α, TGF-β 
IL-17A 
IL-17F 
IL-22 
IL-6 
IFN-γ 
IL-4 
Extracellular bacteria 
& some fungi 
(Klebsiella 
pneumoniae; Candida 
albicans) 
Treg IL-10 TGF-β 
IL-10 
TGF-β IL-6 
Homeostasis – self-
tolerance & control of 
excessive responses 
against non-self 
 
 
 
 
 
 
TABLE 1.1 Summary of the CD4+ T-helper subsets, the cytokines they secrete, the cytokines that 
influence their differentiation, and their main immunological functions. 
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1.6 CYTOKINES 
Cytokines are a group of low molecular weight polypeptides or glycoproteins that are 
produced primarily by immune cells and encompass a wide range of functions. These 
molecules facilitate communication between cells, stimulate proliferation of antigen 
specific effector cells and mediate local and systemic inflammation in an autocrine, 
paracrine and endocrine manner (Sanchez-Munoz, Dominguez-Lopez and 
Yamamoto-Furusho 2008). Cytokines that act as molecular messengers between 
leukocytes are termed interleukins, while those that act against viruses and regulate 
cellular activation are characterized as interferons (IFN). Cytokines that cause 
differentiation and proliferation of stem cells are called colony stimulating factors. 
The cytokine system is a very potent force in homeostasis, when cytokine production 
is sustained they contribute to the pathology of inflammation. Cytokines can be 
classified according to their biological effects; pro-inflammatory and anti-
inflammatory cytokines (Parkin and Cohen 2001a). Pro-inflammatory cytokines are 
involved in the up-regulation of inflammatory reactions (i.e. Th1 and Th17 responses) 
which comprise IL-12, IFN-γ, IL-17 and IL-1β whereas anti-inflammatory cytokines 
are involved in the down-regulation of inflammatory reactions (i.e. Th2 and T 
regulatory responses) which include IL-4, IL-10 and TGF-β (Zidek, Anzenbacher and 
Kmonickova 2009a) [see figure 1.3]. Below I will describe in detail some of the 
cytokines and chemokines relevant to this study table 1.2 
 
 
 
 
 
 20 
Cytokine Source Modes of Action Inflammatory Status 
IL-1β Monocytes, MØ, B 
cells, DC 
Co-stimulates T cells, enhances 
NK cell activity, chemoattractant Pro-inflammatory 
IL-4 TH2 cells, NK cells, Basophils 
TH2 polarising cytokine, MØ 
activation 
Anti-inflammatory    
(TH2) 
IL-6 Monocytes, MØ, DC, TH17 cells 
Activates T and B cells, 
TH17 cell differentiation 
Pro-inflammatory 
IL-10 Treg, DC, Monocytes, MØ, B cells 
Immunosuppressive, inhibits TH1 
response and cytokine production 
Anti-inflammatory 
(Treg) 
IL-12 MØ, monocytes, DC, 
neutrophils 
Directs TH1 cell development, 
stimulates APC, NK cells, and 
CD8+ T cells 
Pro-inflammatory 
IL-13 TH2 cells, NK cells, Basophils 
MØ activation, induces B cell 
isotype switching 
Anti-inflammatory    
(TH2) 
IL-17 
TH17 cells, 
Neutrophils, CD8+ T 
cells 
Induces cytokine and chemokine 
production, DC maturation 
Pro-inflammatory   
(TH17) 
IL-23 Monocytes, MØ & DC 
Expansion and survival of TH17 
cells, induces pro-inflammatory 
cytokine production 
Pro-inflammatory 
IFN-γ 
TH2, CD8+ T cells, 
NK cells, MØ, B 
cells 
TH1 expansion, induces cytokine 
& chemokine secretion, enhances 
NK cell function 
Pro-inflammatory     
(TH1) 
TNF-α MØ, DC, T cells,     NK cells 
Amplifies inflammation & induces 
cytokine release Pro-inflammatory 
TGF-β 
TH3, MØ, 
Neutrophils, many 
non-lymphoid cells 
Immunosuppressive but involved 
in TH17 cell differentiation 
Anti-inflammatory 
but multi-faceted         
(mainly Treg) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1.2 Representative cytokines produced by different cells and their mode of action. Main reference 
sources (Janeway, Charles 2008; Borish,L.C. 2003; Nicod,L.P. 1993)  
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Figure 1.3 Diagrammatic representations of the cytokines involved in promoting and 
inhibiting the differentiation of the distinct T helper cell subsets  
. 
1.6.1 INTERLEUKIN-12 (IL-12) 
 
IL-12 was independently discovered by Trinchieri and colleagues in 1989 as a natural 
killer–stimulatory factor (Kobayashi, et al. 1989). The production of IL-12 by 
phagocytes and antigen presenting cells is essential for host defence against a wide 
range of pathogens. IL-12 functions in both innate and adaptive mechanisms, 
enhancing the phagocytic and bactericidal activities of phagocytes and the generation 
of other pro-inflammatory cytokines. IL-12 is a heterodimeric cytokine formed by a 
35kDa light chain termed p35 and a 40kDa heavy chain termed p40. The p35 subunit 
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has homology to single- chain cytokines while the p40 subunit is homologous to the 
extracellular domain of cytokine receptors (Watford, et al. 2003). The genes encoding 
these subunits are located on different chromosomes and protein expression is 
therefore independently regulated. However, when both genes are co-expressed in the 
same cells, these subunits form the biologically active p70 heterodimer (Agnello, et 
al. 2003). In addition to forming IL-12p70, p40 can associate with a p19 subunit to 
form IL-23, which has similar biological effects to IL-12, but yet are distinc 
t(Kastelein, Hunter and Cua 2007). Induction of IL-12 occurs following stimulation 
with a variety of purified microbial products (i.e. LPS), parasites, viruses and fungi. 
T-cell activation also drives IL-12 production through CD40-CD40L interactions and 
stimulation through CD28 augments the expression of IL-12R (Trinchieri 2003a) . 
Furthermore, IL-12 secretion stimulates the production of a variety of cytokines, most 
significantly IFN-γ but also TNF-α, IL-18 and GM-CSF from T cells, NK cells 
(Bettelli and Kuchroo 2005) [see figure 1.4].  
 
A critical function of IL-12 is its regulation of the adaptive immune response, as IL-
12 is the classic cytokine that directs naïve T helper cells to a Th1 phenotype. In T 
cells IL-12 is synergistic with many activating stimuli, including, IL-2, TCR-CD3 
complex and CD28 ligation for inducing rapid and efficient secretion of IFN-γ. In 
addition IL-12 augments the cytotoxic activity of CTLs and NK cells (Trinchieri 
2003a, Trinchieri 1998). [See Figure 1.4 for a diagrammatic illustration of the main 
roles of IL-12] 
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IL-12 has been shown to be directly and predominantly involved in autoimmune 
diseases including MS, IBD, and RA (Gee, et al. 2009), consequently it represents a 
potential therapeutic target for the treatment of these inflammatory disorders. 
 
 
 
Figure 1.4: Diagrammatic representation of the major biological effects of the 
cytokine IL-12. [Adapted from (Trinchieri 2003a)] 
 
1.6.2 IL-23 
 
IL-23 is a heterodimeric protein that is a member of the IL-12 family of cytokines. It 
is composed of a unique p19 subunit along with a p40 subunit, which is also a 
α 
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component of IL-12. Just like IL-12, the formation of biologically active IL-23 
requires the co-expression of both subunits (p19 and P40) within the same cell 
(Collison and Vignali 2008). The p40-p19 complex is produced by activated DCs and 
macrophages. It is now accepted that IL-23 is not the differentiation factor for IL-17 
producing T helper cells but it does act on previously differentiated Th17 cells to 
induce expansion and survival of the Th17 phenotype. Naïve T cells cultured in the 
presence of TGF-β and IL-6 and in the absence of Th1 producing cytokines IFN-γ or 
IL-4 are polarized to a Th17 phenotype, in addition the IL-23R is up-regulated 
(Langrish, et al. 2004) 
 
Emerging evidence indicates the definitive role of IL-23 and not IL-12 in autoimmune 
pathogenesis, this has been demonstrated using knock out mice. Mice deficient in the 
subunit p19 but not p40 showed resistance to the induction of EAE (Wong, et al. 
2008). Furthermore, elevated levels of IL-17, IL-6, IL-23p19 and TNF-α have been 
found in the biopsies from patients with RA thus implicating IL-23 as a major agent in 
the progression of inflammatory disorders (Li, et al. 2010). 
 
1.6.3 IL-10 
 
IL-10 is the crucial immunoregulator during infection with bacteria, viruses, fungi and 
helminths ameliorating the excessive Th1 and CD8+ T cell responses. IL-10 
modulates expression of cytokines, soluble mediators and cell surface markers by a 
variety of cells including T and B lymphocytes, macrophages, dendritic cells and mast 
cells (Borish and Steinke 2003).  
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IL-10 limits the production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, 
GMCSF, and TNF-α, it also acts directly on Th1 cells, inhibiting the proliferation and 
production of IL-2 and IFN-γ. IL-10 also reduces the production of chemokines 
including, MCP-1α, MIP-1, MIP-2, RANTES and IP-10, this prevents DCs migrating 
to lymph nodes and inducing Th1 differentiation of naïve T cells. In addition IL-10 
inhibits expression of MHC II antigens and co-stimulatory molecules CD80, CD86 
and ICAM-1, all of which impaired T cell activation (Pretolani 1999). Mice deficient 
in IL-10 signalling leads to the excessive production of pro-inflammatory cytokines 
directing the development of chronic inflammatory diseases such as Crohn’s disease 
(CD), psoriasis and RA (Asadullah, et al. 1998).  
1.6.4 TNF-α 
 
TNF-α is a 17kDa pleiotropic cytokine produced by numerous cells such as 
macrophages, dendritic cells, monocytes and activated lymphocytes (Sanchez-Munoz, 
Dominguez-Lopez and Yamamoto-Furusho 2008). The biological responses to TNF-α 
are mediated through two distinct receptors, TNFR1 and TNFR2 (Palladino, et al. 
2003). TNF-α activates a variety of cells including macrophages and NK cells and 
induces the production of pro-inflammatory cytokines (IL-1β and IL-6) and 
chemokines (MCP-1α). TNF-α also interacts with endothelial cells to induce adhesion 
molecules such as ICAM-1, stimulates proliferation of fibroblasts as well as the 
initiation of cytotoxic, apoptotic, acute phase responses and inhibition of apoptosis. 
TNF-α also influences the function of APC by augmenting antigen-presenting 
capability and up-regulating the expression of co-stimulatory molecules but 
conversely inhibits the properties of mature DCs by inducing their apoptosis and 
impairing antigen presentation (O'Shea, Ma and Lipsky 2002) . 
 
 26 
Over-production of TNF-α has been extensively documented in RA, CD, MS and in 
many other autoimmune diseases and consequently its inhibition or blockade has 
proved efficacious in treating many of these disorders (Palladino, et al. 2003). 
1.6.5 INTERFERON (IFN)-γ 
 
IFN-γ is a pleiotropic cytokine and its production by APCs not only enhances innate 
immunity but also adaptive immunity. One of the primary roles of IFN-γ is to activate 
macrophage and dendritic cells leading to increased expression of MHC class I and II 
molecules, and the elevated production of IL-12, which induces the production of 
IFN-γ by NK cells and directs naïve T cells to differentiate into Th1 cells (Borish and 
Steinke 2003).  In addition, IFN-γ aids macrophage and neutrophil intracellular killing 
by increasing NO and superoxide production and by phagocytosis. It also induces the 
production of TNF-α and IL-1 from APC, and upregulates the secretion of pro-
inflammatory chemokines to augment the inflammatory process (Parkin and Cohen 
2001b).   
 
IFN-γ is primarily produced by CD4+ T cells (mainly by Th1 cells), CD8+ T cells and 
NK cells, however other cells including macrophages and DCs have been shown to 
secrete this cytokine but to lesser degree, following CD40-CD40 ligand costimulation 
(Choy and Panayi 2001). The production of IFN-γ by NK cells might play an 
important role in the initial stages of infection, prior to specific recognition of T cells. 
The IL-12 family of cytokines including the newly identified member, IL-35, share 
the common feature of inducing the production of IFN-γ by T cells and NK cells. For 
instance, IL-35 effectively attenuated established collagen-induced arthritis in mice, 
with concomitant suppression of IL-17 production but enhanced IFN-γ. IFN-γ in turn 
promotes IL-12 production from APCs creating a positive feedback loop between the 
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Th1 cytokines and enhancing the Th1 response. Since the production of IFN-γ by Th1 
cells is involved in the pathogenesis of inflammatory disease such as, IBD, antibodies 
that target this specific cytokine could be of therapeutic value. For instance, 
fontolizumab is an anti- IFN-γ drug that has proved efficacious in patients with 
moderate to severe active IBD (Hommes, et al. 2006). Extensive research has also 
indicated IFN-γ as a mediator for disease as the genetic deletion of IFN-γ and/or the 
IFN-γR actually increased disease severity (for example in EAE and collagen-induced 
arthritis (CIA) (Guedez, et al. 2001) however conflicting studies by Komiyama and 
colleagues demonstrated that IFN-γ may be involved in the initiation of EAE 
(Komiyama, et al. 2006) 
1.6.6 IL-17 
 
IL-17 has numerous activities including the proliferation, maturation and chemotaxis 
of neutrophils, co-stimulates T cells, and enhances the maturation of dendritic cells,  
the production of pro-inflammatory cytokines TNF-α, IL-1, IL-6, IL-8 and GMCSF 
and chemokine monocyte chemoattractant protein (MCP-1) and MIP-2 (Korn, et al. 
2009). IL-17 is mainly secreted by CD4+ Th17 cells. In addition, CD8+ T cells lacking 
T-bet can differentiate into an IL-17 secreting lineage. NK cells have been shown to 
be able to produce high levels of IL-17 rapidly upon activation and rapid secretion of 
IL-17 has also been detected upon stimulation of lymphoid tissue inducer cells by 
zymosan (Pernis 2009). IL-17 shares transcriptional pathways with IL-1β and TNF-α. 
IL-17 binding to the IL-17R can activate NFκB and MAPK (p38, JNK, ERK) 
resulting in T cell proliferation and the production of pro-inflammatory cytokines and 
chemokines (Paradowska, et al. 2007). IL-17 has been implicated in the pathology of 
autoimmune diseases such as RA, IBD and MS (Segal 2010, Li, et al. 2010, Kolls 
2010). For instance, numerous studies have detected elevated levels of IL-17 in the 
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sera and synovial fluid in patients with RA also studies by Langrish and colleagues 
demonstrated that mice deficient in IL-17 are resistant to the development of EAE 
(Langrish, et al. 2005) 
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1.7 CHEMOKINES 
Chemokines are a superfamily of small proteins (8-12kDa) able to induce chemotaxis 
in a variety of cells including dendritic cells, macrophages, monocytes and 
lymphocytes (Borish and Steinke 2003). These molecules regulate activity through 
interactions with members of the 7- transmembrane, G-coupled receptor (GPCR) 
superfamily (Lodowski and Palczewski 2009). Chemokines are produced in response 
to Th1 cytokines IFN-γ and IL-2 and other pro-inflammatory cytokines such as IL-1 
and TNF-α. In contrast, the Th2 cytokine IL-4 and Treg cytokines, IL-10 and TGF-β 
are known to down-regulate secretion of chemokines. Chemokines execute numerous 
functions aside from chemotaxis (Sozzani, et al. 1999). They have direct effects on T 
cell differentiation by altering APC migration or cytokine secretion. Chemokines such 
as MIP-1α and RANTES can promote the development of Th1 lymphocytes while in 
contrast chemokines including MCP can inhibit IL-12 production and enhance 
secretion of IL-4 directing a Th2 response (Lodowski and Palczewski 2009, Foti, et 
al. 1999).  Representative Chemokines, their modes of action and the cells that 
produce them are listed in table 1.3 
 
Chemokines Source Modes of Action Inflammatory Status 
MIP-1 α MØ, DC, T cells, NK 
cells, stem cells 
T cell proliferation, enhanced 
CD8+ cytotoxity, cell recruitment, 
Wound Healing 
Pro-inflammatory 
MIP-2 MØ, Monocytes, 
neutophils 
Recruitment of effector cells, 
mucosal lymphocyte migration Pro-inflammatory 
MCP-1 Monocytes, T cells, Basophils, stem cells Inflammatory, Wound Healing Pro-Inflammatory 
MCP-2 
Monocytes, T cells, 
Eosinophils, Mast 
cells 
Recruitment of pro-inflammatory 
cells Pro-inflammatory 
 
TABLE 1.3 Representative chemokines produced by different cells and their mode of action. Main reference 
sources {{91 Lodowski,D.T. 2009; 326 Viola,A. 2008; 345 Wang,Y. 2006}} 
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1.8 INNATE IMMUNE RECEPTORS  
 
The primary role of the immune system is to detect and eliminate microbial 
components following recognition of conserved molecular patterns referred to as 
‘pathogen associated molecular patterns’ (PAMPs). Since PAMPs are highly 
conserved components of microbes, they are not readily altered by mutation or 
selection and provide ideal targets for innate recognition. PAMPs are recognised by a 
limited number of germ line encoded receptors known as ‘pattern recognition 
receptors’ (PRRs). There are numerous types of PRRs which include TLRs, NOD-like 
receptors (NLRs), Scavenger receptors (SRs) and RIG-like receptors (RLRs) (Gordon 
2002). These PRRs are expressed by many cells of the immune system and they all 
play a fundamental role in innate and adaptive immune responses. PRRs can 
recognise and respond to components derived from bacterial, fungal and viral 
pathogens. In addition PRRs respond to danger associated molecules (DAMPs) 
including heat shock proteins, DNA and uric acid (Bianchi 2007). Signalling through 
PRRs activates specific intracellular signalling pathways leading to a cascade of 
events including the production of inflammatory cytokines and chemokines, 
upregulation of surface markers and also the maturation of immune cells. 
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1.9 THE IL-1 (IL-1R)/TOLL-LIKE RECEPTOR (TLR) 
SUPERFAMILY  
 
Toll-like receptors are a family of PRRs that recognize PAMPs. The ligation of these 
receptors involves the maturation of immune cells and activation of intracellular 
signalling pathways leading to the production of cytokines and other inflammatory 
mediators (Sandor and Buc 2005). TLRs were discovered with the identification of 
toll, a receptor expressed by Drosophila meganogaster (Hashimoto, Hudson and 
Anderson 1988). It was observed that Toll displayed remarkable sequence similarity 
in its intracellular domain to that of a mammalian receptor for the IL-1R1, toll was 
shown to have a role in host defence and to be fundamental for antifungal immunity in 
Drosphila (Akira and Takeda 2004a). TLRs play a key role in the initiation of innate 
immunity which is essential for the induction of an adaptive immune response. TLRs 
are expressed on sentinel cells of the immune system, most notably, DCs, 
macrophages and neutrophils. They are also expressed on a variety of other cells 
including vascular endothelial cells, adipocytes and intestinal epithelial cells (O'Neill 
2006). 
 
TLRs are type 1 transmembrane proteins that are evolutionarily conserved between 
insects and humans. They encompass a subfamily within the larger superfamily of 
interleukins (IL-1) receptors based on the similarity within their cytoplasmic regions, 
which is now referred to as the Toll/IL-1 receptor (TIR) domain (O'Neill 2008). In 
contrast, the extracellular (ectodomains) portions of both types of receptors are quite 
distinct. The IL-1 receptors possess three immunoglobulin (Ig) like domains, whereas 
TLRs ectodomains are characterized by the presence of leucine rich regions referred 
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to as leucine rich repeats (LRRs) [see figure 1.5] (Beutler 2009, Akira and Takeda 
2004a)(Beutler 2009, Akira and Takeda 2004b) 
Ten human TLRs have been found to date and they individually have a distinct 
function in innate immune recognition. Based on the chromosomal location, genomic 
structures and amino acid sequence, the human TLRs can be divided into 5 
subfamilies; TLR2, TLR3, TLR4, TLR5, TLR9 (Sandor and Buc 2005). Each TLR 
has the ability to recognise a specific ligand or discrete set of ligands as outline in 
section 1.9.1. The assembly of LRR side chains presents a sole combinational code to 
each TLR facilitating its binding to a particular ligand (Goldstein 2004, Kawai and 
Akira 2006). Imperatively, Charles Janeway and Ruslan Medzhitov identified human 
toll, htoll, now called TLR4, as the fist human toll to be discovered.  
 
 
Figure 1.5: Schematic diagram of toll and toll-like receptors adapted from (Gay, Gangloff 
and Weber 2006) 
 
 
 
 
Leucine rich repeats (LRR)  
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1.9.1 TOLL LIKE RECEPTORS (TLRs)  
 
So far, 10 and 12 functional TLRs have been identified in humans and mice, 
respectively (Georgel, Macquin and Bahram 2009). The most extensively studied is 
TLR4, which recognises the gram negative bacteria lipopolysaccharide (LPS) (Chow, 
et al. 1999). TLR2 is also involved in the recognition of bacterial components which, 
in combination with TLR1, recognises triacylated lipopeptides, or in combination 
with TLR6, recognises diacylated lipopeptides. TLR5 recognises flagellin, a protein 
component of bacterial flagellum (Gomez-Gomez and Boller 2002). Several TLRs are 
involved in the recognition of viral components including TLR3 which recognises 
double stranded RNA (dsRNA), TLR7 and TLR8 which recognise single stranded 
RNA (ssRNA), and TLR9 which recognises bacterial and viral DNA containing 
unmethylated CpG motifs (Yamamoto and Takeda 2010). TLRs, relative adaptor 
molecules, signalling pathways and inducible genes are listed in table 1.2. 
 
1.9.1.1  TLR1, TLR2, TLR5 AND TLR6   
TLR2 recognises numerous different microbial components including lipoproteins 
derived from M.tuberculosis, Treponema pallidum and Mycoplasma fermantans. In 
addition, TLR2 mediates a cellular response from whole gram positive and gram 
negative bacterium, the yeast cell wall component zymosan and peptidoglycan (PGN), 
the Trypanosoma cruzi glycophosphatidylinositol anchor (Aliprantis, et al. 1999, 
Takeuchi, et al. 2000, Underhill, et al. 1999). TLR2 also recognises viral components 
such as herpes simplex virus 1 (HSV-1) and measles virus (MV) wild-type H protein 
(Kurt-Jones, et al. 2000, Bieback, et al. 2002). Amazingly, TLR2 is also able to 
recognise various kinds of LPS that are not recognised by TLR4 for example LPS 
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derived from Porphyromonas gingivalis (Ogawa, et al. 2002). The ability of TLR2 to 
recognise a variety of components and to initiate signalling is based on TLR2’s 
unique ability to form heterodimers with other TLR family members. The 
TLR2/TLR1 heterodimer recognises triacylated lipoproteins such as Pam3CsK4 
whereas TLR2/TLR6 recognises diacylated lipoproteins such as zymosan (West, 
Koblansky and Ghosh 2006). Generally activation of TLR2 leads to the production of 
inflammatory cytokines and not type I interferon by macrophages and dendritic cells 
(DCs), however it can mediate the production of type I interferon by inflammatory 
monocytes following infection with vaccinia virus, which suggests a cell type specific 
role for TLR2 in antiviral responses (Barbalat, et al. 2009). Flagellin is a 55kda 
protein from bacterial flagella which is found on the outer membrane of gram positive 
and gram negative bacteria and is recognised by TLR5. A wide range of acute 
infections are caused by flagellated bacteria such as respiratory tract infection (de C 
Ventura, et al. 2008). The vital function of flagella in bacterial motility creates a 
situation in which the capacity for the molecule to mutate is constrained, and this 
renders it an ideal candidate for innate immune recognition (Hayashi, et al. 2001).  
1.9.1.2          TLR3, TLR7, TLR8 AND TLR9   
TLR3, TLR7, TLR8 and TLR9 are antiviral receptors that execute their functions in 
the intracellular compartment of the cell. TLR3 recognises a synthetic analog termed 
polyinosinic acid (Poly:IC), which is widely used to mimic viral infection. In addition 
TLR3 has been shown to recognise (Koyama, et al. 2008). West Nile Virus (WNV). 
WNV is a positive ssRNA virus that produces dsRNA in its life cycle. WNV causes a 
breakdown in the blood brain barrier leading to an enhanced systemic infection in the 
brain resulting in encephalitis and death.  Mice deficient in TLR3 are more resistant to 
lethality after WNV infection (Wang, et al. 2004). TLR7 and TLR8 are structurally 
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and phylogenetically related. Synthetic compounds of the imidazoquinoline family, 
including imiquimod (R-837) and resquimod (R-848) demonstrate potent anti-viral 
and anti-tumour activities in animal models (Smits, et al. 2008). Hemmi and 
colleagues have shown that TLR7 is involved in the recognition of both imiquimod 
(R-837) and resquimod (R-848) (Hemmi, et al. 2002). However human TLR8 only 
recognises R-837 whereas mouse TLR8 does not recognise either, indicating that 
TLR8 is non-functional in mice (Hemmi, et al. 2002). Both TLR7 and TLR8 have 
recently been discovered as natural receptors for ssRNA including vesicular 
stomatisis virus and influenza virus. Furthermore, Heil and colleagues have 
demonstrated that the guanosine analog, loxoribine (7-allyl-7,8-dihydro-8-oxo-
guanosine), activates NFκB via TLR7 but not TLR8 in a Myd88-dependant manner 
(Heil, et al. 2004). Unmethylated CpG DNA motifs are present in bacterial and viral 
but not vertebrate genomic DNA. Synthetic CpG oligodeoxynucleotides (ODN) are 
recognised by TLR9 which activates host defence mechanisms leading to innate and 
adaptive immune responses (Hemmi, et al. 2000). TLR9 is expressed by numerous 
cells of the immune system including pDCs and B cells. The TLR profile in pDC is 
limited to TLR7 and TLR9 and it is for this reason that these cells are frequently used 
to examine the immunostimulatory effects of CpG DNA and the associated role of 
TLR9 (Rothenfusser, et al. 2002). In addition to recognising DNA, TLR9 directly 
recognises a non-DNA ligand termed hemozoin generated following digestion of host 
haemoglobin by malaria parasites (Coban, et al. 2010) 
1.9.1.3          TLR 4 
 
The founding member of the TLR family, TLR4 recognises and is activated by LPS, a 
component found on the outer membrane of gram negative bacteria such as 
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Escherichia coli and Salmonella Minnesota. LPS is a complex glycolipid composed 
of a hydrophilic polysaccharide and a hydrophobic domain termed lipid A which is 
primarily responsible for the biological activity of LPS and which is responsible for 
instigating the life threatening condition called endotoxic shock (Erridge, et al. 
2008b). In order for TLR4 to initiate signalling LPS needs to bind to LPS-binding 
protein (LBP), an acute phase protein that is found in the bloodstream and produced 
by the liver. The LPS-LBP complex then interacts with cluster of differentiation 14 
(CD14), a leucine rich repeat containing protein, which enables LPS to be transferred 
to the LPS receptor complex TLR4-MD-2 (Akashi-Takamura and Miyake 2008, 
Palsson-McDermott and O'Neill 2004) . In addition TLR4 is involved in the 
recognition of a wide range of molecules including heat shock proteins, fibrinogen, 
taxol and also viruses such as respiratory syncytial virus fusion proteins, mouse 
mammary tumour virus envelope proteins, Streptococcus pneumoniae pneumolysin 
and the plant-derived cytostatic drug paclitaxel, however, LPS remains its most potent 
ligand (Kurt-Jones, et al. 2000, Kawai and Akira 2010). 
 
TLR4 was identified through the examination of a mouse strain C3H/HeJ that was 
hyporesponsive to LPS. This C3H/HeJ mouse strain carries a missense point mutation 
within the tlr4 gene region encoding the cytoplasmic tail. This mutation alters a 
highly conserved proline to a histidine therefore allowing for the generation of mice 
with non-functional TLR4. These TLR4 -/- mice were hyporeresponsive to LPS, 
confirming that TLR4 is essential for LPS signalling (Poltorak, et al. 1998). 
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Table 1.2: Toll-like receptors 1-11 and their corresponding ligands, adaptor molecules and inducible genes. Main reference sources listed in text.  * All 
TLRs activate NF-κB. +Orphan: denotes a receptor of similar structure to other identified receptors but no endogenous ligand has been identified.
 
Toll-like receptor 
 
Ligand 
 
Origin of Ligand 
 
Adaptor/Pathway 
Transcription Factor/ 
Inducible genes 
TLR1/2 Lipopeptide (BLP) Bacteria and mycobacteria Mal, MyD88  NF-κB* 
TLR2/6 Peptidoglycan (PG), BLP Gram +/-bacteria Mal, MyD88 NF-κB 
TLR3 dsRNA Viruses Trif IRF3/Type I IFN α/β,  NF-κB 
TLR4 
Lipopolysaccharide (LPS), 
hsp60, F protein 
Gram +bacteria 
Mal, MyD88 
Trif, TRAM 
NF-κB 
IRF3 
TLR5 Flagellin Gram +/-bacteria MyD88 NF-κB, TNF-α, IL-6 
TLR6 Triacylated BLP, Zymosan Bacteria, Yeast MyD88 NF-κB 
TLR7 ssDNA Viruses MyD88 NF-κB 
TLR8 ssDNA Viruses MyD88 NF-κB 
TLR9 CpG DNA, Hemazoin Bacteria and Viruses MyD88 NF-κB, IRF-3, IRF-7/IFN-α 
TLR10 Orphan + - - NF-κB 
TLR11 Uropathogenic bacteria Toxoplasma gondii - NF-κB 
 38 
1.10 TLR ACTIVATION AND SIGNALLING 
 
TLR detection of PAMPs initiates the intracellular signalling pathways that induce a 
cascade of events including the up-regulation of pro-inflammatory cytokines and 
chemokines, enhancement in the expression of co-stimulatory molecules, activation of 
complement, recruitment of phagocytic cells and mobilization of APCs. There is clear 
evidence that if TLRs are over activated infectious and inflammatory diseases can 
develop therefore they must be tightly controlled (O'Neill 2006, O'Neill 2005). TLRs 
occur as dimers and to date several crystal structures of TLR dimers have been 
elucidated, TLR2 heterodimerize with either TLR1 or TLR6 while TLR4, TLR5 and 
TLR9 homodimerize. The preliminary step in signal transduction of TLRs involves 
the binding of the ligand resulting in dimerization of two receptor chains. This 
induces a conformational change in the dimer, which brings the TIR domains of the 
two TLRs into close proximity [see figure 1.6]. Eventually, association of the TIR 
domains provides a platform that is essential for the recruitment of specific adaptor 
molecules which also contain a TIR domain. Once TIR-adaptors are engaged to TLR-
TIR domain, signalling is initiated which will ultimately lead to the activation of 
specific transcription factors (O'Neill 2008, Miggin and O'Neill 2006). 
 
Figure 1.6: The crystal structures of ‘m’ shaped TLR dimers induced by ligand binding (A) 
TLR1-TLR2-Pam3CSK4, (B) TLR3-dsRNA and (C) a model of TLR4-MD-2-Eritorian 
complex. Double apostrophes mark the second TLR or associated molecule (MD-2) in the 
receptor complex adapted from (Jin and Lee 2008) 
Poly:(IC) 
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Signalling through TLRs via their TIR-domain involves five adaptor molecules and 
include; myeloid differentiating protein 88 (MyD88) (Verstak, et al. 2009), MyD88 
adaptor like/TIR domain-containing adaptor protein (Mal/TIRAP) (Fitzgerald, et al. 
2001), TIR-domain-containing adaptor inducing interferon-β/TIR-containing adaptor 
molecule-1 (Trif/TICAM-1 (Yamamoto and Takeda 2010), Trif-related adaptor 
molecule/TIR-containing adaptor molecule-2 (TRAM/TICAM-2) (Oshiumi, et al. 
2003), and sterile alpha (SAM), HEAT/Armidillo motif and TIR-containing adaptor 
protein (SARM) (Jenkins and Mansell 2010). Some TLRs do not utilize the same set 
of adaptors and the adaptors chosen determine the transcriptional response induced 
following microbial recognition as TLRs lead to the activation of two major signalling 
cascades, namely the MyD88- dependant pathway and the MyD88-independent 
pathway (Bagchi, et al. 2007). 
 
1.10.1 TLR SIGNALLING VIA THE MyD88-DEPENDANT PATHWAY  
 
MyD88 was the first TLR adaptor protein to be described (Burns, et al. 1998). Due to 
the degree of conservation within the TIR domain between family members, it is not 
surprising to discover that signalling via the TLRs paralleled the downstream events 
following ligand binding of the IL-1 or IL-18 receptor complexes, both of which have 
TIR domains. The MyD88- dependant pathway eventually leads to the activation of 
the transcription factor, NFκB, initiating the production of pro-inflammatory 
cytokines such as IL-6, IL-12 and TNF-α. MyD88 is involved in NFκB activation of 
every TLR identified so far with the exception of TLR3,  TLR3 induced activation by 
poly(I:C) was normal in the absence of MyD88 (Matsumoto and Seya 2008).  
Signalling via the MyD88 dependant pathway is initiated by the recruitment of 
MyD88 adaptor. Upon stimulation IL-1R associated kinase (IRAK-4) interacts with 
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the death domain of MyD88. IRAK-4 is required for the recruitment of IRAK-1 to the 
receptor complex which causes the activation and phosphorylation of IRAK-1. 
However the molecular mechanisms of IRAK-4 signalling and the role of its kinase 
activity remain unknown. Phosphorylated IRAK-1 leads to the association of the 
TNF-receptor associated factor 6 (TRAF6) (Akira and Takeda 2004a). TRAF6 was 
established to have a role in the IL-1R signalling pathway when a dominant negative 
form of the protein inhibited activation of NFκB by IL-1. TRAF6 and IRAK1 then 
dissociate from the receptor complex and interact with a membrane bound pre-
associated of TGF-β-activated kinase (TAK-1) and two TAK-1 binding proteins, 
referred to as TAB-1 and TAB-2. A series of ubiquitinylation reactions occur on 
TRAF-6 and TAK-1. This then activates inhibitor of NFκB protein (IκB) kinase 
(IKK), IKKα and IKKβ (O'Neill 2008). Once activated the IKK complex induces 
phosphorylation and subsequent degradation of IκB which leads to the release of 
NFκB enabling it to translocate into the nucleus culminating in NFκB activation and 
the expression of pro-inflammatory cytokines. Activation of the Myd88- dependant 
pathway also allows for the activation of mitogen activated protein kinases (MAPK) 
including JNK, P38 and ERK (Takeda and Akira 2007, Watters, Kenny and O'Neill 
2007). TLR7, TLR8 and TLR9 act through MyD88 to induce pro-inflammatory 
cytokine secretion and the IFNs. 
1.10.2 TLR SIGNALLING VIA THE MyD88-INDEPENDANT PATHWAY  
 
Experiments in MyD88 deficient mice show no production of inflammatory cytokines 
and no activation of NFκB in response to TLR2, TLR7 and TLR9 ligands and LPS 
induced activation of NFκB is observed with delayed kinetics when compared with 
wild type mice [see figure 1.7]. These findings led to the identification of an alternative 
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pathway utilised by TLR4, independent of MyD88 which leads to the activation of the 
transcription factor (IFN) regulatory factor-3, (IRF3) (Takeda and Akira 2005). 
Ultimately IRF3 activation leads to the production of type-1 interferons, IFN-α and 
IFN-β, and other IFN inducible genes. The MyD88 independent pathway requires the 
recruitment of the adaptor TRIF. TRIF is the sole adaptor used by TLR-3 in the 
activation of IRF3 and activation of NFκB (Yamamoto, et al. 2003a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Diagrammatic representation of TLR4 signalling through the MYD88 dependant 
and Independent pathways. MYD88-independent pathway activates IRF-3 and the late phase 
activation of NFκB  
 
In contrast to TLR3 signalling, TLR4 signalling independent of MyD88 utilises both 
TRIF and TRAM to activate IRF3. TLR4 is unique in that it is the only know TLR 
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that engages all four TIR containing adaptors (Palsson-McDermott, et al. 2009). TRIF 
uses some shared and unique signalling molecules compared with MyD88. TRIF 
allows for the activation of IRF3, NFκB and is also involved in the induction of 
apoptosis. TRIF binds to TLR3 and recruits TRAF6 by binding to its N-terminal 
domain in an IRAK1 and IRAK4 independent manner. This leads to TAK1 activation 
and subsequent NFκB activation. However, to mediate IRF3 activation the N-terminal 
region of TRIF engages with tank-binding-kinase-1 (TBK-1) and IKKi (Yamamoto, et 
al. 2003a). These kinases then phosphorylate IRF3 resulting in its dimerization and 
translocation to the nucleus initiating in the transcription of IFN-inducible genes via 
the binding to an interferon stimulated response element (Beutler 2009, Akira and 
Takeda 2004a, Brikos and O'Neill 2008). Schematic representation of TLR activation 
of MyD88 dependant and independent pathways is outlined in figure 1.8. 
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Figure 1.8: Diagrammatic representation of TLR signalling with specific TLR ligands through the MyD88 dependant and independant pathways  
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1.11 MAL  
 
Mal was the second TIR domain containing adaptor to be identified which is capable 
of driving NFκB activation. It is a 25kDa protein, 235 amino acids in length and 
contains a TIR domain at the C-terminus (Fitzgerald, et al. 2001). It was initially 
assumed that Mal was involved in the TLR4 MyD88-independent pathway. However, 
mice deficient in Mal demonstrated that Mal is not involved in the MyD88-
independent pathway but is critically involved in the MyD88-dependant pathway. In 
Mal deficient mice, IL-1, TLR5, TLR7 and TLR9 signalling were normal whereas 
deficiency in the activation of NFκB and cytokine production was observed following 
stimulation with LPS, though with delayed kinetics (Horng, et al. 2002a). 
Furthermore, overexpression of Mal in human embryonic kidney cells (HEK293) 
leads to the activation of NFκB, MAPK, JNK and p38, indicating its involvement 
with TLR4, but not with other receptors of the TLR family (Fitzgerald, et al. 2001, 
Horng, Barton and Medzhitov 2001b). Interestingly, Mal deficient mice showed 
impairment in response to TLR2 activation, indicating that Mal is an essential adaptor 
for TLR2-mediated innate host defence (Yamamoto, et al. 2002). This led to the 
conclusion that Mal is fundamental for signalling only through TLR4 and TLR2 
(figure 1.9).  
 
It has been clearly demonstrated that Mal serves as a bridging adaptor for MyD88, 
aiding the recruitment of MyD88 to the plasma membrane, where it can activate 
downstream signalling components. Mal contains a phosphatidylinositol-4,5-
bisphosphate (PIP2)-binding domain in its N-terminus which mediates the recruitment 
of Mal to PIP2-rich regions in the plasma membrane (Kagan and Medzhitov 2006). 
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Obstructing this localisation of Mal to PIP2-rich regions inhibits TLR4-MyD88-
dependant signalling (McLaughlin, et al. 2002). TLR4 does not bind directly with 
MyD88 but alternatively interacts with Mal in association with TLR4. This is 
consistent with the electrostatic surfaces of the TIR domains of Mal and MyD88. 
MyD88, TLR2 and TLR4 are greatly electropositive on their surfaces therefore 
MyD88 is unable to bind these TLRs. Whereas Mal is mainly electronegative on its 
surface enabling it to interact with TLR2 and TLR4 and bring MyD88 into the 
signalling complex (Sheedy and O'Neill 2007). LPS signalling in Mal deficient mice 
was restored when PIP2-binding domain was grafted onto the N-terminus of MyD88, 
which indicates that the sole function of Mal in relation to the NFκB pathway is to 
recruit MyD88 (McLaughlin, et al. 2002) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Diagrammatic representation of TLR2 and TLR4 Mal mediated-signalling  
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Mal contains a caspase-1 cleavage site in its C terminus, which is an essential 
inflammatory caspase responsible for the cleavage of pro-IL-1β into their bioactive 
forms (Kenny and O'Neill 2008). The caspase-1 inhibitor YVAD-Cmk prevented 
NFκB activation, in response to LPS and phosphorylation of p38 in response to 
Pam3Cys. Moreover, TLR7 or IL-1 NFκB activation was not impaired, indicating that 
cleavage of Mal by caspase-1 is fundamental for Mal to signal (Miggin, et al. 2007) 
[see figure 1.10].  
 
Mal contains a TRAF6-binding domain within its TIR domain. Mal can interact with 
TRAF6 directly and mutating this TRAF6 binding inhibits Mal-induced MAPK 
activation and NFκB activation and was able to impede TLR2- and TLR4-mediated 
activation of NFκB (Verstak, et al. 2009).  A study by Gray and colleagues 
demonstrated that Mal undergoes tyrosine-phosphorylation at residues 86 and 106 by 
Bruton’s tyrosine kinase (Btk) during TLR2 and TLR4 signalling (Gray, et al. 2006). 
This phosphorylation of Mal is fundamental for the activation of a pathway 
culminating in transactivation of the NFκB subunit p65 by phosphorylation on serine 
536 and mutations in Mal at these residues results in decreased ability to activate 
phosphorylation of p38, IκBα degradation and NFκB (Doyle, Jefferies and O'Neill 
2005). In addition, Tyrosine-phosphorylated Mal is subsequently degraded following 
stimulation of TLR2 and TLR4. This degradation is mediated by suppressor of 
cytokine signalling 1 (SOCS1) and requires tyrosine phosphorylation of Mal by Btk. 
Cells deficient in SOCS1 demonstrate enhanced NFκB activation and excessive 
cytokine production (Baetz, et al. 2004, Nakagawa, et al. 2002) [see figure 1.10]  
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A variant of Mal was discovered in humans in which the serine at position 180 is 
mutated to a leucine (Watters, Kenny and O'Neill 2007). It was discovered by Khor 
and colleagues that heterozygous carriage of this variant confers resistance against 
numerous infections diseases including malaria, tuberculosis (TB), bacteraemia and 
pneumococcal pneumonia (Khor, et al. 2007). In addition it was observed that S180L 
mutation inhibited TLR2 signalling. Therefore, due to the decreased level of TLR2 
and TLR4 signal heterozygotes are protected from diseases which are sufficient for 
host defence but not for inflammatory diseases such as RA (Sheedy and O'Neill 
2007).  
 
 
 
Figure 1.10: Diagrammatic representation of the three main findings in Mal signalling: (A) 
Caspase-1 cleavage of Mal is required for signalling, (B) A mutation in Mal at the serine 
residue to a leucine results in protection against certain disease, (C) Mal is phosphorylated at 
tyrosine residues in order for the activation of the MyD88-dependant pathway adapted from 
(Kenny and O'Neill 2008) 
 
 
 
NFκB         NFκB 
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1.12 INTRACELLULAR SIGNALLING 
 
Intracellular signalling is the fundamental mechanism by which cellular activation 
occurs. Innate immune stimuli, including pathogens, cytokines and stress signals 
function through distinct intracellular signalling pathways to activate protein kinases, 
instigating phosphorylation and ubquitination events that lead to the activation of 
specific transcription factors controlling gene expression. There are numerous 
signalling pathways and transcription factors that are known to be involved in the 
development of inflammatory disease such as IBD and RA (Brown, Claudio and 
Siebenlist 2008). The two transcription factors relevant to this study will be discussed 
in details below.  
1.12.1 NUCLEAR FACTOR (Fib) 
 
NFκB is a vital transcription factor in inflammation, regulating genes that encode pro-
inflammatory cytokines, such as TNF-α, IL-1β, IL-12 and IL-6, chemokines, adhesion 
molecules, immune receptors, matrix metalloproteinases (MMPs) and cyclooxygenase 
(COX) (Tak and Firestein 2001, Plevy, et al. 1997). NFκB was originally identified 
by its ability to bind to the promoter of the kappa light chain in B cells (Sen and 
Baltimore 2006) but it has since been shown to be present and functional in many 
cells types including DC, macrophages, neutrophils and mast cells (Wan and Lenardo 
2010). Five related transcription factors of the NFκB family have been identified to 
date; NFκB1 (p50/p105), NFκB2 (p52/p100), RelA (p65), RelB, and c-Rel. The p50 
and p52 subunits are transcriptionally inactive but can induce gene expression when 
they form heterodimers with p65, c-Rel, or RelB. Homodimers of p50/p50 or p52/p52 
subunits can repress transcription, however the most frequently observed active form 
of NFκB is the p65/p50 heterodimer (Yan and Polk 2010). The IL-12 p40 promoter 
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has been reported to bind NFκB (p50/p65 and p50/c-Rel) in macrophages activated by 
a number of IL-12 activating pathogens, including LPS and S. aureus (Murphy, et al. 
1995).  All NFκB family members contain a highly conserved REL-homology domain 
(RHD) which is responsible for DNA binding, dimerization and interaction with 
inhibitors of NFκB (IκB) (Ghosh and Karin 2002). 
 
Homodimers or heterodimers of NFκB are bound to NFκB (IκB) inhibitory proteins. 
This binding causes the dimers to be sequestered in the cytoplasm and are unable to 
initiate transcription of target genes. Like NFκB, IκBs are also members of a 
multigene family containing eight members IκBα, IκBβ, IκBγ, IκBε, IκBζ, Bcl-3 and 
the precursor Rel-proteins p105 and p100. Stimulation by numerous innate stimuli, 
such as LPS and cytokines such as TNF-α and IL-1 results in the activation of NFκB 
(Li and Verma 2002). Ultimately, these stimuli lead to the activation of IκB kinase 
(IKK), which is a complex composed of two catalytic subunits, IKKα and IKKβ, and 
a scaffold protein called NEMO (NFκB essential modulator - also known as IKKγ). 
IKKβ activation phosphorylates IκB which is then ubquitinated, which targets it for 
degradation by the 26S proteasome, releasing NFκB dimers from the cytoplasm and 
allowing to translocate to the nucleus (Yan and Polk 2010). Due to the 
phosphorylation of the p65 subunit of NFκB, NFκB allows the basal transcription 
initiation complex to interact with cofactors and coactivators and subsequently allows 
for full transactivation of its target genes (Chen 2005). IκBα is then degraded and is 
rapidly resynthesised to allow inhibition of the pathway. IKK also phosphorylates 
IκBβ leading to prolonged NFκB activation whereas phosphorylation of IκBα 
regulates transient NFκB activation (Krappmann and Scheidereit 1997). The role of 
NFκB as a key regulator in innate and adaptive immunity is demonstrated by studies 
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using transgenic mice whose T cells lack the NFκB signalling pathway. This shows 
that NFκB plays a vital role in Th1 responses. Furthermore DC maturation appears to 
be NFκB-dependant; following in vitro stimulation, NFκB is activated to facilitate DC 
maturation which is characterised by an up-regulation of co-stimulatory molecules 
and MHC II expression. Interestingly, NFκB activation can have anti-inflammatory 
roles by directly inhibiting expression of pro-inflammatory genes and by directing the 
expression of anti-inflammatory cytokines such as IL-10 thus inhibiting NFκB during 
the resolution stage of inflammation (Tak and Firestein 2001). Excessive activation of 
NFκB is extensively implicated in inflammatory diseases such as RA, IBD and MS 
and much attention has focused on the development of anti-inflammatory drugs 
targeting NFκB (Yan and Greer 2008, Wei and Feng 2010, Boyce, Yao and Xing 
2010). 
1.12.2 INTERFERON REGULATORY FACTOR 3 (IRF3) 
 
The interferon regulatory factors (IRF) are a family of unique transcription factors and 
they are present in high levels in the cytoplasm of all cell types. IRF play a critical 
role in anti-viral responses and are responsible for the production of type I interferons, 
which include IFN-α and IFN-β (Taniguchi, et al. 2001). In addition to the anti-viral 
responses, IFN have further pleiotropic effects, including essential roles in apoptosis 
and growth inhibition via increased expression of MHC class I. IRF-3 and IRF-7 are 
closely related and are the only members of the IRF family that can initiate production 
of both IFN-α and IFN-β (Yoneyama, Suhara and Fujita 2002). Human type I 
interferon promotes differentiation of DCs and induces Th1 polarization. IRF-3 is 
activated in many ways including through TLR3 by recognition of viral dsRNA, by 
intracellular receptors such as retinoic acid-inducible gene I (RIG-I) and recognition 
of bacterial components (McCoy, et al. 2008). Upon stimulation IRF-3 is 
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phosphorylated at multiple sites at the C terminus of the protein by two non-canonical 
IκB kinases; TBK-1 and IKKε, resulting in IRF-3 dimerization, allowing for 
association with co-factor CAMP-response element binding protein (CREB), and 
following translocation to the nucleus (McCoy, et al. 2008, Servant, Grandvaux and 
Hiscott 2002). Entry of IRF3 into the nucleus facilitates binding to a consensus DNA 
sequence known as the interferon-response-element (ISRE) and the induction of IFN-
inducible genes including; IFN-α, IFN-β, CXCL10 and RANTES (Servant, et al. 
2001, Servant, Tenoever and Lin 2002). 
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1.13 THE MARINE INDUSTRY 
 
Three quarters of the Earth’s surface is covered by oceans and life on Earth has its 
origin in the sea. It contains an extraordinary reservoir of biological and chemical 
diversity and it is estimated that the biological diversity is higher than in tropical 
rainforests. The ocean represents a rich source of novel compounds with huge 
potential as pharmaceuticals, nutritional supplements, cosmetics, molecular probes, 
agrichemicals and enzymes with each marine bioproduct having huge market 
potential (Faulkner 2002). Already compounds isolated from marine species have 
been shown to have enormous potential in the clinical setting for treatment of many 
diseases and disorders (Blunt, et al. 2011). 
 
Many marine species are soft bodied and produce novel secondary metabolites and 
compounds. This is due to the harsh conditions in which they live which require them 
to synthesize these unique compounds to survive. They are also linked to the 
defensive mechanisms by which the species protects itself from predators (Haefner 
2003). The marine environment is the source of a large group of unique natural 
products that are mainly found in sessile marine invertebrates such as sponges, 
tunicates and bryozoans. A number of these molecules have been shown to possess a 
variety of functions including anti-tumour, anti-bacterial, anti-viral and anti-
inflammatory activities and are therefore candidates for the development of 
therapeutics (Haefner 2003, Bhadury and Wright 2004). Attention has been focused 
on sponges as a source of biomedically important metabolites due to the discovery of 
spongouridine, a potent tumour inhibitor isolated from the Caribbean sponge 
Cryptotethia crypta (Kaul and Daftari 1986). Since then marine sponges have become 
a rich source of biologically active compounds with almost 100 anti-inflammatory 
 53 
compounds isolated to date. Two of these, bolinaquinone and petrosaspongiolide, 
have recently been shown to have anti-inflammatory activity in animal models of RA 
and IBD (Busserolles, et al. 2005, Garcia-Pastor, et al. 1999, Lucas, et al. 2003).  
 
1.13.1 COMPOUNDS IN PRECLINICAL AND CLINICIAL EVALUATION 
 
In recent years numerous marine species have been shown to be candidates for anti- 
cancer and anti-inflammatory therapies [see table 1.4] 
  
Table 1.4: Anti-cancer/anti-inflammatory compounds isolated from marine organisms in 
clinical trials 
 
1.13.2 BRYOSTATIN-1  
The bryostatins are macrocyclic lactones isolated from the bryozoans, Bugula 
neritina. They have been extensively studied for their therapeutic potential since 1986 
(Hale, et al. 2002). Bryostatin-1 is the most studied compound of this species. It is a 
potent anti-cancer compound in combination with other drugs showing remarkable 
Chemical 
compound Source organism Application 
Bryostatin-1 Bugula neritina sp Anti-cancer 
Ara-C Cryptotethya crypta sp Anti-cancer 
Salinosporamide A Salinospora sp Anti-cancer 
Manoalide Luffariella variabilis sp Anti-inflammatory 
Avarol Dysidea avara sp Anti-inflammatory 
Contignasterol Petrosia contignata sp Anti-inflammatory 
Capnellene Capnella imbricate sp Anti-inflammatory 
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selectivity against human leukaemia, renal cancer and melanoma. It has also been 
shown to bind to and modulate the signal transduction enzyme protein kinase-C 
(PKC) (Barr, et al. 2009). Owing to their therapeutic potential, scientists at Stanford 
University have synthesised numerous analogues which have been shown to be more 
potent against tumour cell lines (Haefner 2003). Additionally Neristatin-1, an 
analogue of bryostatin-1, reduced the production of IL-8 and prostaglandin E2 in 
human cells, showing that it has anti-inflammatory activity (Breton and Chabot-
Fletcher 1997).  
1.13.2 NFκB INHIBITORS 
 
NFκB is a crucial mediator in the inflammatory process and this transcription factor is 
an attractive target in suppressing an overactive inflammatory response (Atreya, 
Atreya and Neurath 2008). Many products isolated from marine species have been 
found to possess potent anti-inflammatory effects through their inhibition of NFκB 
[see figure 1.11]. One of the interesting explanations for the discovery of NFκB 
inhibitors from marine species comes from an evolutionary point of view (Folmer, et 
al. 2008). Marine invertebrates in many cases possess NFκB or closely related 
analogues and are therefore more likely to have developed metabolites that can 
counterbalance the effect of NFκB.  Sea urchins have been shown to use spNFκB, an 
analogue of NFκB, to protect themselves against predators and also to respond to 
bacterial infection (Pancer, Rast and Davidson 1999).  
 
Marine compounds that act as NFκB inhibitors can be divided into four categories: (1) 
compounds targeting IκB degradation, (2) compounds that impede the proteolytic 
activity of the 26S proteasome, (3) compounds that interfere with the translocation of 
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NFκB to the nucleus, and (4) compounds with unknown molecular targets (Folmer, et 
al. 2008). Scytonemin, Cacospongioloide B and Petrospongiolide M have all been 
shown to interfere with the degradation of IκB (Stevenson, et al. 2002, Posadas, et al. 
2003). Marine products that have been shown to interfere with the proteosome include 
Salinosporamide A, Mycalolide A and acetate agosterol C (Folmer, et al. 2008, 
Macherla, et al. 2005, Tsukamoto, et al. 2003). However the mechanisms of action of 
most of the NFκB inhibitors remain unknown including the isolates Curacin A, 
Ilimaquinone, Verracurin A and Cycloprodigiosin Hydrochloride (Folmer, et al. 
2008). Helenaquinone has been shown to inhibit PI3K, and the sesterterpene 
scalaradial has been shown to impede the phosphorylation of Akt. Akt is 
phosphorylated downstream of PI3K and both have been shown to be potent 
activators of NKκB (Xie, et al. 2005).  
 
The anti-inflammatory potential of bolinaquinone and petrosaspongiolide M were 
assessed by (Busserolles, et al. 2005). Bolinaquinone was acquired from the Dysidea 
species of marine sponge while Petrosaspongiolide was acquired from the 
Petrosaspongia nigra marine sponge. These experiments were performed on mice 
treated with 2,4,6-trinitrobenzenesulphonic acid (TNBS) which induced Crohn’s 
disease like symptoms. After administration with TNBS the size of the colon 
increased due to inflammation. Administration of bolinaquinone and 
petrosaspongiolide decreased the size of the colon.. The level of NFκB expression in 
the nucleus was found to be low after treatment with petrosaspongiolide which shows 
that it must inhibit its translocation to the nucleus by blocking the degradation of 
IκB(Busserolles, et al. 2005). These marine products have so far shown no 
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complications or side-effects which make them a potential candidate in the future 
treatment of inflammatory conditions (Busserolles, et al. 2005). 
 
 
 
Figure 1.11: Diagrammatic representation of the molecular targets of marine compounds 
known to inhibit NFκB activation adapted from (Folmer, et al. 2008) 
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AIMS AND OBJECTIVES  
Although numerous marine natural products have been reported to have 
pharmaceutical activity, relatively few marine compounds have been shown to have 
therapeutic effects in inflammatory disorders. This work aims to identify a novel 
marine compound with anti-inflammatory effects and also to elucidate its molecular 
target. 
 
 To screen crude and fractionated marine extracts to find an individual 
compound showing anti-inflammatory potential, by examining the effects of 
marine extracts on macrophage, DC maturation, migration, phagocytosis, 
cytokine and chemokine production 
 
 To ascertain the possible mechanisms utilized by the marine compound to 
elicit its anti-inflammatory effects in DC, by examining alterations in NFκB 
and IRF-3 downstream of TLR4 
 
 To determine if the marine extract elicits its anti-inflammatory effects by 
interacting with the adaptor molecule, Mal.  
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2.1 MATERIALS 
 
TISSUE CULTURE MATERIALS/REAGENTS 
Materials Source  
Tissue culture flasks T-75 cm2/T-175cm2 Nunc™ 
6.5mm Transwell® plate (8.0 µm pore) Corning Inc. 
Sterile Petri Dishes Nunc™ 
6, 24, 96-well tissue culture plates Nunc™ 
96 round bottom plates Sarstedt 
Dimethyl sulphoxide (DMSO) Sigma® 
OVA Peptide 323-339                                  Genescript Corp 
GMCSF  J558 GMCSF producing cell line 
CCL19 R&D Systems® 
GM-CSF R&D Systems® 
Recombinant IL-2  BD Pharmigen 
Trypan blue (0.4% v/v) Sigma® 
Anti-mouse CD3e monoclonal antibody BD Pharmingen  
Anti-mouse CD28 monoclonal antibody BD Pharmingen 
CellTiter 96® Aqueous One Solution Pierce 
RPMI-1640 Invitrogen™ 
Foetal Calf Serum (FCS) Invitrogen™ 
Penicillin Streptomycin Invitrogen™ 
LPS (E.Coli serotype R515) Alexis Biochemicals 
PGN Invitrogen™ 
PamC3S4 Invitrogen™ 
Poly:IC Invitrogen™ 
Zymosan Invitrogen™ 
Flagellin Invitrogen™ 
CPG Invitrogen™ 
DMEM Invitrogen™ 
LPS (E.Coli serotype R515) Alexis Biochemicals 
Hygrogold Invitrogen™ 
Blasticidin Invitrogen™ 
TABLE 2.1: All tissue culture materials/reagents and corresponding sources. 
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PROTEIN PURIFICATION REAGENTS 
Materials Source 
BCA Protein Assay Pierce 
Potassium Chloride (KCl) Sigma® 
Sodium phosphate dibasic (Na2PHO4) Sigma® 
Dithiothreitol (DTT) Sigma® 
Potassium phosphate (KH2PO4) Sigma® 
Glycerol 99.99 % Sigma® 
Trizma Base Sigma® 
Sodium dodecylsulphate (SDS) Sigma® 
Tween® 20  Sigma® 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma® 
Ammonium persulphate (APS) Sigma® 
Phenylmethanesulfonyl fluoride (PMSF) Sigma® 
Propan-2-ol (isopropanol) VWR International Ltd. 
30 % Acrylamide/Bis solution Bio-Rad 
Sodium Orthovanidate Sigma® 
Leupeptin Sigma® 
Aprotinin Sigma® 
Immobilon Western HRP Substrate Millipore 
Re-Blot Plus Solution (10 X) Millipore 
Ponceau S Solution Sigma® 
Nitrocellulose membranes  Biosciences 
Fuji SuperRX film FujiFilm Ireland Ltd. 
Precision Plus Protein™ Dual Color Standard Bio-Rad 
Nitrocellulose membrane  Biosciences 
TABLE 2.2: All reagents/materials used for protein purification, quantification, western 
blotting, and lysis buffers. 
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WESTERN BLOTTING ANTIBODIES 
Antibody  Source 
Anti-Phospho NFκB-p65 Cell Signalling 
Anti-Phospho-p38 Cell Signalling  
Anti-IκB Cell Signalling 
Anti-Phospho-IRF3 Cell Signalling 
Anti-NFκBp65 (C-21) Santa-Cruz Biotechnology Inc. 
Anti- p38 Cell Signalling 
Anti-βatin Sigma® 
Anti-Phosphotyrosine, clone 4G10 Millipore 
HA-MAL Sigma® 
Anti-mouse IgG peroxidase Sigma® 
Anti-rabbit IgG peroxidase Sigma® 
TABLE 2.3: All antibodies used for western blotting analysis. 
 
 
 
 
ELISAs 
Materials Source 
96-well microtitre plate Nunc™ 
3,3’,5,5’-tetramethyl-benzidine (TMB) Sigma® 
Tween® 20 Sigma® 
Bovine serum albumin (BSA) Sigma® 
DuoSet ELISA kits R&D Systems® 
1X PBS Biosciences 
TABLE 2.4: All ELISA materials/reagents and corresponding sources. 
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FLOW CYTOMETRY 
Antibody Fluorochrome Source Isotype Control Concentration/ 106 cells 
TLR4-MD-2 PE BD RatIgG2a 0.5 µg 
CCR5 PE BD Rat IgG2a 0.5 µg 
CD11c APC Caltag Rat IgG2b 0.5 µg 
CD40 FITC/PE BD Ham IgM 0.5 µg 
CD80 PE BD Ham IgG 0.5 µg 
CD86 FITC BD Rat IgG2a 0.5 µg 
MHCII FITC/PE BD Rat IgG2a 0.5 µg 
TABLE 2.5: Antibodies used for FACs analysis of cell surface markers; suppliers and 
concentrations used. 
 
 
 
 
FACS MACHINE/PREPARATION FACS MACHINE/PREPARATION 
Materials Source 
FACS Flow BD 
FACSRinse BfD 
FACSClean BD 
37% (v/v) paraformaldehyde Sigma® 
TABLE 2.6: Materials/reagents used for flow cytometry and FACS preparation. 
 
 
 
DNA MANIPULATION AND LUCIFERASE ASSAYS 
Materials Source 
geneJuice® Transfection Reagent Novagen® 
QIAprep Spin Maxiprep kit QIAgen© 
10 X Passive Lysis buffer Promega 
TABLE 2.7: Materials used for manipulation of DNA plasmids in transient transfections. 
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2.2 METHODS  
 
PREPARATION OF MAIN BUFFERS/ ELECTROPHORESIS GELS  
Buffer Composition 
10 X Phosphate Buffered Saline (10 X 
PBS) 
8 mM Na2HPO4, 1.5 M KH2PO4, 137 Mm 
NaCl, 2.7 mM KCL, pH 7.4 
PBS-Tween (PBS-T) 1 X PBS with 0.05% Tween® 20 
10 X Tris Buffered Saline (10 X TBS) 20 mM Trizma, 150 mM NaCl pH 7.2 – 7.4 
TBS-Tween (TBS-T) 1 X TBS with 0.05% Tween® 20 
Electrode Running Buffer (10X) 25mM Tris Base, 200mM Glycine, 17mM SDS         
Low Stringency Lysis Buffer 50mM HEPES, 100mM NaCl, 10% glycerol, 0.4% NP40, 1mM EDTA 
Sample Buffer (5X) 
0.5mM Tris-HCL pH 6.8, 10% Glycerol, 
10% SDS, 5% β-mercaptoethanol, 0.05% 
w/v Bromophenol blue 
Separating Gel (12%) 
33% v/v Bisacrylamide (30% stock), 1.5M 
Tris-HCL pH 8.8, 1% w/v SDS, 1% 
w/vAmmonium persulphate, dH2O, 0.1% 
TEMED  
Stacking Gel 
6.5% v/v Bisacrylamide (30% stock), 
0.5M Tris-HCL pH 6.8 1% w/v SDS, 1% 
w/vAmmonium persulphate, dH2O, 0.1% 
TEMED 
 
TABLE 2.8: Composition of most commonly used buffers. 
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2.3 CELL CULTURE 
All tissue culture was carried out using aseptic techniques in a class II laminar airflow 
unit (Holten 2010- ThermoElectron Corporation, OH, USA). Cells were maintained in 
a 37°C incubator with 5% CO2 and 95% humidified air (Model381- ThermoElectron 
Corporation, OH, USA).Cells were grown in complete RPMI-1640 medium as 
indicated in Appendix A. FCS was heat inactivated (56°C for 30mins) to order to 
inactivate complement and then aliquoted for storage at -20°C. Supplemented 
medium was stored at 4°C. 
2.3.1 CELL ENUMERATION AND VIABILITY ASSESSMENT 
Cell viability was assessed using the trypan blue dye exclusion test. This test is based 
on the principle that live cells possess intact cell membranes that exclude certain dyes 
were as dead cells are unable to exclude the dye and appear blue when viewed under a 
microscope. 100µl of cell suspension was mixed with 150µl PBS and 250µl trypan 
blue solution (0.4% (v/v)). After ~2mins cells were applied to a brightline 
haemocytometer (Sigma®) and examined under high power magnification (x40) 
using an inverted microscope (Olympus CKX31, Olympus Corporation, Tokyo, 
Japan). Cells inside the central grid were counted [see Figure 2.1]. 
 
A viable cell count was determined using the following formula: Cell/ml= N x 5 x 104 
Where, N= average cell number counted, 5 = dilution factor, and 104 = constant. 
 
FIGURE 2.1: Diagrammatic Representation of haemocytometer used to count cells 
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2.3.2 MURINE MACROPHAGE CELL LINE J774 
The murine macrophage cell line J774A.1 was used in this study and is referred to 
solely as J774 throughout. The J774 cell line was purchased from the European 
Collection of Cell Cultures (ECACC). J774A.1 cells were maintained in complete 
RPMI-1640 [see Appendix] in 75 cm2 flasks. Cell monolayers were passaged at a 
confluency of 80 % (every 3 to 4 days). Cells were detached by gentle tapping and 
transferred to a 50 ml falcon. Cells were spun at 1200 rpm for 5 min and supernatant 
discarded. Cells were resuspended in 10 ml of complete RPMI-1640. Each 75 cm2 
flask yielded approximately 20 x 106 cells. For subculture, cells were split 1 in 10 into 
25 ml complete RPMI-1640 in a fresh 75 cm2 flask. For experiments cells were 
counted as described [see section 2.2.1]. 
2.3.3 HUMAN EMBRYONIC KIDNEY CELL LINES HEK293 
 
Human embryonic kidney cell line HEK293 stably transfected with TLR4, CD14 and 
MD-2, (HEK293-MTC) were a kind gift from Prof. Luke O’Neill, School of 
Biochemistry, Trinity College Dublin. The HEK293-MTC cell line was cultured with 
appropriately supplemented complete DMEM media [see Appendix]. Cells were 
cultured in 175 cm2
 
flasks as follows; HEK-MTC: complete DMEM supplemented 
with 50 µg/ml Hygrogold and 1 µg/ml Blasticidin to maintain expression of TLR4, 
CD14 and MD-2. Cells were passaged every 3 to 4 days based on confluency. For 
subculture, the media was removed from the flasks and cells washed twice with 5 ml 
ice cold sterile PBS (Invitrogen™). Following this cells were removed from the 
surface of the flasks by incubating them with 2 ml of 1 X Trypsin solution (Sigma®) 
for 5 min at 37 °C. 10 ml of complete media was then added to resuspend cells and 
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cells were spun at 1200 rpm for 5 min. Finally cells were resuspended in media, 
subcultured or counted for experiments. 
2.3.4 PREPARATION OF CELL STOCKS 
Cells were grown to a state of sub-confluency and were harvested and counted as 
previously described in section 2.3.1-2.3.3. Cells were removed from culture as 
appropriate and resuspended in 1 ml cryoprotectant (10 % (v/v) dimethylsulphoxide 
(DMSO), 40 % (v/v) FCS and 50% RPMI) and transferred to labelled and dated 
cryovials (Nalgene®, Cryoware). These aliquots are placed at -20ºC for 2 hrs and then 
at -80ºC for 3 hrs before being stored in a liquid nitrogen vessel. 
2.3.5 REVIVAL OF FROZEN STOCKS 
Cryovials were carefully removed from liquid nitrogen tank and quickly thawed in a 
37 °C water bath. Thawed cells were transferred to 10 ml RPMI on ice and carefully 
resuspended. Cells were spun at 1200 rpm for 5 min to remove excess DMSO. 
Following this supernatant was discarded and cells resuspended in 10 ml of room 
temp RPMI. Cells were spun again and a third wash carried out using 37 °C RPMI. 
After the final wash cells were resuspended in 1 ml of the appropriate medium and 
transferred to a 75 cm2 flask with appropriately supplemented media [see Appendix]. 
2.3.6  ISOLATION OF BONE MARROW-DERIVED DENDRITIC CELLS 
2.3.6.1  DAY 1 - BONE MARROW HARVEST 
Bone marrow from the tibiae and femurs of BALB/C mice was extracted by flushing 
RPMI through the bones using a syringe and a 27.5g needle into a sterile petri dish. 
The bone marrow was then broken up using a syringe and a 19.5g needle and then 
transferred to a 50ml falcon. Cells were centrifuged for 5 mins at 1200 rpm, 
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supernatant removed and the bone marrow cells were resuspended in RPMI to allow 
1ml of cells per petri dish required. A cell count was preformed using the trypan blue 
exclusion method to make certain an adequate number of viable cells had been 
obtained. 9mls of RPMI supplemented with GMCSF and 1ml of cells were added to 
each petri dish. The cells were incubated at 37°C. 
2.3.6.2  DAY 4 – FEEDING CELLS 
Petri dishes were tilted slightly so the cell monolayer was easily visible, and using a 
transfer pipette approximately 6-7mls of media was removed. 10mls of pre-warmed 
RPMI supplemented with GMCSF was then added gently to each petri dish. Cells 
were incubated at 37°C. 
2.3.6.3  DAY 7 – COUNTING AND PLATING CELLS 
To remove semi-detached and therefore immature dendritic cells, the cells were 
scraped using cell scrapers and media was collected using transfer pipettes and 
transferred to a 50ml falcon. Each petri dish was examined under the microscope to 
verify that the majority of the cells were removed. Falcons were spun at 1200rpm for 
5mins, supernatant removed and the cells were resuspended in RPMI and then 
counted using the trypan blue exclusion method. The cell concentration was adjusted 
with RPMI – generally cells were plated at 1x106 cells/ml. 
2.3.7 CULTURE OF THE J558 GMCSF-SECRETING CELL LINE 
 
The mouse gene for GMCSF (granulocyte macrophage colony stimulating factor) was 
cloned into a mammalian expression vector (Karasuyama, Kudo and Melchers 1990) 
and transfected into the plasmacytoma line X63-AgS.  Cell stocks were kindly 
donated by Professor Kingston Mills (Trinity College, Dublin). 
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After removal from liquid nitrogen and rapid thawing, cells were washed in 30mls 
cRPMI, then resuspended in 5mls of selection medium consisting of 1mg/ml G418 
Geneticin (GibcoBRL) in complete RPMI for 2 passages.  Cells were seeded at 1x106 
cells/ml each time and culture flasks stood upright in the incubator.  After the second 
passage cells were washed twice in cRPMI, counted and seeded in cRPMI at 1x106 
cells/ml.  When cells reached a medium density they were subsequently seeded at 
2.5x105 cells/ml at each passage.  Up to and including passage 9, supernatant was 
collected from the J558 cells and the amount of secreted GMCSF quantified by 
ELISA (R&D).  For bone marrow culture, GMCSF was used at a concentration of 
40ng/ml.   
2.3.8  MARINE EXTRACTS 
Marine extracts were received from UCD and dissolved in DMSO. Stability tests were 
carried out to ensure the optimum storage temperature for these extracts. The marine 
extracts were stored at 4ºC and -20ºC and cytokine analysis of the extracts confirmed 
that they are stable at both 4ºC and -20ºC. Therefore marine extracts were aliquoted 
and stored at 4ºC.  Marine extracts were added on day 7 of culture. On day 7 of 
culture the cells were treated with a vehicle control (DMSO), or the marine extracts, 
Alcyonium digitia and Membranipora membranacea at a range of different dilutions 
(1:100, 1:1000, 1:10000) 1 hr prior to activation with TLR ligand.  
 
2.3.8.1 FRACTIONATION AND PURIFICATION OF MARINE EXTRACTS  
 
Initial extractions from Membranipora membranacea and Alyconium digitia crude 
extracts were carried out based on compound polarity and a series of fractionations 
were performed with an equal quantity of sample in each fractionation using a 
different solvent. The solvents chosen were used to represent the spectrum of polarity 
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from polar to non-polar (pentane, DCM and methanol). The extracts were stirred in 
these solvents for 24-48 hours before the solvents were filtered and evaporated to 
leave a mix of fractionated compounds. These mixes were then tested for activity, and 
the most active fractions underwent a second round of fractionation. This round of 
fractionation used a new selection of solvents (cyclohexane and ethanol) which were 
chosen based on the solvent which gave the most active mix in the first round of 
fractionation. The mixing, filtration, evaporation and testing were carried out again 
until the highest solvent extraction system – bioactivity relationship has been reached.   
 
Once satisfied with the solvent extraction system, further purification step took place, 
based on the properties of the compound mixture; column chromatography was 
chosen as the method to purify the compounds. This purification step led to the 
isolation of the pure compound INV013. INV013 was then submitted for a large array 
of spectroscopic tests in order to identify the structure of the compound. 
2.3.9 TOLL-LIKE RECEPTOR ACTIVATION 
Cells were activated with TLR ligands which are outlined in Table 2.9, and incubated 
for 24 hrs before being used in the relevant assays. 
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TLR 
TLR 
Ligand 
Stock 
Concentration 
Working 
Concentration 
2/1 PamC3S4 1 mg/ml  1.0 µg/ml 
2/6 Zymosan 1 mg/ml 10 µg/ml 
3 Poly:(IC) 1mg/ml  10 µg/ml 
4 LPS 1 mg/ml 100 ng/ml 
5 Flagellin 100 ug/ml 5.0 µg/ml 
7 Loxoribine 10 mM 1mM 
9 CPG 500uM 2µM 
 
2.3.10 ADDITION OF OVA PEPTIDE (323-339) 
The OVA peptide sequence is given below and represents a T and B cell epitope of 
OVA:  ISQAVHAAHAEINEAGR [C74H120N26O25: MW 1773.9] 
1g vials of lyophilized OVA peptide were kept at -20°C and dissolved in 1ml of 
sterile water to give a 1mg/ml stock which was also kept at -20°C. OVA was added to 
DCs at 5µg/ml for 24 hrs before use in the co-culture experiments. 
2.3.11 CYTOTOXICITY ASSAY FOR MARINE EXTRACT DOSE 
RESPONSE 
 
The CellTiter 96® Aqueous One Solution (Promega) is a colorimetric method for 
determining the number of viable cells in a sample. It contains an MTS tetrazolium 
compound (Owen’s reagent) which is bioreduced by cells into a soluble coloured 
formazan product. The quantity of formazan product is measured at an absorbance 
reading of 450nm and is directly proportional to the number of living cells in the 
culture medium. Bone marrow-derived dendritic cells were cultured for 7 days. On 
TABLE 2.9: Concentrations of the TLR ligands used for the activation of dendritic 
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day 7 cells were collected, counted and plated in a 96- well plate with 100µl per well 
at 1x106 cells/ml. Marine extracts were then added at different dilutions (1:100, 
1:1000, 1:10,000) 1 hr prior to stimulation with LPS (100ng/ml). 24 hrs after the 
addition of LPS, 20µl of the CellTiter 96® Aqueous One Solution was added to each 
well of the 96-well plate. The plates were incubated for 2 hrs at 37°C in 5% CO2 and 
absorbance read at 490nm. The cell viability of each sample was calculated by 
treating the absorbance of the vehicle control, DMSO as 100% and comparing the 
remaining samples to this and expressing results as percentage viability. 
 
The CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) is an alternative 
colorimetric cytotoxicity assays that we used in the study to assess the viability of 
cells following treatment with marine extracts. The CytoTox 96® Assay 
quantitatively measures lactate dehydrogenase (LDH), a stable cytosolic enzyme that 
is released upon cell lysis. Released LDH in culture supernatants is measured with a 
30-minute coupled enzymatic assay that results in the conversion of a tetrazolium salt 
(INT) into a red formazan product. The quantity of formazan product is measured at 
an absorbance reading of 450nm and is directly proportional to the number of living 
cells in the culture medium. HEK293-MTC cells were counted and plated in a 96- 
well plate with 100µl per well at 1x105 cells/ml. Marine extracts were then added at 
different dilutions (1:100, 1:1000, 1:10,000) 1 hr prior to stimulation with LPS 
(100ng/ml). 24 hrs after the addition of LPS, cells were lysed with 10X lysis solution 
to Target Cell Maximum LDH Release Control and then centrifuged at 250 x g for 4 
mins. 50µl of 1:5000 dilution of LDH positive control was added to separate wells 
and 50µl of substrate mix was then added to each well. The plate was then incubated 
for 30 mins in the dark at room temperature. Following this incubation 50µl of stop 
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solution was added to each well and absorbance read at 490nm. The cell viability of 
each sample was calculated by treating the absorbance of the vehicle control, DMSO 
as 100% and comparing the remaining samples to this and expressing results as 
percentage viability 
2.3.12  CD4+ T CELL ISOLATION 
2.3.12.1 ERYTHROCYTE LYSIS  
(R&D Systems - mouse erythrocyte lysing kit WL2000) 
Spleens were removed aseptically and collected in HBSS/10% FCS on ice.  A single 
cell suspension was achieved by pushing each spleen through a cell strainer (40µm, 
BD falcon).  Cells were then washed in HBSS/10% FCS and erythrocytes lysed by 
adding a 1x solution of M-lyse for approximately 10 minutes at room temperature 
(2ml of 1x solution per spleen).  Following incubation, cells were vortexed for 2 
seconds.  40ml of wash buffer was then added and the cells centrifuged and 
resuspended in 2ml of 1x column wash before being counted and adjusted to ≤ 2x108 
cells/ml. 
2.3.12.2 CD4+ T CELL ISOLATION 
(R&D Systems - Mouse T cell CD4 Subset Column Kit MCD4C-1000) 
≤ 2x108 of cells (in 2ml of column wash) was mixed with 1 vial of monoclonal 
antibody cocktail (1ml CD4+ enrichment cocktail) and incubated at room temperature 
for 15 minutes.  During this incubation period the column was washed with 10ml of 
column buffer. After incubation, cells were washed twice with 10mls of 1x column 
wash and finally resuspended in 1ml column wash.  The cells were added to the 
column and any liquid displaced from the column collected in a sterile falcon tube.  
Once the cells had moved onto the column, the bottom cap was replaced and the cells 
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left in the column at room temperature for 10 minutes. This allowed B cells, non-
selected T cells and monocytes to bind to the glass beads coated with anti-
immunoglobin via both F(ab) and Fc interactions.  The column was eluted with 10mls 
of column buffer.  Eluted and therefore CD4 positive T cells were centrifuged (250g 
for 5 minutes), resuspended in cRPMI, and counted using the trypan blue exclusion 
method.  Cells were adjusted to the required concentration with cRPMI. 
2.3.13   DC-T CELL CO-CULTURE 
Dendritic cells were grown as previously described for 7 days.  At this time (i.e., 24 
hrs prior to commencement of the co-culture experiment) cells were treated with the 
M.membrancea for 1 hr prior to activation with OVA peptide (5µg/ml).  The cells 
were incubated for a further 24 hrs at 37oC in 5% CO2.  After 24 hrs, DCs were 
collected and washed twice in sterile PBS/2%FCS to remove any traces of RPMI 
before being irradiated.  DC were irradiated with 40Gy (4000rads) using a gamma 
irradiator with a Caesium-137 source. Irradiation of DCs is necessary to terminate DC 
maturation. Cells were then counted and resuspended in cRPMI at a final 
concentration of 2x105cells/ml. 
 
CD4+ T cells were isolated from the spleens of OVA transgenic D011.10 mice as 
described in section 2.3.12.  A large portion of the T lymphocytes from these mice 
express a TCR specific for a peptide within the ovalbumin (OVA) molecule (OVA 
(323-339)).  When this antigen is presented by DCs complexed to MHCII (together 
with costimulation), these naive CD4+ T cells become activated and proliferate 
(Pompos and Fritsche 2002) 
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Following purification, OVA transgenic CD4+ T cells were adjusted to 2x106cells/ml.  
Equal volumes of T cells and DCs were added to a sterile 96-well plate to give a final 
volume of 200µl/well.  Plates were incubated at 37oC in 5% CO2 for 5 days.  On day 5 
of the co-culture, plates were centrifugally pulsed to move cells to the bottom of the 
wells.  200µl of fresh media was added to each well and plates were incubated at 37oC 
in 5% CO2 until day 7. 
 
On day 7 of the co-culture, plates were again pulsed before 100µl of media was 
removed.  100µl of newly harvested OVA-activated DCs pre-treated with 
M.membrancea were added at a concentration of 2x105cells/ml for the second round 
of T cell stimulation.  Recombinant murine IL-2 (Becton Dickinson) was also added 
at this time (10U/ml).  At the end-point of the co-culture experiment (day 10), 200µl 
of media was removed after plates were pulsed and the supernatant frozen for future 
cytokine analysis. 
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2.4 FLOW CYTOMETRY 
Flow cytometry is a means of quantitating structural features of cells by optical 
means. By using up to 4 different fluorescently tagged markers different 
characteristics can be measured at the same time in one mixture. Cells containing the 
desired features are measured individually and then aggregated. The FACScan™ 
system can process thousands of cells in seconds.  
2.4.1 CELL SURFACE MARKER STAINING 
 
DCs were cultured for 7 days as previously described in (see section 2.3.6). Cells 
were then plated at a concentration of 1x106 cells/ml into a 6-well plate (2ml/well). 
Cells were treated with the marine extract 1 hr prior to stimulation with LPS 
(100ng/ml) and incubated at 37°C in 5% CO2 for 24 hrs. Following incubation, cells 
were scraped using cells scrapers and collected in falcon tubes. An equal volume of 
FCS was added for 15 minutes to prevent non-specific binding. Tubes were then spun 
at 1200rpm for 5 mins and cells resuspended in 1ml of FACs buffer [see Appendix]. 
200µl of cells were added to a 96-well round bottom plate to give approximately 
400,000 cells/well. One well per treatment group (i.e., each marine extract treatment 
+/- LPS) was assigned for each antibody group and one well for each corresponding 
isotype control group- [see Table 2.5]. 
 
Plates were spun at 2000rpm for 10 mins and supernatant carefully removed from the 
wells. 100µl of the correct antibody and isotype was added to the appropriate wells.  
Plates were incubated for 30 mins in the dark at 4°C. Following incubation, plates 
were spun at 2000rpm for 10mins. Cells were washed twice by resuspending in 200µl 
of FACs buffer and were then fixed in 200µl of 4% formaldehyde/PBS before being 
 76 
transferred to labelled FACs tubes. Samples were acquired immediately or left 
overnight at 4°C in the dark. 30,000 events were acquired per sample using a 4-colour 
FACS Calibur (fluorescence activated cell sorter) Becton Dickson (BD). Data was 
analysed using CellQuest software and samples gated on CD11c+ cells for DC 
samples to ensure histograms and dot plots represented pure cell populations. 
2.4.2 PHAGOCYTOSIS ASSAY 
 
J774 macrophage were cultured as described [see section 2.3.7]. 5 x 105 cells were 
plated onto 6 well plates in a total volume of 2 ml/well and left to rest overnight at 37 
ºC. The next day cells were treated with DMSO (vehicle control) or marine extracts 
1hr prior to activation with LPS (100ng/ml) or loxoribine (1mM). On the third day, to 
investigate phagocytosis 2.5 µl of flourescently labelled latex beads were added at a 
concentration of 1 x 106 beads/µl for a period of 0, 2, 4, 6, 12 and 24 h. Following this 
media was removed and each well washed twice with ice cold PBS. Cells were then 
scraped and transferred to 15 ml falcons. Cells were spun at 1200 rpm for 5 min and 
resuspended in 200 µl 4% (v/v) paraformaldehyde/PBS. Phagocytosis of latex beads 
was assessed by flow cytometry on BD FACSCalibur™. Note: latex beads were 
sourced from Sigma® and were 1 µm in diameter.  
2.4.3  CHEMOTAXIS ASSAY 
Bone marrow-generated DC were cultured for 7 days as described in [see section 
2.3.6]. Cells were counted and plated at a concentration of 1x106 cells/ml in a 6 well 
plate (3mls/well). Marine extract was then added to each required well 1 hr prior to 
stimulation with LPS (100ng/ml) or loxoribine (1mM). Cells were incubated at 37°C 
for 24 hrs. Following incubation, cells were removed from wells using a transfer 
pipette and counted. Transwell® plates were used in accordance with the 
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manufacturer’s instructions; 3x105 cells were added to the insert well in 100µl of 
media, and 600µl of media supplemented with or without the chemokine CCL19 
(100ng/ml) for DCs and GM-CSF (10 ng/ml) and IL-2 (10 BRMP/ml; where 1 BRMP 
= 40 pg/ml) for macrophages, was added to the bottom chambers- see Figure 2.2. 
Plates were incubated for 5 hrs at 37°C. Cells that had migrated to the bottom 
chamber were collected and transferred to eppendorf tubes, spun and resuspended in 
4% formaldehyde/PBS before being transferred to FACS tubes. Migrated cells were 
counted for 60 seconds on a BD FACsCalibur. 
 
 
 
FIGURE 2.2: Diagrammatic representation of Chemotaxis Assay Transwell™. Schematic 
taken from Transwell® Permeable Supports Selection and Use Guide, Corning. 
 
 
 
 
 
 
 
 
 
3x105 cells  
CCL19 (100ng/ml) – DCs 
GM-CSF (10ng/ml)/IL-2BRPM/ml -- MØ 
Transwell® Insert 
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2.5 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA) 
The concentration of cytokines IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, 
IL-17, IL-23, TNF-α, IFN-γ, IFN-β and chemokines MIP-1α, MIP-2, MCP-1 and 
Rantes in cell supernatants was established using ELISA Duoset kits from R&D 
Systems in accordance with the manufacturer’s instructions. A diagrammatic 
representation of the principles of a sandwich ELISA are shown in Figure 2.3 
 
.   
FIGURE 2.3: Schematic representation of sandwhich ELISA. Schematic taken from ELISA 
Kit Technology Principals on www.epitomics.com. 
 
2.5.1 IL-6, IL-10, IL-12p40, IL-12p70, IL-23, TNF-α ELISA 
 
                        96- well NuncTM microtitre plates were coated with 50µl of the appropriate capture 
antibody diluted to working concentration in PBS [see Table 2.10] and incubated 
overnight at room temperature. Following overnight incubation, plates were washed 3 
times with was buffer (PBS/0.05% Tween®) before wells were blocked with 300µl of 
reagent diluent (PBS/1% BSA) for at minimum of 1 hr at room temperature. After 
repeating the washing step, 25µl of reagent diluent and 25µl of supernatant or serially 
diluted standards (top standard serially diluted x6 in reagent diluent- see table 2.10) 
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were added to wells in duplicate, and plates were incubated overnight at 4ºC. The 
following day plates were washed x3 with wash buffer. 50µl of the appropriate 
biotinylated detection antibody, diluted in reagent diluent- [see Table 2.10], was 
added to each well and plates were incubated at room temperature for 2 hrs. Plates 
were washed x3 with wash buffer and 50µl of streptavidin-HRP (1:200 dilution in 
reagent diluent) was added to each well. Plates were incubated for 20 mins at room 
temperature. Finally, wells were washed x3 with wash buffer and 100µl of TMB 
(Sigma Aldrich) was added to each well and plates were then incubated in the dark. 
Once the colour had developed sufficiently plates were stopped by adding 25µl of 2N 
H2SO4 per well. Optical densities were read immediately at 450nm on VERSA Amax 
microplate reader (Molecular devices, CA, USA). The cytokine/chemokine 
concentrations in the supernatants were determined from the standard curves. 
2.5.2 IL-1β 
The method above was followed with two variations: 
Blocking buffer used was 1%BSA/PBS + 0.05% NaN3 and the reagent diluent was 
0.1%BSA/TBS + 0.05% Tween. 
2.5.3 IL-12p40, IL-6 
Samples were diluted 1:100 in reagent diluent and 50µl of diluted samples and 
undiluted standards were added to the plates in duplicate. Concentrations of samples 
were multiplied by the dilution factor once calculated from the standard curve. 
2.5.4 TNF-α 
Samples were diluted 1:10 in reagent diluent and 50µl of diluted sample and undiluted 
standards were added to the plates in duplicate. Concentrations of samples were were 
multiplied by the dilution factor once calculated from the standard curve. 
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Cytokine 
Capture Antibody 
(µg/ml) 
Top Standard 
(pg/ml) 
Detection Antibody 
(ng/ml) 
IL-1β 4.0 1000 400 
IL-4 4.0 1000 600 
IL-6 2.0 1000 200 
IL-8 4.0 2000 20 
IL-10 4.0 2000 500 
IL-12p40 4.0 2000 400 
IL-12p70 4.0 2500 400 
IL-17 2.0 1000 400 
IL-23 4.0 2500 200 
TNF-α 0.8 2000 75 
IFN-γ 4.0 2000 800 
Chemokine 
Capture Antibody 
(µg/ml) 
Top Standard 
(pg/ml) 
Detection Antibody 
(ng/ml) 
MCP 0.2 250 50 
MIP-1α 0.4 1000 100 
MIP-2 2.0 500 75 
Rantes 2.0 2000 400 
TABLE 2.10: Concentration of standards, capture and detection antibodies used in sandwich 
ELISA assays. 
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2.6 WESTERN BLOT ANALYSIS 
2.6.1 PREPARATION OF WHOLE CELL LYSATES  
Cells were seeded at 1 x 106 cell/ml in a 6-well plate (2 ml/well) and left to rest 
overnight. Cells were then treated with marine extract 1 hr prior to stimulation with 
LPS (100ng/ml) or loxoribine (1mM). Following activation, cells were washed with 
PBS and scraped in 100µl of low stringency lysis buffer-see Table 2.8. Protease and 
phophatase inhibitor were added just before use as follows: 1 µg/ml aprotinin, 1 
µg/ml leupeptin, 100 µM sodium orthovanidate and 0.5 M PMSF. Cells were then 
incubated on ice for 30 mins. Following this incubation period samples were 
centrifuged at 13,000 x g for 5 mins at 4ºC. The protein concentration of the samples 
were then determined using Bradford assay see section and aliquots containing equal 
amounts of protein were mixed with 5X SDS sample buffer, before loading on gels 
samples were boiled at 95 oC for 5 min to denature proteins. 
2.6.2 DENATURING POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE) 
 
Proteins were fractionated by SDS denaturing polyacrylamide gel electrophoresis 
(SDS PAGE).  Acrylamide gels (12 %) [see Appendix] were cast between two glass 
plates and affixed to the electrophoresis unit using spring clamps. Electrode running 
buffer [see Appendix] was added to the upper and lower reservoirs.  20µl of prepared 
samples were loaded into the wells and run at 30 mA per gel for approximately 45 
minutes.  Pre-stained protein molecular weight markers (Bio-Rad laboratories) 
ranging from 10 – 250 kDa were added to the first lane in each gel. 
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2.6.3 TRANSFER OF PROTEINS TO MEMBRANE   
The resolved proteins were quantitatively transferred to nitrocellulose membranes 
using the iBlot® Dry Blotting System (Invitrogen™). The iBlot® efficiently and 
reliably blots proteins from polyacrylamide gels in 7 min without the need for 
additional buffers or an external power supply in a self-contained unit. Following 
transfer, the nitrocellulose membrane was removed and processed for 
immunoblotting. 
2.6.4 IMMUNODETECTION AND DEVELOPMENT 
Following transfer, membranes were blocked for non-specific binding by incubation 
with freshly prepared blocking buffer, 5 % (w/v) non-fat dried skimmed milk/TBS-T 
[see Table 2.11] for 1 h on a slow rocker at room temperature. The membranes were 
then washed for 5 mins in TBS-T (wash buffer) three times. The membrane was then 
incubated with appropriate primary antibodies diluted in TBS/5% dried milk or BSA 
/0.05% Tween 20® (reagent diluent). Membranes were gently agitated with the 
primary antibodies overnight at 4 ºC.  Following overnight incubation, membranes 
were washed four times for 5 min in wash buffer. Membranes were then incubated 
with the appropriate secondary antibodies (horseradish peroxidase (HRP) conjugated 
secondary antibody) [see Table 2.11] and incubated with gentle agitation at room 
temperature for 2 h. Following incubation with secondary antibody, membranes were 
washed four times for 5 min with washing buffer.  
HRP-labelled antibody complexes were visualised using enhanced 
chemiluminescence (ECL). Membranes were incubated for 5 minutes in 3 ml of 
Immobilon Western HRP Substrate (Millipore).  Excess substrate was decanted and 
the membrane placed between acetate sheets and immediately exposed to FujiFilm 
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SuperRX film in a dark room under red light.  The film was developed using a film 
Hyperprocessor (Amersham Pharmacia Biotech).  Exposure times varied depending 
on the concentration of protein used and the intensity of signals obtained. In general 
exposure times varied between 15 sec to 5 min. The density of resultant bands was 
calculated using the densitometry program on the Syngene gel analysis and 
documentation system (Syngene NJ USA). 
2.6.5 STRIPPING AND RE-PROBING MEMBRANES 
 
To reprobe membranes, antibody complexes were removed by incubating membranes 
in 10 ml 1 X Re-Blot Plus Solution and was made according to manufacturers’ 
instructions (Millipore) for 10 min with gentle agitation. Following this membranes 
were washed in 5 ml of blocking buffer three times for 5 min to remove excess 
stripping solution. At this point membranes were either re-probed with antibodies or 
stored in TBS-T at 4 °C for later use.   
1° ANTIBODY DILUTION 2° ANTIBODY DILUTION 
NFκB p65    
Phospho-IRF3    
Phospho-P38    
IκB 
Total NFκBp65 
Total P38 
   
Phospho tryosine 1:1000  1:2000 
HA-Mal 1:1000    1:2000 
βactin 1:10000  1:20000 
TABLE 2.11: Dilution of primary and secondary antibodies for western blotting. 
 
1:1000 
 
 
 
α-rabbit IgG- 
HRP 
 
1:2000 
 
α-mouse 
IgG- HRP 
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2.7 DNA MANIPULATION 
2.7.1 DNA TRANSFORMATION INTO BACTERIA 
Chemically competent DH5α E. coli cells and cloned DNA were generated by Kathy 
Banahan (Biochemistry, Trinity College Dublin). For transformation cells were 
thawed on ice after which, ligated DNA (5-10 µl) was added, mixed gently to ensure 
the cells were evenly suspended and left for 5 min on ice. The cells were heat shocked 
in a water bath at 42 ºC for exactly 2 min and then cooled on ice for a further 2 min. 
As ligation DNA contained an ampicillin cassette for transformation, cells were plated 
onto selective LB agar plates containing 100µg/ml ampicillin and grown for 16-18 hrs 
at 37 ºC.  Transformed cells were then single colony purified and used to purify 
plasmids for transfection.  
2.7.2 PURIFICATION OF PLASMID DNA FROM BACTERIA 
To prepare milligram quantities of plasmid DNA an individual quantity of plasmid 
transformed bacteria was inoculated into 4 ml LB broth for 6 h. This starter culture 
was then used to inoculate a 500 ml LB broth supplemented with 100 µg/ml 
ampicillin and grown overnight at 37 °C in a shaking incubator. Bacterial cells were 
harvested by centrifugation at 300 rpm for 15 min at 4 °C. Milligram quantities of 
plasmid DNA were purified using a QIAprep Spin Maxiprep kit according to 
manufacturers’ instructions. The DNA was quantified using a NanoDrop3300. Stocks 
were stored at 4 ºC and used for transient transfection of HEK293 cell line. A 500 ml 
culture typically yielded 1 – 3 mg/ml of plasmid DNA. Glycerol stocks were made by 
aseptically mixing 930µl bacterial culture and 70µl of DMSO and storing at -80ºC. 
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2.7.3  TRANSIENT TRANSFECTION USING GENEJUICE® 
GeneJuice® (Novagene) transfection reagent is a liposomal based transfection reagent 
from Novagen and is used for the transfection of HEK293 cells. The ISRE luciferase 
plasmid, NFκB luciferase plasmid, Renilla luciferase plasmid and empty pcDNA3.1 
vector (Invitrogen™) were kind gifts from Prof. Luke O’Neill, School of 
Biochemistry, Trinity College Dublin. For 96 well plate transfections, HEK-MTC 
cells were seeded at at 4 x 105 cell/ml with a total volume of 200µl. Cells were 
incubated overnight and transfected the following day using geneJuice®  transfection 
reagent according to the manufacturers’ instructions.  Cells were transfected in 
triplicate. For ISRE/NFκB luciferase assays, 75 ng of ISRE/NFκB luciferase plasmid, 
30 ng of Renilla luciferase, and 115 ng empty pcDNA3.1 vector made up to a total of 
220 ng of DNA were transfected into each well of a 96-well plate.  For both ISRE and 
NFκB luciferase assays cells were harvested 24hrs following transfection.  
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2.8  LUCIFERASE REPORTER GENE ASSAY  
HEK293-MTC cells were transfected in 96 well plates as described in section 2.7.3. 
Following 24hr transfection cells were treated with marine extract 1hr prior to 
stimulation with 100ng/ml of LPS. Media was then aspirated from each well and cells 
were lysed for 15 min on a rocking platform at room temperature with 50µl of 1 X 
Passive Lysis Buffer (Promega, Southampton, UK). 
2.8.1  MEASUREMENT OF LUCIFERASE ACTIVITY 
Firefly luciferase activity was assayed by the addition of 40 µl of luciferase assay mix 
(20 mM Tricine, 1.07 mM (MgCO3)4Mg(OH)2·5H2O, 2.67 MgSO4, 0.1 M EDTA, 
33.3 mM DTT, 270 mM coenzyme A, 470 mM luciferin, 530 mM ATP) to the sample 
and Renilla luciferase was read by the addition of 40 µl of a 1:1000 dilution of 
Coelentrazine (Argus Fine Chemicals) in PBS to 20 µl of lysed sample. Luminescence 
was read using a Reporter microplate luminometer (Turner Designs). Firefly 
luminescence readings were corrected for Renilla activity and expressed as fold 
stimulation over unstimulated empty vetor (EV) control.  
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2.9  IMMUNOPRECIPATION  
HEK293-MTC cells were cultured into 10cm dishes (1x105 cells/ml) 24hr prior to 
transfection. Transfections were carried out using Genejuice® Transfection Reagent 
(Novagen) as previously described in section 2.7.3. 4µg of Mal construct was 
tranfected and after 24hr transfection cells were treated with marine extract 1 hr prior 
to stimulation with LPS (100ng/ml). The cells were washed in 5mls of PBS and then 
scraped in 850µl of low stringency lysis buffer. Cells were then incubated on ice for 
30 mins. Following this incubation period samples were centrifuged at 13,000 x g for 
5 mins at 4ºC.  Protein concentrations of the supernatant were determined by Bradford 
assay and lysates containing equal protein were added to 30ul of protein A/G 
sepharose beads. 1ug of relevant antibodies (HA-Mal) was then added and the 
samples were incubated for 2h at 4ºC with gentle rotation. A portion of the lysate was 
retained to confirm that the protein of interest was expressed, this was added to 
sample buffer and boiled for 5 mins. Following the 2 hr incubation the immune 
complexes were spun at 2300rpm and then washed three times with 1ml lysis buffer. 
All supernatants were aspirated off and beads were resuspended in 60µl of 5X sample 
buffer. The samples were boiled for 5 mins and SDS-PAGE analysis were preformed 
on the precipitated complexes as described in section 2.6.2-2.6.4.  
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2.10 STATISICAL ANALYSIS  
One-way analysis of variance (ANOVA) was used to determine significant 
differences between conditions.  When this indicated significance (p<0.05), post-hoc 
Student-Newmann-Keul test was used to determine which conditions were 
significantly different from each other. There was no significant difference between 
cells alone and DMSO (vehicle control) treated cells, therefore DMSO was used as 
the reference treatment.  
 
The luciferase and immunoprecipitaions experiments in chapter 5 represented 
by figure 5.23 - 5.25  and figure 5.30, respectively were carried out in conjunction 
with Dr. Jennifer Dowling in the Biochemistry Group in TCD.  
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3.1 INTRODUCTION 
The ocean is a major source of organisms with a diverse range of biological materials 
which may be a source of novel compounds with promising therapeutic applications. 
To date only a limited portion of the oceans biodiversity has been explored which 
suggests that there is still enormous potential which has not yet been uncovered. 
Compounds isolated from marine species have received much attention recently as 
studies have shown that marine compounds have beneficial effects. These molecules 
and compounds have come from a variety of marine species including sponges, algae, 
sea slugs and marine bacteria (Haefner 2003, Schwartsmann, et al. 2003)and have 
been shown  to offer some protection against tumour progression and the development 
of autoimmune diseases (Jean, et al. 2008, Taddei, et al. 2006). In addition they have 
been shown to possess anti-viral and anti-bacterial activities (Haefner 2003). The 
prevalence of inflammatory diseases such as RA is increasing and current treatments 
for these diseases are not entirely efficacious and are associated with severe side 
effects. Therefore there is a huge need for new treatments that combat these diseases. 
This study aimed to screen a range of marine species to identify those compounds 
with anti-inflammatory activity.  
 
Marine extracts isolated by our collaborators in UCD were screened and active 
fractions were then further fractionated into numerous compounds. These fractions 
were then assessed in order to find those containing the anti-inflammatory compounds 
[see figure 3.1.1]. 
  
In order to carry out this study we screened compounds for their effects on DCs. DCs 
play a key role in the initiation and progression of autoimmunity (Gutcher and Becher 
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2007). Indeed, the role of DCs in various inflammatory and autoimmune disorders has 
been well documented including IBD, RA and MS (Gottenberg and Chiocchia 2007, 
Gutcher and Becher 2007, Blanco, et al. 2008, Karni, et al. 2006)Therefore we 
hypothesized that DCs may be logical targets of these compounds and that their 
effects on DC may suppress inflammation and have substantial beneficial effects.  
 
The activation of DCs leads to the up-regulation of co-stimulatory molecules, pattern 
recognition receptor (PRR) and surface markers including CD40, CD80, CD86, 
TLR4-MD-2 and MHCII. These surface markers have a pivotal role in the activation 
of an effective T helper cell response as absence of co-stimulation can result in cell 
anergy or apoptosis (Kobata, et al. 2000). Alterations in co-stimulatory surface marker 
expression could modulate the ability of DCs to activate T cells, therefore we 
examined the effects of the marine extracts on these markers. 
 
While the upregulation of co-stimulatory markers is important, the differentiation of T 
cells into numerous subsets is partially determined by the cytokines DCs produce i.e. 
IL-12 induces the generation of T cells to a Th1 phenotype; IL-23, IL-6 and IL-1β are 
involved in generating a Th17 response; IL-4 drives a Th2 phenotype and IL-10 
promotes the induction of type 1 regulatory cells (Agnello, et al. 2003, de Jong, Smits 
and Kapsenberg 2005, Guermonprez, et al. 2002). Indeed the secretion of IL-10 acts 
as a potent deactivator of DC pro-inflammatory cytokine production. Consequently, 
altering the production of these cytokines by DCs may modulate the subsequent 
adaptive immune response. Therefore we examined the effects of marine extracts on 
LPS-induced cytokine production from DCs. 
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Given that impaired expression of chemokines and or/ chemokine receptors can be 
involved in the development of autoimmune diseases (Borish and Steinke 2003, 
Cravens and Lipsky 2002), we also assessed whether the extracts effected chemokines 
such as MCP-1, MIP-1α and MIP-2α. Finally the ability of DCs to migrate to the 
lymph node homing chemokine CCL19 was also examined.  
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3.2 RESULTS 
 
Figure 3.1.1: Diagrammatic representation of the outline of this project.  
Crude Extract  
C001/C002/C008 C001/C002/C008 
Both crude extracts showed anti-inflammatory 
abilities so where fractionated into numerous 
compounds by our chemists at UCD 
M. membrancea C002 demonstrated 
the most significant anti-
inflammatory effects so was therefore 
further fractionated 
C001/C005/C0017/C021/C023/C027 
Chapter 4  Chapter 5 
• Examined the effects of  
the second fractions on a 
panel of TLR ligands 
• Carried out advanced 
mechanistic studies on 
INV013 to determine its 
molecular target  
1st fractionation   
2nd fractionation 
• Examined the effects of 
the second fractions on 
macrophage function 
following stimulation 
with TLR4 and TLR7 
ligands 
C023/C021 fractions where 
further fractionated 
generating the individual 
compound INV013  
Final fractionation  
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3.2 RESULTS 
3.2.1 THE DOSES OF CRUDE MARINE EXTRACTS USED HAVE NO 
SIGNIFICANT EFFECT ON CELL VIABILITY. 
We examined the effects of the crude marine extract Alcyonium digitia and 
Membranipora membranacea on DCs cytokine production and surface marker 
expression following stimulation with LPS. Crude extracts that demonstrated anti-
inflammatory activity were then sent to our collaborators in UCD where they were 
fractionated. Initially we examined the toxicity of the crude extracts by exposing DCs 
to a range of dilutions. Following marine extract treatment the cell viability was 
assessed using Cell Titer 96 Aqueous One Solution (Promega, WI, USA) according to 
the manufacturer’s instructions. The doses of marine extracts (1:100, 1:1,000, 
1:10,000) chosen for use in future experiments did not have any significant cytotoxic 
effect on DC in vitro [Figure 3.1] 
3.2.2 CRUDE MARINE EXTRACTS DOSE-DEPENDENTLY MODULATE 
LPS-INDUCED CYTOKINE PRODUCTION BY DENDRITIC CELLS 
IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), marine extracts; Alcyonium digitia or Membranipora 
membranacea at different dilutions (1:100, 1:1000, 1:10,000) for 1 hr prior to 
stimulation with 100ng/ml LPS (E.Coli serotype R515). After 24 hrs supernatants 
were removed and analysed for levels of IL-12p40 and IL-12p70 [Figure 3.2], IL-23 
and IL-6 [Figure 3.3], IL-1β and TNF-α [Figure 3.4] and IL-10 [Figure 3.5] using 
specific immunoassays. 
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The production of the pro-inflammatory cytokines, IL-12p70 and IL-12p40 following 
LPS activation [Figure 3.2] were significantly reduced, in a dose dependant manner 
in DCs pretreated with A.digitia and M.membrancea (p<0.001) compared to the 
DMSO control group. A significant reduction was also observed in the pro-
inflammatory cytokines, IL-23, IL-6 [Figure 3.4] and IL-1β [Figure 3.4] following 
treatment with both marine extracts (p<0.001). Furthermore, the levels of TNF-α 
remained relatively unchanged regardless of marine extract treatment, indicating that 
the effects of the extracts are specific [Figure 3.4]. 
 
In contrast the production of IL-10 post LPS stimulation was significantly increased 
in the marine extract treated- DC [Figure 3.5].  
3.2.3 CRUDE MARINE EXTRACTS MODULATE CELL SURFACE 
MARKER EXPRESSION ON DENDRITIC CELLS IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), marine extracts; A.digitia or M.membranacea at 1:1000 
dilution for 1 hr prior to stimulation with 100ng/ml LPS (E.Coli serotype R515). 
Control cells and LPS-stimulated cells were subsequently washed and stained with 
flurochrome-labelled monoclonal antibodies for various cell surface markers (i.e., 
CD11c, CD40, CD80, CD86, MHCII, TLR4-MD-2 and CCR5) [see Table 2.7] in 
preparation for cytometric analysis by flow cytometry. .  
 
As expected, stimulation with LPS enhanced the surface marker expression of CD40 
[Figure 3.6], CD86 [Figure 3.7], CD80 [Figure 3.8], MHCII [Figure 3.10] and 
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TLR-4-MD-2 [Figure 3.11] and decreased the expression of the chemokine receptor 
CCR5 [Figure 3.9], where control DMSO cells are shown by the filled purple 
histogram and LPS-treated cells are overlaid with a green line. The marine extracts 
A.digitia and M.membranacea did not alter the levels of key surface markers in 
unstimulated DCs cells, however they were able to suppress the upregulation of some 
of these surface markers following LPS stimulation. Expression of MHCII [Figure 
3.10] and TLR4-MD-2 [Figure 3.11] were markedly suppressed in A.digitia-treated 
DCs in response to LPS while levels of expression of CD40 [Figure 3.6], CD80 
[Figure 3.7] and CD86 [Figure 3.8] remained relatively unchanged compared to 
DMSO-treated cells. Whereas M.membranacea had no suppressive effect on 
expression of MHCII [Figure 3.10] and TLR4-MD-2 [Figure 3.11] but significantly 
inhibited the expression of CD40 [Figure 3.6], CD86 [Figure 3.7] and CD80 [Figure 
3.8] following LPS stimulation. In addition both extracts blocked the suppression of 
CCR5 normally seen in mature DC with levels higher than in DMSO-treated cells 
[Figure 3.9]. 
 
3.2.4 THE DOSES OF FIRST-ROUND FRACTIONS OF MARINE 
EXTRACTS USED HAVE NO SIGNIFICANT EFFECT ON CELL 
VIABILITY.   
After establishing that crude marine extracts of A.digitia and M.membrancea had the 
ability to suppress DC maturation and also modulate cytokine production, these crude 
extracts were then fractionated. These fractions were then further examined to 
determine the active fractions. We first assessed their toxicity by exposing DCs to a 
range of dilutions. After treatment with fractions of marine extract the viability of 
cells was determined using Cell Titer 96 Aqueous One Solution (Promega, WI, USA) 
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according to manufacturer’s instructions. The doses of fractions of marine extracts 
selected for use in future experiments did not have any significant cytotoxic effect on 
DC in vitro [Figure 3.12]. 
3.2.5 FIRST-ROUND FRACTIONS OF MARINE EXTRACTS DOSE- 
DEPENDENTLY MODULATE LPS-INDUCED CYTOKINE 
PRODUCTION BY DENDRITIC CELLS IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), marine extracts; A. digitia (C001, C002, C008) or M. 
membranacea (C001, C002, C008) at different dilutions (1:100, 1:1000, 1:10,000) for 
1 hr prior to stimulation with 100ng/ml LPS (E.Coli serotype R515). After 24 hrs 
supernatants were removed and assessed for levels of IL-12p40 and IL-12p70 [Figure 
3.13], IL-23 and IL-6 [Figure 3.14], IL-1β and TNF-α [Figure 3.15] and IL-10 
[Figure 3.16] using specific immunoassays. 
 
The production of the pro-inflammatory cytokines, IL-12p40, IL-12p70 [Figure 
3.13], IL-23 and IL-6 [Figure 3.14] were inhibited significantly after exposure to 
fractions of marine extracts. A. digitia (C001, C008) (p<0.001) had the greatest 
suppressive effect on IL-12p40, IL-12p70 [Figure 3.13] and IL-23 [Figure 3.14]. The 
production of these cytokines was also significantly reduced after exposure to M. 
membranacea (C002, C008) (p<0.001). M. membranacea C001 (p<0.01) and A. 
digitia C002 (p<0.01) also decreased IL-12p70 [Figure 3.13] and IL-23 [Figure 3.14] 
production but to a lesser extent at 1:1000 and 1:10000 dilutions. Furthermore, a 
significant decrease was observed in the production of IL-1β [Figure 3.14] and IL-6 
[Figure 3.15] with the fractions, A. digitia (C001, C008) (p<0.001) and M. 
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membranacea (C002, C008) while A. digitia C002 and M. membranacea C001 
exhibited no effect. In contrast to the other cytokines, which were modulated 
significantly, levels of  TNF-α remained relatively unchanged regardless of treatment 
with marine extract fractions, suggesting that the effects of the extracts are specific 
[Figure 3.15]. 
 
The production of the anti-inflammatory cytokine, IL-10, was substantially increased 
in marine treated-DCs following activation with LPS [Figure 3.16]. A. digitia (C001, 
C008) (p<0.001) and M. membranacea (C001, C002, C008) (p<0.001)  significantly 
enhanced  IL-10 production at 1:100 dilution however 1:1000 and 1:10,000 dilutions 
of these marine extracts had no effect following stimulation with LPS.  
3.2.6 FIRST-ROUND FRACTIONS OF MARINE EXTRACTS MODULATE 
LPS-INDUCED CHEMOKINE PRODUCTION BY DCs IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), marine extracts; A.digitia (C001, C008) or M.membranacea 
(C002, C008) at different dilutions (1:100, 1:1000, 1:10,000) for 1 hr prior to 
stimulation with 100ng/ml LPS (E.Coli serotype R515). Supernatants were then 
removed and assessed for levels of MIP-1α, MIP-2 and MCP [Figure 3.17] using 
specific immunoassays. 
 
The production of the pro-inflammatory chemokines, MIP-1α and MCP-1 were 
significantly suppressed by A. digitia C008 (p<0.001) following LPS stimulation, 
while A. digitia C001 exhibited no effect [Figure 3.17]. However, A. digitia C001 
(p<0.001) enhanced MIP-2α expression [Figure 3.17]. In contrast, M.membrancea 
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C002 (p<0.001) significantly suppressed the production of MIP-1α and MCP-1 post 
LPS activation. Again, an increase in the production of MIP-2α was seen following 
exposure to M.membrancea C008 (p<0.001) whereas M.membrancea C002 exhibited 
no alteration [Figure 3.17].  
3.2.7 FIRST-ROUND FRACTIONS OF MARINE EXTRACTS INHIBIT DC 
CHEMOTAXIS 
 
CCL19, also known as MIP-3β, is a ligand for CCR7. Following maturation of DC, 
CCR7 is up-regulated on the surface of DCs which assists in directing them to T cell 
areas of draining lymph nodes where they interact with and activate naïve T cells. The 
chemotaxis of DCs following LPS activation towards the chemokine MIP-3β [Figure 
3.18] was significantly suppressed by culturing cells with A. digitia C008 (p<0.001) 
and M. membranacea C008 (p<0.001) and to a lesser extent with M. membranacea 
C002 (p<0.01) [Figure 3.18]. In contrast, A. digitia C001 did not have an inhibitory 
effect on DC migration following LPS activation [Figure 3.18].  
3.2.8 FIRST-ROUND FRACTIONS OF MARINE EXTRACTS MODULATE 
CELL SURFACE MARKER EXPRESSION ON DENDRITIC CELLS 
IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), marine extracts; A. digitia (C001, C002, C008) or M. 
membranacea (C001, C002, C008) at 1:1000 dilution for 1 hr prior to stimulation 
with 100ng/ml LPS (E.Coli serotype R515). Control cells and LPS-stimulated cells 
were subsequently washed and stained with flurochrome-labelled monoclonal 
antibodies for various cell surface markers (CD11c, CD40, CD80, CD86, MHCII, 
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TLR4-MD-2 and CCR5) [see Table 2.7] in preparation for cytometric analysis by 
flow cytometry. . 
 
As expected, LPS increased the expression of CD40 [Figure 3.19], CD80 [Figure 
3.20], CD86 [Figure 3.21], MHCII [Figure 3.23] and TLR4-MD-2 [Figure 3.24] and 
decreased the expression of CCR5 [Figure 3.22] with control DMSO cells 
represented by the filled purple histogram and LPS-treated cells overlaid with a green 
line. The fractions were able to alter the expression of pivotal surface markers. 
Expression of MHCII [Figure 3.23] and TLR4-MD-2 [Figure 3.24] were 
significantly downregulated by the fractionated A.digitia marine extract following 
LPS activation, with C001 and C008 showing the greatest suppression. Furthermore 
A.digitia fractions C001 and C002 slightly decreased the expression of CD86 and 
CD40, respectively following activation with LPS while no alteration was 
demonstrated with C008. No modification was seen in the levels of CD80 [Figure 
3.20] expression with any of the A.digitia fractions post stimulation with LPS. In 
contrast fractionated marine extract M.membranacea treated DCs in response to LPS 
showed relatively no change in surface expression of MHCII [Figure 3.23] and 
TLR4-MD-2 [Figure 3.24]. However expression of CD40 [Figure 3.19], CD86 and 
CD80 [Figure 3.20-3.21] were significantly suppressed in fractionated 
M.membranacea treated DCs following LPS activation, with fractions C001 and C008 
having the greatest effects. Expression of CCR5 was enhanced with M.membrancea 
C008 following stimulation with LPS however no alteration was demonstrated 
following treatment with M.membrancea C001,C002 fraction and also A.digitia 
fractions C001, C002 and C008 [Figure 3.22].  
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3.2.9 SECOND-ROUND FRACTIONS OF MARINE EXRACT Membranipora 
membranacea HAVE NO SIGNIFICANT EFFECT ON CELL 
VIABILITY 
The surface markers CD80 and CD86 are essential in DC maturation and initiating T 
cell differentiation. Furthermore numerous studies have demonstrated that pro-
inflammatory cytokines such as IL-12, IL-6 and IL-1β and chemokines such as MCP-
1 and MIP-1α are involved in the progression of numerous inflammatory diseases. 
Therefore we decided to concentrate on the marine extract M.membrancea C002 as 
this fraction was able to significantly downregulate the expression of these co-
stimulatory. In addition M.membrancea C002 also modulated the secretion of pro-
inflammatory cytokines and chemokines post activation with LPS. Following second-
round fractionation of M.membrancea C002 we received numerous fractions (C002, 
C017, C021, C023, and C027) which we examined to determine the active 
component.  Firstly we examined the toxicity of the fractions by using Cell Titer 96 
Aqueous One Solution (Promega, WI, USA) according to manufacturer’s instructions. 
The 1:200 dilutions of marine fractions chosen for use in future experiments did not 
have any significant cytotoxic effect on DC in vitro [Figure 3.25]. 
 
3.2.10 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE LPS-INDUCED CYTOKINE 
PRODUCTION BY DENDRITIC CELLS IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), fractions of marine extracts; M. membranacea (C002, C004, 
C017, C021, C023 or C027) at 1:200 dilution for 1 hr prior to stimulation with or 
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without 100ng/ml LPS (E.Coli serotype R515). After 24 hrs supernatants were 
removed and assessed for levels of IL-12p70, IL-12p40, IL-23 [Figure 3.26] IL-1β, 
IL-6, TNF-α and IL-10 [Figure 3.27] using specific immunoassays. 
 
The M.membrancea fractions (C017, C021, C023 and C027) suppressed the 
production of IL-12p40 and IL-12p70 following stimulation with LPS (p<0.001) 
while C002 and C004 suppressed IL-12p70 production, they had no effect on IL-
12p40 secretion [Figure 3.26]. In addition the fractions C017 (p<0.01), C021 
(p<0.001) and C027 (p<0.01) were capable of significantly inhibiting the production 
of IL-23p19 [Figure 3.26].  
 
In contrast levels of TNF-α remained relatively unchanged regardless of the fraction 
of marine extract used. Fractions, C017, C021, C023 and C027 (p<0.001), 
significantly decreased IL-6 production in LPS stimulated DCs while C002 and C004 
showed no effect [Figure 3.27]. However fractions C002 and C021 (p<0.05) were the 
only fractions capable of inhibiting the production of IL-1β [Figure 3.27].  
 
The production of the regulatory cytokine, IL-10 [Figure 3.27] was substantially 
increased in M.membrancea fractionated-treated DCs following LPS activation. 
M.membrancea fractions, C002, C017, C021 and C027 (p<0.001-p<0.05), had the 
most profound effects on IL-10 production following stimulation of DCs while, C004 
and C023 demonstrated no significant effect.  
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3.2.11 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE CELL SURFACE MARKER 
EXPRESSION ON DENDRITIC CELLS IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), second fractions of M. membranacea (C021, C023 or C027) 
at 1:200 dilution for 1 hr prior to stimulation with or without 100ng/ml LPS (E.Coli 
serotype R515) for 24 hrs. Control and LPS-stimulated cells were subsequently 
stained with flurochrome-labelled monoclonal antibodies for various cell surface 
markers (CD11c, CD40, CD80, CD86, MHCII and TLR4-MD-2) [see Table 2.7] in 
preparation for cytometric analysis by flow cytometry [Figure 3.28]. 
 
As expected LPS stimulation enhanced the surface marker expression of CD40, 
CD80, CD86 TLR4-MD-2 and MHCII as seen in the first row in figure 3.28 where 
DMSO control cells are shown by the filled purple histogram and LPS-treated cells 
are overlaid with a green line. All the M.membrancea fractions including, C021, C023 
and C027 were able to significantly reduce the levels of key surface markers CD40, 
CD86 and MHCII post activation with LPS [Figure 3.28]. There was no alteration in 
the expression of CD80 or TLR4-MD-2 [Figure 3.28] again indicating that the marine 
extracts are acting specifically.  
3.2.12 Membranipora membranacea MODULATED DCs CAN ALTER 
CYTOKINE PRODUCTION PROFILES OF CD4+ T CELLS.  
The cytokines secreted by DCs and their expression of co-stimulatory molecules are 
critical for activating T helper cells. Given that fractions from M.membrancea can 
alter DC activation we next assessed whether their effect on DCs had consequences 
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for T cell activation and cytokine production. DCs were harvested for 7 days as 
previously described [see section 2.26]. On day 7 cells were pretreated with marine 
extract at 1:200 dilution for 1 hr prior to activation with OVA peptide. Following 
activation DCs were co-incubated with CD4+ T cells isolated from the spleens of 
D011.10 mice which express a TCR specific for a peptide within the ovalbumin 
(OVA) molecule (OVA (323-339)). When this OVA antigen is presented by DC 
complexed to MHCII (together with costimulation), the naive CD4+ T cells become 
activated and proliferate (Pompos and Fritsche 2002).  Figure 3.29 shows that T cells 
activated with marine-treated DC produce significantly less IFN-γ (p<0.001), less IL-
17 (p<0.001), and less IL-4 (p<0.001) on day 10 of culture.   
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FIGURE 3.1: The concentrations of crude marine extracts used do not significantly 
affect the viability DCs. 
BMDCs were grown for 7 days and then treated with a range of dilutions (1:100, 1:1000, 
1:10000) of DMSO (vehicle control), crude A.digitia and M.membranacea for 24 hrs. 
Following 24 hr treatment cellular viability was assessed using an MTS assay (Cell Titer 96 
Aqueous One Solution – Promega, WI, USA). Results are expressed as a percentage of 
untreated cells. 
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FIGURE 3.2: Marine extracts suppress LPS-induced IL-12p40 and IL-12p70 production 
in DCs. BMDCs were differentiated in the presence of GMCSF for 7 days, plated at (1x106 
cells/ml) and then treated with either DMSO (vehicle control), crude marine extracts- 
A.digitia and M.membranacea for 1 hr prior to stimulation with 100ng/ml of LPS. 
Supernatants were recovered after 24 hrs and assessed for levels of IL-12p40 and IL-12p70 
using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.3: Marine extracts suppress LPS-induced IL-23 and IL-6 production in DCs. 
BMDCs were differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) 
and then treated with either DMSO (vehicle control), crude marine extracts- A.digitia and 
M.membranacea for 1 hr prior to stimulation with 100ng/ml of LPS. Supernatants were 
recovered after 24 hrs and assessed for levels of IL-23 and IL-6 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.4: Marine extracts suppress LPS-induced IL-1β production but do not alter 
TNF-α production in DCs. BMDCs were differentiated in the presence of GMCSF for 7 
days, plated at (1x106 cells/ml) and then treated with either DMSO (vehicle control), crude 
marine extracts- A.digitia and M.membranacea for 1 hr prior to stimulation with 100ng/ml of 
LPS. Supernatants were recovered after 24 hrs and assessed for levels of IL-1β and TNF-α 
using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.5: Marine extracts enhance LPS-induced IL-10 production in DCs. BMDCs 
were differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), crude marine extracts- A.digitia and 
M.membranacea for 1 hr prior to stimulation with 100ng/ml of LPS. Supernatants were 
recovered after 24 hrs and assessed for levels of IL-10 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.6: Marine extracts modulate the expression of CD40 on the surface of DCs. 
BMDC were differentiated in the presence of GMCSF for 7days and then treated with crude 
A.digitia and M.membrancea for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, 
cells were washed and stained with antibody specific for CD40 or with an isotype matched 
control. Results of flow cytometric analysis and corresponding MFI values are shown.Top 
row:  DMSO-treated DCs (filled purple histogram) vs LPS stimulated DCs (green line) and 
isotype control (pink dotted line). Bottom two rows: DMSO-treated DCs (filled purple 
histogram) vs. marine extract-treated DCs (green line) for unstimulated [Control] vs. 
stimulated [LPS] cells. MFI values for marine treated cells are also displayed on all 
histograms for comparison of those of DMSO groups indicated in the top row. Profiles are 
shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.7: Marine extracts modulate the expression of CD86 on the surface of DCs. 
BMDC were differentiated in the presence of GMCSF for 7days and then treated with crude 
A.digitia and M.membrancea for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, 
cells were washed and stained with antibody specific for CD86 or with an isotype matched 
control. Results of flow cytometric analysis and corresponding MFI values are shown. Top 
row:  DMSO-treated DCs (filled purple histogram) vs LPS stimulated DCs (green line) and 
isotype control (pink dotted line). Bottom two rows: DMSO-treated DCs (filled purple 
histogram) vs. marine extract-treated DCs (green line) for unstimulated [Control] vs. 
stimulated [LPS] cells. MFI values for marine treated cells are also displayed on all 
histograms for comparison of those of DMSO groups indicated in the top row. Profiles are 
shown for a single experiment and are representative of 3 experiments. 
CD86 
A. digitia  
M.membrancea 
   310.2    1230.2 
LPS CONTROL 
   764.9 
   214.9 
R
EL
A
TI
V
E 
CE
LL
 
N
U
M
BE
R
   192.7    516.1 
   202.2 
   501.2 
DMSO/LPS 
(A. digitia)  
DMSO/LPS 
(M.membrancea)  
   192.7 
   310.2 
   516.1 
   1230.2 
 112 
 
 
 
 
 
                        
       
                                                          
                                                      MEAN FLUORESCENCE INTENSITY 
 
 
FIGURE 3.8: Marine extracts modulate the expression of CD80 on the surface of DCs. 
BMDC were differentiated in the presence of GMCSF for 7days and then treated with crude 
A.digitia and M.membrancea for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, 
cells were washed and stained with antibody specific for CD80 or with an isotype matched 
control. Results of flow cytometric analysis and corresponding MFI values are shown. Top 
row:  DMSO-treated DCs (filled purple histogram) vs LPS stimulated DCs (green line) and 
isotype control (pink dotted line). Bottom two rows: DMSO-treated DCs (filled purple 
histogram) vs. marine extract-treated DCs (green line) for unstimulated [Control] vs. 
stimulated [LPS] cells. MFI values for marine treated cells are also displayed on all 
histograms for comparison of those of DMSO groups indicated in the top row. Profiles are 
shown for a single experiment and are representative of 3 experiments. 
R
EL
A
TI
V
E 
CE
LL
 
N
U
M
BE
R
CONTROL LPS 
CD80 
A. digitia  
M.membrancea  
   24.89 
   45.98 
   23.36    48.26 
   62.89    163.28 
   77.69 
   271.16 
   24.89 
   77.69 
   271.16 
   45.98 
DMSO/LPS 
(A. digitia)  
DMSO/LPS 
(M.membrancea)  
 113 
 
 
 
 
 
 
 
                                                        MEAN FLUORESCENCE INTENSITY 
 
FIGURE 3.9: Marine extracts modulate the expression of CCR5 on the surface of DCs. 
BMDC were differentiated in the presence of GMCSF for 7days and then treated with crude 
A.digitia and M.membrancea for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, 
cells were washed and stained with antibody specific for CCR5 or with an isotype matched 
control. Results of flow cytometric analysis and corresponding MFI values are shown.  Top 
row:  DMSO-treated DCs (filled purple histogram) vs LPS stimulated DCs (green line) and 
isotype control (pink dotted line). Bottom two rows: DMSO-treated DCs (filled purple 
histogram) vs. marine extract-treated DCs (green line) for unstimulated [Control] vs. 
stimulated [LPS] cells. MFI values for marine treated cells are also displayed on all 
histograms for comparison of those of DMSO groups indicated in the top row. Profiles are 
shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.10: Marine extracts modulate the expression of MHCII on the surface of 
DCs. BMDC were differentiated in the presence of GMCSF for 7days and then treated with 
crude A.digitia and M.membrancea for 1 hr prior to stimulation with LPS 
(100ng/ml).Subsequently, cells were washed and stained with antibody specific for MHCII or 
with an isotype matched control. Results of flow cytometric analysis and corresponding MFI 
values are shown.  Top row:  DMSO-treated DCs (filled purple histogram) vs LPS stimulated 
DCs (green line) and isotype control (pink dotted line). Bottom two rows: DMSO-treated 
DCs (filled purple histogram) vs. marine extract-treated DCs (green line) for unstimulated 
[Control] vs. stimulated [LPS] cells. MFI values for marine treated cells are also displayed 
on all histograms for comparison of those of DMSO groups indicated in the top row. Profiles 
are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.11: Marine extracts modulate the expression of TLR4-MD-2 on the surface 
of DCs. BMDC were differentiated in the presence of GMCSF for 7days and then treated 
with crude A.digitia and M.membrancea for 1 hr prior to stimulation with LPS 
(100ng/ml).Subsequently, cells were washed and stained with antibody specific for TLR4-
MD-2 or with an isotype matched control. Results of flow cytometric analysis and 
corresponding MFI values are shown. Top row:  DMSO-treated DCs (filled purple 
histogram) vs LPS stimulated DCs (green line) and isotype control (pink dotted line). Bottom 
two rows: DMSO-treated DCs (filled purple histogram) vs. marine extract-treated DCs (green 
line) for unstimulated [Control] vs. stimulated [LPS] cells. MFI values for marine treated 
cells are also displayed on all histograms for comparison of those of DMSO groups indicated 
in the top row. Profiles are shown for a single experiment and are representative of 3 
experiments. 
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FIGURE 3.12: The concentrations of first-round fractions extracts used do not 
significantly affect the viability of DCs. 
BMDCs were grown for 7 days and then treated with a range of dilutions (1:100, 1:1000, 
1:10000) of either DMSO (vehicle control) or A.digitia (C008, C009) and M.membranacea 
(C009, C008) for 24hrs. Following 24 hr treatment cellular viability was assessed using an 
MTS assay (Cell Titer 96 Aqueous One Solution – Promega, WI, USA). Results are 
expressed as a percentage of untreated cells. 
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FIGURE 3.13: First-round fractions of marine extracts suppress LPS-induced IL-12p40 
and IL-12p70 production in DCs. BMDCs were differentiated in the presence of GMCSF 
for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO (vehicle control), 
fractions of marine extracts- A.digitia (C001, C002, C008) and M.membranacea (C001, 
C002, C008) for 1 hr prior to stimulation with 100ng/ml of LPS. Supernatants were recovered 
after 24 hrs and assessed for levels of IL-12p40 and IL-12p70 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.14: First-round fractions of marine extracts suppress LPS-induced IL-23 
and IL-6 production in DCs. BMDCs were differentiated in the presence of GMCSF for 7 
days, plated at (1x106 cells/ml) and then treated with either DMSO (vehicle control), fractions 
of marine extracts- A.digitia (C001, C002, C008) and M.membranacea (C001, C002, C008) 
for 1 hr prior to stimulation with 100ng/ml of LPS. Supernatants were recovered after 24 hrs 
and assessed for levels of IL-23 and IL-6 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.15: First-round fractions of marine extracts suppress LPS-induced IL-1β 
production in DCs. BMDCs were differentiated in the presence of GMCSF for 7 days, plated 
at (1x106 cells/ml) and then treated with either DMSO (vehicle control), fractions of marine 
extracts- A.digitia (C001, C002, C008) and M.membranacea (C001, C002, C008) for 1 hr 
prior to stimulation with 100ng/ml of LPS. Supernatants were recovered after 24 hrs and 
assessed for levels of IL-1β and TNF-α using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.16: First-round fractions of marine extracts enhance LPS-induced IL-10 
production in DCs. BMDCs were differentiated in the presence of GMCSF for 7 days, plated 
at (1x106 cells/ml) and then treated with either DMSO (vehicle control), fractions of marine 
extracts- A.digitia (C001, C002, C008) and M.membranacea (C001, C002, C008) for 1 hr 
prior to stimulation with 100ng/ml of LPS. Supernatants were recovered after 24 hrs and 
assessed for levels of IL-10 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.17: First-round fractions of marine extracts modulate LPS-induced 
chemokine production in DCs. BMDCs were differentiated in the presence of GMCSF for 7 
days, plated at (1x106 cells/ml) and then treated with either DMSO (vehicle control), fractions 
of marine extracts- A.digitia (C001, C008) and M.membranacea (C002, C008) for 1 hr prior 
to stimulation with 100ng/ml of LPS. Supernatants were recovered after 24 hrs and assessed 
for levels of MIP-1α, MIP-2α and MCP-1 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.18: Fractions of marine extracts modulate the migration of DCs towards the 
chemokine MIP-3β (CCL19).  DC were cultured in the presence A.digitia (C001, C008) and 
M.membranacea (C002, C008) and stimulated with LPS (100ng/ml) before 3x105 cells were 
placed in the upper chamber of a Transwell plate (8.0µm).  Media containing recombinant 
CCL19 (100ng/ml) was added to the lower chamber and plates were incubated for 5 hrs at 
37ºC.  To determine the number of migrated cells, media from the bottom well was collected 
and events (cells) for 1 min were counted on a BD FACsCalibur™. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.19: First-round fractions of marine extracts modulate the expression of 
CD40 on DCs. BMDC were differentiated in the presence of GMCSF for 7days and then 
treated with fractions of A.digitia (C001, C002, C008) and M.membrancea (C001, C002, 
C008) for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, cells were washed and 
stained with antibody specific for CD40 or with an isotype matched control.  Results of flow 
cytometric analysis and corresponding MFI values are shown. Top row: DMSO-treated DCs 
(filled purple histogram) vs LPS stimulated DCs (green line) and isotype control (pink dotted 
line). Bottow three rows: DMSO-treated DCs (filled purple histogram) vs. LPS induced 
marine extract-treated DCs (green line). MFI values for marine treated cells are also displayed 
on all histograms for comparison of those of DMSO groups indicated in the top panel. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.20: First-round of fractions of marine extracts modulate the expression of 
CD80 on DCs. BMDC were differentiated in the presence of GMCSF for 7days and then 
treated with fractions of A.digitia (C001, C002, C008) and M.membrancea (C001, C002, 
C008) for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, cells were washed and 
stained with antibody specific for CD80 or with an isotype matched control. Results of flow 
cytometric analysis and corresponding MFI values are shown. Top row: DMSO-treated DCs 
(filled purple histogram) vs LPS stimulated DCs (green line) and isotype control (pink dotted 
line). Bottow three rows: DMSO-treated DCs (filled purple histogram) vs. LPS induced 
marine extract-treated DCs (green line). MFI values for marine treated cells are also displayed 
on all histograms for comparison of those of DMSO groups indicated in the top panel. 
Profiles are shown for a single experiment and are representative of 3 experiments.. 
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FIGURE 3.21: First-round fractions of marine extracts modulate the expression of 
CD86 on DCs. BMDC were differentiated in the presence of GMCSF for 7days and then 
treated with fractions of A.digitia (C001, C002, C008) and M.membrancea (C001, C002, 
C008) for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, cells were washed and 
stained with antibody specific for CD86 or with an isotype matched control.  Results of flow 
cytometric analysis and corresponding MFI values are shown. Top row: DMSO-treated DCs 
(filled purple histogram) vs LPS stimulated DCs (green line) and isotype control (pink dotted 
line). Bottow three rows: DMSO-treated DCs (filled purple histogram) vs. LPS induced 
marine extract-treated DCs (green line). MFI values for marine treated cells are also displayed 
on all histograms for comparison of those of DMSO groups indicated in the top panel. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.22: First-round fractions of marine extracts modulate the expression of 
CCR5 on DCs. BMDC were differentiated in the presence of GMCSF for 7days and then 
treated with fractions of A.digitia (C001, C002, C008) and M.membrancea (C001, C002, 
C008) for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, cells were washed and 
stained with antibody specific for CCR5 or with an isotype matched control.  Results of flow 
cytometric analysis and corresponding MFI values are shown. Top row: DMSO-treated DCs 
(filled purple histogram) vs LPS stimulated DCs (green line) and isotype control (pink dotted 
line). Bottow three rows: DMSO-treated DCs (filled purple histogram) vs. LPS induced 
marine extract-treated DCs (green line). MFI values for marine treated cells are also displayed 
on all histograms for comparison of those of DMSO groups indicated in the top panel. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.23: First-round fractions of marine extracts modulate the expression of 
MHCII on DCs. BMDC were differentiated in the presence of GMCSF for 7days and then 
treated with fractions of A.digitia (C001, C002, C008) and M.membrancea (C001, C002, 
C008) for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, cells were washed and 
stained with antibody specific for MHCII or with an isotype matched control.  Results of flow 
cytometric analysis and corresponding MFI values are shown. Top row: DMSO-treated DCs 
(filled purple histogram) vs LPS stimulated DCs (green line) and isotype control (pink dotted 
line). Bottow three rows: DMSO-treated DCs (filled purple histogram) vs. LPS induced 
marine extract-treated DCs (green line). MFI values for marine treated cells are also displayed 
on all histograms for comparison of those of DMSO groups indicated in the top panel. 
Profiles are shown for a single experiment and are representative of 3 experiments. 
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                                                 MEAN FLUORESCENCE INTENSITY 
 
FIGURE 3.23: First-round fractions of marine extracts modulate the expression of 
TLR4-MD-2 on DCs. BMDC were differentiated in the presence of GMCSF for 7days and 
then treated with fractions of A.digitia (C001, C002, C008) and M.membrancea (C001, C002, 
C008) for 1 hr prior to stimulation with LPS (100ng/ml).Subsequently, cells were washed and 
stained with antibody specific for TLR4-MD-2 or with an isotype matched control. Results of 
flow cytometric analysis and corresponding MFI values are shown. Top row: DMSO-treated 
DCs (filled purple histogram) vs LPS stimulated DCs (green line) and isotype control (pink 
dotted line). Bottow three rows: DMSO-treated DCs (filled purple histogram) vs. LPS 
induced marine extract-treated DCs (green line). MFI values for marine treated cells are also 
displayed on all histograms for comparison of those of DMSO groups indicated in the top 
panel. Profiles are shown for a single experiment and are representative of 3 experiments. 
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FIGURE 3.25: The concentration of second-round M.membrancea fractions used did not 
significantly affect the viability of DCs. 
An assay was carried out in DCs to assess the possible toxicity of the fractions of marine 
extracts used:  BMDCs were grown for 7 days and then treated with a 1:200 dilution of either 
DMSO (vehicle control) or M.membranacea (C002, C004, C017, C021, C023, C027) for 
24hrs. Following 24 hr treatment cellular viability was assessed using an MTS assay (Cell 
Titer 96 Aqueous One Solution – Promega, WI, USA). Results are expressed as a percentage 
of untreated cells. 
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FIGURE 3.26: Second-round M.membrancea fractions suppress LPS-induced IL-12p40, 
IL-12p70 and IL-23 production in DCs. BMDCs were differentiated in the presence of 
GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO (vehicle 
control), second fractions of M.membranacea (C002, C004, C017, C021, C023, C027) for 1 
hr prior to stimulation with 100ng/ml of LPS. Supernatants were recovered after 24 hrs and 
assessed for levels of IL-12p40, IL-12p70 and IL-23 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.27: Second-round  M.membrancea fractions suppress LPS-induced IL-6, IL-
1β production and enhance IL-10 production in DCs. BMDCs were differentiated in the 
presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO 
(vehicle control), second fractions of M.membranacea (C002, C004, C017, C021, C023, 
C027) for 1 hr prior to stimulation with 100ng/ml of LPS. Supernatants were recovered after 
24 hrs and assessed for levels of IL-6, IL-1β, TNF-α and IL-10 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing DMSO/LPS vs marine extract/LPS groups as 
determined by one-way ANOVA test  
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FIGURE 3.28: Second-round M.membrancea fractions modulate the expression of CD40, CD86 and MHCII on DCs. BMDC were differentiated in the 
presence of GMCSF for 7days and then treated with second M.membrancea fractions (C021, C023, C027) for 1 hr prior to stimulation with LPS 
(100ng/ml).Subsequently, cells were washed and stained with the specific antibodies or with an isotype matched control.  Results of flow cytometric analysis 
and corresponding MFI values are shown. Top row: DMSO-treated DCs (filled purple histogram) vs LPS stimulated DCs (green line) and isotype control 
(pink dotted line). Bottom three rows: DMSO-treated DCs (filled purple histogram) vs. LPS induced marine extract-treated DCs (green line). MFI values for 
marine treated cells are also displayed on all histograms for comparison of those of DMSO groups indicated in the top panel. Profiles are shown for a single 
experiment and are representative of 3 experiments. 
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FIGURE 3.29: Crude extract of M.membrancea-modulated DCs can inhibit subsequent 
T cell cytokine production. DCs were treated with DMSO (control), or marine extract 
M.membrancea for 1 hr prior to activation with OVA peptide (5µg/ml).  After 24 hrs DCs 
(2x105/ml) were added to CD4+ T cells (2x106/ml) purified from the spleens of OVA D011.10 
transgenic mice.  Fresh M.membrancea-treated pre-activated DCs were added on day 7 plus 
rIL-2 (10U/ml), and supernatants removed on day 10.  Samples were analysed for levels of 
IL-4, IL-17 and IFNγ using specific immunoassays. 
 Results are ± SEM of quadruplicate assays and represent three independent experiments.   
*** p<0.001, **p<0.01, *p<0.05 vs DMSO vehicle control determined by one-way ANOVA 
test 
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3.3 DISCUSSION 
Autoimmune diseases are responsible for significant ill-health and morbidity 
worldwide and several findings have demonstrated that DCs are key players in both 
the initiation and progression of autoimmunity. Studies have shown DCs are present 
in high numbers in the synovial fluid of patients with RA and high levels of 
circulating DCs secreting pro-inflammatory cytokines are associated with MS 
(Drakesmith, Chain and Beverley 2000). Additionally, numerous studies have 
demonstrated that DCs play an early and fundamental role in the pathogenesis of IBD 
(Stagg, et al. 2003, Ikeda, et al. 2001). Consequently, altering DC responses possess 
tremendous therapeutic potential. In this study we carried out a screening process of 
different marine extracts. Firstly we examined the effects of crude marine extracts 
A.digitia and M.membrancea on LPS-stimulated DCs. Those that showed to have 
anti-inflammatory activity were then sent to our collaborators in UCD where they 
were fractionated. These fractions were then screened in order to determine the active 
ones. From these fractions we decided to fractionate the marine extract 
M.membrancea further as it was able to suppress pro-inflammatory cytokines and 
chemokines and also downregulate DC surface markers CD80 and CD86 which are 
essential for T cell activation and differentiation. 
 
Results here demonstrate that the crude marine extracts and their first round fractions 
of A.digitia and M.membranace (C001, C002, C008) and second round fractions of 
M.membrancea (C017, C021, C023, C027) strongly inhibit the production of 
important pro-inflammatory cytokines IL-12p40, IL-12p70 and IL-23.  IL-12 is a key 
cytokine that links innate and adaptive immunity as its targets include DCs, T cells 
and NK cells. IL-12 has pleiotrophic functions, and one of its fundamental functions 
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is to differentiate naïve T cells into a Th1 phenotype. In addition it has an essential 
role in maintaining the balance between Th1 and Th2 responses in vivo (Brahmachari 
and Pahan 2008, Caprioli, Pallone and Monteleone 2011). Several studies have 
addressed the role of IL-12 in autoimmune diseases such as RA, IBD and MS by 
using IL-12 deficient mice and overproduction is important in inflammatory states 
such as septic shock (Adorini 1999b, Adorini, et al. 1997). For instance, the 
expression of IL-12p40 is enhanced in inflamed colonic tissue from patients with IBD 
(Ng, et al. 2010). Furthermore, a study by Smith and workers showed decreased 
production of IL-12p40 in endotoxemic mice following treatment with cannabinoid 
agonist, tetrahydracannabinal (THC) (Smith, Terminelli and Denhardt 2000). 
Therefore targeting this cytokine may have therapeutic advantage. Given that the 
crude marine extracts and their fractions are able to impede the secretion of IL-12 
suggests that they may be beneficial in disease.   
 
IL-23 is a heterodimeric cytokine that is also a member of the IL-12 family of 
cytokines. It is composed of a p40 subunit and a unique p19 subunit. Similar to IL-12, 
formation of biologically active IL-23 requires synthesis of both p19 and p40 subunits 
within the same cell. IL-23 binds to the IL-23R on CD4+ T cells promoting their 
development into Th17 cells, characterized by the secretion of IL-17 and IL-6 
(Langrish, et al. 2004, Bettelli, Oukka and Kuchroo 2007). IL-23 appears to be an 
essential player in numerous chronic inflammatory diseases such as IBD and collagen 
induced arthritis (Yago, et al. 2007). IL-23 is produced by DCs and promotes the 
expansion and survival of already differentiated Th17 cells but it is not involved in 
Th17 initial differentiation. Naïve T cells cultured in the presence of TGF-β and IL-6 
are polarized to Th17 cells and also allows for the up-regulation of IL-12R (Kikly, et 
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al. 2007). Studies have shown that IL-1β and TNF-α have a synergistic effect on IL-
23 mediated IL-17 production in a model of EAE (Brahmachari and Pahan 2008). Our 
study demonstrates a robust reduction in the secretion of IL-23 following treatment 
with crude extracts and both rounds of fractionated marine extracts. Numerous studies 
have demonstrated that inhibiting the production of IL-23 can have therapeutic 
advantage. For example, a study by Xiao and colleagues showed that the vitamin A 
metabolite retinoic acid (RA) resolved EAE by decreasing the production of IL-23 
and enforcing the generation of T regulatory cells therefore inhibiting the 
development of Th17 cells (Xiao, et al. 2008). Our findings highlight for the first time 
the effects of marine extracts on IL-23 production. Furthermore a significant 
downregulation was also observed in the production of IL-6 and IL-1β in crude and 
fractionated treated DCs post activation with LPS. This may point to a consequential 
downstream effect of marine extract-treated DCs on Th17 cell development or 
maintenance. In addition, it suggests that these marine compounds may have 
therapeutic potential in the treatment of inflammatory diseases including RA and IBD.  
Other compounds isolated from marine species have been primarily demonstrated to 
reduce the secretion of IL-1β and IL-6. For instance, extracts isolated from 
Staphylococcus arlettae and Planococcus maritimus showed a robust reduction in the 
secretion of IL-1β in PMBCs (Krishnaveni and Jayachandran 2009). No alteration 
was observed in TNF-α production in both crude and fractionated marine treated DCs 
which indicates that the extracts are acting specifically. 
 
In contrast to the above mentioned cytokines, IL-10 is considered an anti-
inflammatory or regulatory cytokine. It down-regulates the production of pro-
inflammatory cytokines including IL-1, IL-6, IL-12 and TNF-α from APCs. IL-10 can 
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also act directly on CD4 T cells, inhibiting proliferation and production of IL-2, IFN-γ 
and IL-4 (Asadullah, et al. 1998, Asadullah, Sterry and Volk 2003) . Indeed, ablation 
of IL-10 leads to the overproduction of pro-inflammatory cytokines and the 
development of chronic diseases; this has been studied extensively in IL-10 deficient 
mouse models (Conti, et al. 2003). Primarily, an increase in IL-10 can inhibit Th1 cell 
differentiation or direct cells to a regulatory response (Asadullah, Sterry and Volk 
2003). The crude marine extracts and their fractions robustly enhance the expression 
of IL-10. Indeed a crude extract isolated from the carribean sponge Agrococcus 
jenensis has already shown to significantly upregulate IL-10 production in 
macrophages (Tabares, et al. 2011). Interestingly, IL-10 can suppress IL-12 
production and Loscher et al has shown that the decrease in IL-12 induced by the n-6 
polyunsaturated fatty acid, CLA is dependant on IL-10 (Loscher, et al. 2005). Further 
to its effects on cytokine production, IL-10 can also modulate surface marker 
expression by inhibiting the complete maturation of DC by downregulating the 
expression of CD80 and CD86 (de Jong, Smits and Kapsenberg 2005). In addition, 
IL-10 has the ability to prevent the peptide-MHCII complexes translocating to the DC 
plasma membrane (Banchereau, et al. 2000) all of which lead to impaired T helper 
cell responses. In contrast, IL-12 causes the upregulation of MHCII, CD80 and CD86 
expression on APC (Bettelli and Kuchroo 2005). The changes seen in the production 
of IL-10 and IL-12 in this study with the marine fractions could also explain the 
recorded alterations in cell surface marker expression.  
 
The engagement of CD80, CD86 on APCs with CD28 on T cells initiates T cell 
proliferation and differentiation and also cytokine production. CD80 and CD86 play 
important pathogenic roles in T-cell responses. For instance Odobasic and colleagues 
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demonstrated that monoclonal antibodies for CD80 and CD86 significantly decreased 
the production of IL-17 in the synvioum of mice therefore suppressing the 
development of arthritis (Odobasic, et al. 2008). In addition the interactions between 
CD40 and CD40L are bi-directional as it not only activates DCs but also enhances T 
cell activation. Ligation of CD40 with CD40L also triggers the production of 
extremely high levels of IL-12 (Danese, Sans and Fiocchi 2004, Kato, Yamane and 
Nariuchi 1997). Predictably, over expression of these surface markers have been 
associated in the pathology of tissues from patients with IBD, RA and MS (Kobata, et 
al. 2000, Toubi and Shoenfeld 2004, Polese, et al. 2003). Altering these markers on 
the surface would have detrimental consequences for T cells responses, ultimately 
indicating that co-stimulatory molecules are potential targets for treating 
inflammatory diseases. 
 
In the present study, it was demonstrated that treating DCs with crude marine extract 
M.membranacea significantly downregulated the surface marker expression of CD40, 
CD80 and CD86 in LPS-induced DCs. It is possible that the strong suppression of 
CD40 may contribute to the notable reduction in IL-12 secretion in treated marine 
extracts post LPS activation. A study by Walker and workers demonstrated that the 
inhibiton of IL-12 by neuroblastoma (NB)-derived gangliosides in DCs is mediated by 
deficient CD40 expression and signalling. Furthermore the decrease in expression of 
CD86 may attribute to the enhancement in IL-10 production in LPS induced treated 
cells (Walker, Redlinger and Barksdale 2005). A significant reduction in the 
expression of CD40, CD80 and CD86 was still observed in M.membrancea treated 
DCs from both rounds of fractionation, indicating that these fractions are active and 
have tremendous anti-inflammatory potential. A study by Platten and workers 
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demonstrated that catabolites of the amino acid tryptophan suppressed the expression 
of CD40, CD80 and CD86 reversing paralysis in mice with EAE (Platten, et al. 2005). 
The treatment with crude marine extract, A.digitia, showed a significant reduction in 
the expression of TLR4-MD-2 following LPS activation. Since TLR4 is required for 
the initiation of intracellular signalling pathways, ultimately leading to the activation 
of transcription factors, NFκB and IRF3, and subsequent secretion of pro-
inflammatory cytokines and IFN’s, this suggests that A.ditgitia extracts may affect 
TLR4 signalling. The expression of MHCII was also distinctly suppressed by crude 
and fractionated A.digitia extracts following LPS stimulation. DCs are capable of 
activating naïve T cells specifically because they express MHCII for antigen 
presentation along with the necessary co-stimulatory surface molecules for T cell 
activation. Since marine extracts A.digitia decrease MHCII suggests this treatment 
would have downstream affects on T cell response. 
 
The recruitment of leukocytes in response to chemokines is paramount in clearing 
infection, however elevated levels of chemokines are also implicated in inflammatory 
disease (Godessart and Kunkel 2001). The most active fractions for A.digitia, C002 
and C008, and for M.membranacea, C002 and C008, were investigated further in this 
study by assessing their modulatory effects on numerous cytokines including MCP-1, 
MIP-1α and MIP-2. In addition the chemotaxis of DCs towards the chemokine 
CCL19 was also assessed.  
 
Effects on chemokine secretion was specific for each fraction but the most potent 
effects were with, A.digitia fraction C008 and M.membrancea fraction C002 which 
significantly suppressed production of MIP-1α and MCP post stimulation with LPS. 
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MIP-1α acts as a robust chemoattractant to a variety of leukocytes and elevated levels 
of this chemokine have been shown in inflammatory disorders including RA and IBD 
(Pender, et al. 2005). Furthermore increased levels of MIP-1α have been demonstrated 
in biopsy samples of asthmatic patients (Alam, et al. 1996). Correspondingly, MCP-1 
is implicated in MS and RA (González-Escribano, et al. 2003). Indeed triptolide, a 
compound isolated from the vine plant Tripterygium wilfordii Hook F (TWHF) was 
shown to significantly inhibit MCP-1 and MIP-1α in rats induced with adjuvant 
arthritis (AA) (Wang, et al. 2006). A decrease in the chemotaxis of DC to CCL19 was 
also demonstrated with these M.membrancea fractions and it would also be 
reasonable to assume that the decrease in DC chemotaxis would have serious 
consequences for T cell responses considering the DC must migrate to the lymph 
nodes in order to activate naïve T cells and initiate adaptive immunity. A variety of 
compounds have been generated that antagonize chemokine receptor function, some 
of which are currently undergoing clinical trials (Zidek, Anzenbacher and 
Kmonickova 2009a). A study by Yang and workers reported that a compound purified 
from the marine sponge Ircinia sp downregulated the expression of the receptor for 
CCL19 (Yang, et al. 2003). 
 
Numerous molecules have been described that have demonstrated cytokine, 
chemokine and surface marker alteration similar to the results obtained in our study. 
For instance, Kong and collagues demonstrated that docosahexaenoic acid (DHA) a 
long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) from fish oils suppressed the 
production of pro-inflammatory cytokines IL-12p70 and IL-23 and increased the 
production of the regulatory cytokine IL-10. In addition DHA downregulated the 
expression of CD40, CD80, CD86 and MHCII in bone marrow derived DC following 
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stimulation with LPS (Kong, et al. 2010). Furthermore findings by Panther and 
workers showed that treatment of DCs with adenosine simultaneously showed a 
downregulation in the production of IL-12 and an enhancement in IL-10 secretion 
following activation with LPS. In addition a decrease in the pro-inflammatory 
chemokine, IP-10 was observed (Panther, et al. 2003). However the authors reported 
an increase in the surface marker expression of CD40, CD80, CD86 and MHCII in 
immature and mature DCs.  
 
Since the marine extracts were able to modulate LPS induced DC cytokine production 
and surface marker expression which is vital for DC maturation, and T helper cell 
activation, we decided to see if the marine extract M.membrancea, had an overall 
effect on subsequent T helper cell responses. Results demonstrated that 
M.membrancea-treated DCs had consequences for the resulting adaptive immune 
response. This was demonstrated when M.membrancea -modified DCs suppressed the 
production of IFN-γ, IL-17 and IL-4 by CD4+ T cells in a DC-T cell co-culture model 
suggesting that M.membrancea-altered DCs can destabilise Th1, Th2 and Th17 
responses by reducing IFN-γ, IL-4 and IL-17 production respectively. Levels of IFN-γ 
were significantly suppressed.  IFN-γ is a pro-inflammatory cytokine and is the 
signature cytokine of Th1 dominated autoimmune processes. The involvement of 
IFN-γ in the development of autoimmune diseases has been well documented over the 
years. One of the vital roles of IFN-γ is to activate numerous cells in the immune 
system including macrophages and DCs and also induce the production of IL-12 
(Watford, et al. 2003). However the role of IFN-γ in autoimmunity is continuously 
questioned as the ablation of IFN-γ either enhances or inhibits collagen induced 
arthritis in mice and also augments disease severity in EAE mice models. In contrast, 
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certain molecules have demonstrated therapeutic potential by altering IFN-γ 
production. For instance, Peroxisome proliferator-activated receptor-γ (PPARγ) 
ligands inhibit IFN-γ production and this was demonstrated in numerous studies to 
ameliorate RA (Giaginis, Giagini and Theocharis 2009). IL-17 is the cytokine that is 
responsible for the progression of EAE where as IFN-γ had a protective effect. The 
presence of M.membrancea robustly decreased the secretion of IL-17. IL-17 is the 
principal cytokine produced by Th17 cells and plays a pathogenic role in numerous 
autoimmune diseases including MS and RA which was previously accredited to the 
dysregulated Th1 response (Pernis 2009). Therefore this makes Th17 cells and their 
producing cytokine IL-17 possible therapeutic targets. For example, treatment with 
the synthetic glucocorticod, methylprednisolone (MP) reduced the production of IL-
17 in cells isolated from the CNS of rats with EAE thus ameliorating the disease 
(Miljkovic, et al. 2009).  
 
In conclusion our findings highlight for the first time distinct effects of extracts and 
fractions from the marine species A.digita and M.membrancea on cytokine, 
chemokine and cell surface marker expression in dendritic cells. These effects point to 
their potential as anti-inflammatory compounds. Furthermore, their ability to target 
cytokines such as IL-12, IL-23 and IL-6, known to be involved in inflammatory 
diseases further supports this. One of the main objectives of this study was to 
determine which fraction showed to have the most potent anti-inflammatory 
properties and fractions that demonstrated the greatest bioactivity were then sent to 
UCD to begin the final purification step in order to determine the identity of the active 
compound that possess these anti-inflammatory effects. 
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4.1 INTRODUCTION  
Macrophage, (MØ) execute many roles within innate immunity and their activation is 
fundamental for the initiation of host defence and in directing adaptive immune 
responses. MØ are prodigious phagocytic cells that have the ability to recognise, 
engulf and destroy invading pathogens (Geissmann, et al. 2010). They are actively 
involved in the clearance of infection and without this crucial function the host would 
not survive. While the innate immune response generated against a pathogen is 
essential in controlling infection, a persistent inflammatory reaction can actually do 
more harm than the pathogen itself.  The role of MØ in various inflammatory 
disorders has been well documented including; IBD, RA, schistosmiasis and 
atherosclerosis (Zhang and Mosser 2008). In order to develop new therapeutics for 
inflammatory diseases it is important to determine their effects on the cells that 
initiate the immune responses. Since we demonstrated the second fractions of 
M.membrancea to have potent anti-inflammatory effects on activated DCs we 
therefore decided to examine their effects on MØ, to determine if they affected them 
in a similar way. Furthermore, given their role in pathogen clearance we wanted to see 
if this was affected by the fractions. We examined the effects of the fractions on MØ 
following stimulation with a bacterial ligand via TLR4 and a viral ligand via TLR7.  
TLR7 is an anti-viral receptor that carry’s out its function in intracellular 
compartments in the cell leading to the activation of the transcription factors NFκB 
and IRF7. It recognises ssRNA from viruses such as HIV and influenza (Hemmi, et al. 
2002). Contrastingly, TLR4 is found on the surface of cells and recognises 
components found on the outer membrane of gram negative bacteria such as 
Escherichia coli and Salmonella Minnesota (Yan 2006). 
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There are a number of parameters of MØ activation which the marine extracts may 
affect. Activation signifies a change in the secretary profile and morphology of MØ. 
Continued stimulation of MØ in the presence of infection leads to increased 
production of the pro-inflammatory cytokines TNF-α, IL-1 and IL-6 through the 
activation of NFκB (Geissmann, et al. 2010). These cytokines affect organs such as 
the brain and liver which are far removed from the site of infection. IL-1 acts on the 
brain and is involved in the regulation of sleep, appetite and fever (Apte, et al. 2006), 
while IL-6 plays an important role in the acute phase response (Maggio, et al. 2005). 
Over production of IL-6 and TNF-α has been extensively documented in RA, Crohn’s 
disease (CD), MS and in many other autoimmune diseases and consequently 
inhibition or blockade of these cytokines has proved efficacious in treating many of 
these disorders (Palladino, et al. 2003, Fonseca, et al. 2009).  Differentiation of T cells 
into various subsets is partially determined by the cytokines that MØ produce. MØ 
secrete the pro-inflammatory cytokines IL-12 and IL-23 which are involved in Th1 
and Th17 polarization respectively (Jager, et al. 2009, Bettelli and Kuchroo 2005). 
Therefore, the effect of the M.membrancea on cytokine release from MØ following 
stimulation with TLR4 and TLR7 ligands was assessed to evaluate any beneficial 
effects. 
 
In addition, activation of MØ initiates the secretion of various chemokines which 
trigger the migration of monocytes into injured tissue, thereby initiating a central step 
during infection. These chemokines include MIP-1α/CCLS, MIP-2/CXCL2 and MCP 
(Zidek, Anzenbacher and Kmonickova 2009b).  Chemokines are essential mediators 
of inflammation and are important for controlling infection and ablation of these 
chemokines causes reduced ability to clear infections such as Listeria monocytogenes 
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(Heesen, et al. 2006).  Dysregulated expression of chemokines and their receptors has 
been implicated in the development of many human diseases including; allergy, 
psoriasis, atherosclerosis, and malaria (Murdoch and Finn 2000).  Numerous therapies 
are now being developed to combat these chemokine-mediated diseases (Viola and 
Luster 2008). As a result we have examined the effects of the second fractions of 
M.membrancea on MØ chemokine production following stimulation with LPS and 
loxoribine to evaluate any advantageous changes. Furthermore, the response of cells 
to chemokines and subsequent migration to sites of inflammation remains crucial 
during an immune response, therefore we have also assessed whether the fractions 
affect the chemotaxis of MØ in response to TLR4 and TLR7 stimuli.  
 
Phagocytosis is a hallmark function of MØ in the resolution of inflammation (Aderem 
2003). In addition to eliminating microbial pathogens, phagocytosis triggers the 
secretion of pro-inflammatory cytokines and chemokines and activates antigen 
processing and presentation by up-regulating key surface markers including MHCII, 
CD40, CD80 and CD86 leading to subsequent adaptive immune responses (Kang, et 
al. 2008). Phagocytosis is vital in clearing infection and disruption to this process can 
lead to systemic inflammatory diseases such as malaria (Urban and Roberts 2002). As 
key phagocytes, the rate of phagocytosis by MØ was investigated following exposure 
to M.membrancea in order to determine if the extracts were able to alter susceptibility 
to infection following activation with a bacterial pathogen mediated through TLR4 or 
a viral infection mediated through TLR7. 
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4.2 RESULTS 
4.2.1 SECOND-ROUND FRACTIONS OF MARINE EXRACT Membranipora 
membranacea HAVE NO SIGNIFICANT EFFECT ON CELL 
VIABILITY IN J774 MACROPHAGES.  
Since M.membrancea fractions (C017, C021, C023 and C027) demonstrated 
significant anti-inflammatory effects we decided to determine their effects on 
macrophages function following stimulation with two different TLR ligands.  Firstly 
we examined the toxicity of the fractions by using Cell Titer 96 Aqueous One 
Solution (Promega, WI, USA) according to manufacturer’s instructions. The 1:200 
dilutions of marine fractions chosen for use in future experiments did not have any 
significant cytotoxic on J774 macrophage in vitro [Figure 4.1]. 
 
4.2.2 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE CYTOKINE PRODUCTION 
BY J774 MACROPHAGES FOLLOWING STIMULATION WITH 
TLR4 LIGAND ONLY IN VITRO 
J774 macrophages were plated at a concentration of 1 x 106 cell/ml and pretreated 
with DMSO (vehicle control) or M.membrancea marine fractions (C017, C021, C023 
or C027) at 1:200 dilution for 1 hr prior to activation with 100 ng/ml LPS (E.Coli 
serotype R515) or loxoribine (1mM).  After 24 hrs, supernatants were removed and 
assessed for levels of IL-12p40, IL-23p19 [Figure 4.2], IL-6 , IL-1β [Figure 4.3], IL-
10 and TNF-α [Figure 4.4] and using specific immunoassays. 
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The production of the pro-inflammatory cytokines IL-12p40 and to a lesser extent IL-
23 were both decreased in the supernatant of marine fractionated-treated macrophages 
following LPS stimulation compared to the DMSO control group. All marine 
fractions were able to significantly decrease the production of IL-12p40 (p<0.001) 
[Figure 4.2]. IL-23, IL-6 and IL-1β production was also significantly decreased by all 
fractions (p<0.05-p<0.001) [Figure 4.2-4.4]. Similar to what we have seen in DCs, 
the marine fractions did not alter the production of TNF-α demonstrating that the 
marine extract is acting specifically [Figure 4.4].  The production of IL-10 was 
increased in marine-treated macrophage post activation with LPS with C027 (p<0.01) 
having the most profound effect on IL-10 production and fractions C021 and C023 
also increasing IL-10 but to a lesser extent (p<0.05). The marine fraction, C017, had 
no effect on IL-10 production following LPS stimulation [Figure 4.4]. 
 
In contrast to LPS stimulation, the M.membrancea second-round fractions had no 
effect on cytokine production when macrophages were activated with the TLR7 
agonist, loxoribine [Figure 4.2-4.4].   
4.2.3 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE CHEMOKINE 
PRODUCTION BY J774 MACROPHAGES FOLLOWING 
STIMULATION WITH TLR4 LIGAND ONLY IN VITRO 
J774 macrophages were plated at a concentration of 1 x 106 cell/ml and pretreated 
with DMSO (vehicle control) or M.membrancea marine fractions (C017, C021, C023 
or C027) at 1:200 dilution for 1 hr prior to activation with 100 ng/ml LPS (E.Coli 
serotype R515) or loxoribine (1mM). After 24 hrs, supernatants were removed and 
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assessed for levels of MIP-1α, MIP-2α [Figure 4.5] and MCP-1 [Figure 4.6] using 
specific immunoassays. 
 
The production of MIP-2α was not significantly affected by marine fractionated-
treated macrophage regardless of whether cells were activated with LPS or loxoribine 
[Figure 4.5]. M.membrancea fractions C021, C023 and C027 were able to 
downregulate the production of MIP-1α and MCP-1 following activation with LPS 
[Figure 4.5-4.6].  In contrast, no alteration in the production of any of the chemokines 
was demonstrated following loxoribine stimulation [Figure 4.5-4.6] 
4.2.4 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea INHIBIT MØ CHEMOTAXIS  
GM-CSF and IL-2 are frequently used in macrophage chemotaxis studies and have 
also been employed here (Stagg, et al. 2004, Perri, Annabi and Galipeau 2007). IL-2 
is a ligand for CXCR2, which is largely expressed on macrophage and is involved in 
the recruitment of macrophage to sites of inflammation (Boisvert, et al. 1998).  GM-
CSF (granulocyte-macrophage colony stimulating factor) is a cytokine that initiates 
the activation of monocytes and macrophages (Hasskamp, Elias and Zapas 2006). The 
migration of J774 macrophages towards the chemokines IL-2 and GM-CSF was 
significantly upregulated when cells were activated with LPS or loxoribine. The LPS-
induced chemotaxis was significantly inhibited by culturing cells with marine 
fractions C021, and C027 (p<0.001) [Figure 4.7]. In contrast the marine extracts had 
no effect on loxoribine-induced chemotaxis [Figure 4.7]. 
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4.2.5 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE THE RATE OF 
PHAGOCYTOSIS IN J774 MACROPAHGE IN VITRO 
J774 macrophages were plated at 2.5 x 105 cell/well and left to rest overnight. To 
assess the rate of phagocytosis in stimulated cells, cells were treated with 
M.membrancea fractions (C021, C023 or C027) for 1 hr before stimulation with LPS 
(100ng/ml) or loxoribine (1mM) for 24 hrs before addition of fluorescently labelled 
latex beads (Sigma®). On the following day, 2.5 x 106 fluorescently labelled latex 
beads were added to the required wells for 2, 4, 6, 12, 20 and 24 hr. At each time 
point wells were washed to remove excess beads and cells scraped and fixed in 200 µl 
4 % (v/v) paraformaldehyde/PBS. The rate of phagocytosis over time in macrophage 
was assessed using a BD FACSCalibur™ to measure the fluorescence of cells from 
bead uptake. The rate of phagocytosis increased over time in LPS and loxoribine 
stimulated macrophages where LPS or loxoribine-stimulated cells are shown by the 
filled purple histogram and marine treated-LPS or loxoribine-activated cells with the 
addition of latex beads are overlaid with a green line (top row) [Figure 4.8-4.9].  
 
Fractions, C021 and C023 and to a lesser extent C027 decreased phagocytosis at 2 h, 
4 h, 6 h and 12 hrs after LPS stimulation (bottom three rows) [Figure 4.8]. In contrast 
phagocytosis remained relatively unchanged in M.membrancea-treated macrophages 
post loxoribine activation with compared to control [Figure 4.9]. Confirmation that 
latex beads were phagocytosed following stimulation with LPS can be observed in 
figure 4.9a.  
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4.2.6 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE CELL SURFACE MARKER 
EXPRESSION ON J774 MACROPHAGES IN VITRO 
J774 macrophages were plated at a concentration of 1 x 106 cell/ml and pretreated 
with a 1:200 dilution of M.membrancea fractions (C021, C023 or C027) 1 hr before 
activating with 100 ng/ml LPS (E.Coli serotype R515) or loxoribine (1mM) for 24 
hrs.  Cells were subsequently washed and stained with fluorochrome-labelled 
monoclonal antibodies for numerous cell surface markers (i.e., CD40, CD80, CD86, 
TLR4-MD-2 and MHCII) [See Table 2.7] in preparation for cytometric analysis by 
flow cytometry [Figure 4.10-4.11].  
 
As expected, LPS and loxoribine enhanced the surface marker expression of CD40, 
CD80, CD86, TLR4-MD-2 and MHCII as seen in the top row of Figure 4.10-4.11 
where control DMSO cells are shown by the filled purple histogram and LPS or 
loxoribine-treated cells are overlaid with a green line. 
 
Marine fractions decreased the levels of key surface markers in J774 macrophages 
activated with LPS however no reduction in surface marker expression was 
demonstrated post activation with loxoribine [Figure 4.10-4.11]. M.membrancea 
fractions C023 and C027 had similar effects on most of the cell surface markers 
analysed; following LPS stimulation these fractions reduced the expression of CD40, 
CD80, MHCII and CD86 expression. Similarly fraction C021 was able to 
downregulate the surface expression of CD40, but to a greater extent than the other 
fractions. Furthermore, expression of TLR4-MD-2 was also markedly suppressed in 
C021-treated macrophages in response to LPS however levels of TLR4-MD-2 
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remained relatively unchanged in both C023- and C027-treated macrophage [Figure 
4.10].  
4.2.7 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea INHIBITS PHOSPHORYLATION OF 
NFκB-P65 BY TLR4 LIGAND ONLY 
J774 macrophages were plated at a concentration of 1 x 106 cell/ml and pretreated 
with DMSO (vehicle control) or M.membrancea fraction C027 at 1:200 dilution. The 
cells were then stimulated with LPS or loxoribine for a number of time-points (0, 5, 
15, 30 and 45 mins) and lysates were generated as described in [section 2.6]. Lysates 
were then run on SDS gels, transferred onto nitrocellulose membranes and 
immunoblotted for phospho-NFκB-p65 and phosphor-IRF3 [Figure 4.12-4.14]. 
 
As shown in figure 4.12 NFκB-p65 was phosphorylated rapidly with maximum 
phosphorylation occurring at 15 mins in LPS-stimulated cells. In cells pretreated with 
the M.membrancea fraction C027 this phosphorylation of p65 was significantly 
reduced at 15, 30 and 45 mins following activation with LPS compared to the control 
which can be seen in all three phospho-NFκB-p65 blots [Figure 4.12]. Densiometric 
analysis of the blots revealed that the changes at 5, 15 and 30 mins were statistically 
significant (p<0.001) [Figure 4.12]. Contrastingly, there was no alteration in the 
phosphorylation of NFκB-p65 in M.membrancea C027-treated cells post stimulation 
with loxoribine at any time point [Figure 4.13]. The phosphorylation of IRF3 was not 
modulated in cells treated with M.membrancea fraction C027 compared to control 
cells [Figure 4.14].  Again densiometric analysis demonstrated there was no 
significant change in phospho-IRF3 [Figure 4.14]. 
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FIGURE 4.1: The concentration of second-round M.membrancea fractions used did not 
significantly affect the viability of J774 macrophages 
Macrophage were pretreated with the specified dilutions (1:200, 1:500 and 1:1000) of either 
DMSO (vehicle control) or M.membrancea fractions (C002, C004, C017, C021, C023 and 
C027) for 1 hr prior  to stimulation with LPS (100ng/ml) for 24 hrs. Following 24hr activation 
cellular viability was assessed using an MTS assay (CellTiter 96® AQueous One Solution 
(Promega)). Results are expressed as a percentage of untreated cells 
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FIGURE 4.2: Second-round M.membrancea fractions suppress LPS-induced IL-12p40 
and IL-23 production in J774 macrophages. J774 macrophages were plated at (1x106 
cells/ml) and then treated with either DMSO (vehicle control) or second fractions of 
M.membranacea (C017, C021, C023, C027) for 1 hr prior to stimulation with 100ng/ml of 
LPS or loxoribine (1mM). Supernatants were recovered after 24 hs and assessed for levels of 
IL-12p40 and IL-23 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 4.3: Second-round M.membrancea fractions suppress LPS-induced IL-6 and 
IL-1 production in J774 macrophages. J774 macrophages were plated at (1x106 cells/ml) 
and then treated with either DMSO (vehicle control), second fractions of M.membranacea 
(C017, C021, C023, C027) for 1 hr prior to stimulation with 100ng/ml of LPS or loxoribine  
(1mM). Supernatants were recovered after 24 hrs and assessed for levels of IL-6 and IL-1β 
using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 4.4: Second-round M.membrancea fractions enhance LPS-induced IL-10 
production in J774 macrophages. J774 macrophages were plated at (1x106 cells/ml) and 
then treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with 100ng/ml of LPS or loxoribine (1mM). 
Supernatants were recovered after 24 hrs and assessed for levels of IL-10 and TNF-α using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 4.5: Second-round M.membrancea fractions suppress LPS-induced MIP-1α 
production in J774 macrophages. J774 macrophages were plated at (1x106 cells/ml) and 
then treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with 100ng/ml of LPS or loxoribine (1mM). 
Supernatants were recovered after 24 hrs and assessed for levels of MIP-1α and MIP-2α using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 4.6: Second-round M.membrancea fractions suppress LPS-induced MCP-1 
production in J774 macrophages. J774 macrophages were plated at (1x106 cells/ml) and 
then treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with 100ng/ml of LPS or loxoribine (1mM). 
Supernatants were recovered after 24 hrs and assessed for levels of MCP-1 using specific 
immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 4.7: Second-round M.membrancea fractions modulate the migration of J774 
macrophages in response to LPS. MØ were cultured with either DMSO (vehicle control), 
second fractions of M.membranacea (C017, C021, C023, C027) for 1 hr prior to stimulation 
with 100ng/ml of LPS or loxoribine (1mM).  3 x 105 cells were placed in the upper chamber 
of a Transwell® plate (8.0 µm).  Media containing recombinant GMCSF (10 ng/ml) and IL-2 
(10 BRMP/ml; were 1 BRMP = 40 pg/ml) was added to the lower chamber and plates were 
incubated for 5 hrs at 37 ºC. To determine the number of migrated cells, media from the 
bottom well was collected and events (cells) counted for 1 min on a BD FACsCalibur™.   
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 4.8: Second-round M.membrancea fractions modulate the rate of phagocytosis in J774 macrophage following LPS activation. Cells were 
plated at 5 x 105 cell/well in a 6-well plate and left to rest overnight. The next day, cells were treated with DMSO or second fractions of M.membrancea 
(C017, C021, C023 and C027) for 1 hr prior to stimulation with LPS (100ng/m). On the third day 2.5 x 106 fluorescently labelled latex beads (Sigma®) were 
added to each well at the indicated times. After the completed time course all wells were washed to remove excess beads and fixed in 200 µl 4 % (v/v) 
paraformaldehyde/PBS. The rate of phagocytosis over time in MØ was assessed using a BD FACSCalibur™. Top row: LPS-stimulated MØ (filled purple 
histogram) vs. LPS-stimulated MØ with the addition of latex beads (green line). Bottom three rows: LPS-stimulated MØ with the addition of latex beads 
(filled purple histogram) vs. marine extract-treated MØ with the addition of latex beads (green line). 
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FIGURE 4.9: Second-round M.membrancea fractions modulate the rate of phagocytosis in J774 macrophage following Loxoribine activation. MØ 
were plated at 5 x 105 cell/well in a 6-well plate and left to rest overnight. The next day, cells were treated with DMSO or second fractions of M.membrancea 
(C017, C021, C023 and C027) 1 hr prior to stimulation with loxoribine (1mM). On the third day 2.5 x 106 fluorescently labelled latex beads (Sigma®) were 
added to each well at the indicated times. After the completed time course all wells were washed to remove excess beads and fixed in 200 µl 4 % (v/v) 
paraformaldehyde/PBS. The rate of phagocytosis over time in MØ was assessed using a BD FACSCalibur™. Top row: loxoribine-stimulated MØ (filled 
purple histogram) vs. loxoribine -stimulated MØ with the addition of latex beads (green line). Bottom three rows: loxoribine-stimulated MØ with the 
addition of latex beads (filled purple histogram) vs. marine extract-treated MØ with the addition of latex beads (green line).
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FIGURE 4.9a: Confirmation that latex beads were phagocytosed following stimulation with 
LPS (100ng/ml) by fluorescent imaging (60X).  
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FIGURE 4.10: Second-round M.membrancea fractions modulate the expression of CD40, CD80, CD86 and MHCII on J774 Macrophages following 
LPS stimulation. MØ were treated with second fractions of M.membrancea (C021, C023, C027) for 1 hr prior to stimulation with LPS (100ng/ml). 
Subsequently, cells were washed and stained with specific antibodies.  Results of flow cytometric analysis and corresponding MFI values are shown. Top 
row:  DMSO-treated MØ (filled histogram) vs LPS stimulated MØ (green line). Bottom three rows: LPS-stimulated MØ (filled purple histogram) vs. LPS 
induced marine extract-treated MØ (green line). MFI values for marine treated cells are also displayed on all histograms for comparison of those of DMSO 
groups indicated in the top panel.  
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FIGURE 4.11: Second-round M.membrancea fractions modulate the expression of CD40, CD80, CD86 and MHCII on J774 Macrophages following 
Loxoribine activation. MØ were treated with DMSO or second fractions of M.membrancea (C021, C023, C027) for 1 hr prior to stimulation with loxoribine 
(1mM). Subsequently, cells were washed and stained with specific antibodies.  Results of flow cytometric analysis and corresponding MFI values are shown. 
Top row: DMSO-treated MØ (filled histogram) vs loxoribine stimulated MØ (green line). Bottom three rows: Loxoribine-stimulated MØ (filled purple 
histogram) vs. loxoribine induced marine extract-treated MØ (green line).MFI values for marine treated cells are also displayed on all histograms for 
comparison of those of DMSO groups indicated in the top panel.  
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FIGURE 4.12: Second-round M.membrancea fraction (C023) suppresses 
phosphorylation of NFκB-p65 in J774 macrophages following LPS activation. J774 
macrophages were plated at (1x106 cells/ml) and then treated with either DMSO (vehicle 
control), M.membranacea fraction C023 for 1 hr prior to stimulation with 100ng/ml of LPS 
over a time-course, after which cells were lysed and immunoblotted for phospho-NFκB-p65. 
Total cellular levels of total NFκB-p65 were used as a loading control. Densitometric analysis 
was conducted on immunoblots and graphical representation of phospho-NFκB-p65 
expression in arbitrary units (AU) is shown. 
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FIGURE 4.13: Second-round M.membrancea fraction (C023) does not suppress the 
phosphorylation of NFκB-p65 in J774 macrophages following loxoribine stimulation. 
J774 macrophages were plated at (1x106 cells/ml) and then treated with either DMSO (vehicle 
control), M.membranacea fraction C023 for 1 hr prior to stimulation with 100ng/ml of 
loxoribine over a time-course, after which celsl were lysed and immunoblotted for phospho-
NFκB-p65. Total cellular levels of total NFκB-p65 were used as a loading control. 
Densitometric analysis was conducted on immunoblots and graphical representation of 
phospho-NFκB-p65 expression in arbitrary units (AU) is shown. 
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FIGURE 4.14: M.membrancea fraction (C023) does not suppress the phosphorylation of 
IRF3 in J774 macrophages. J774 macrophages were plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), M.membranacea fraction C023 for 1 hr prior to 
stimulation with 100ng/ml of LPS over a time-course, after which cells were lysed and 
immunoblotted for phospho-IRF3. Total cellular levels of βactin were used as a loading 
control. Densitometric analysis was conducted on immunoblots and graphical representation 
of phospho-IRF3 expression in arbitrary units (AU) is shown. 
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4.3 DISCUSSION  
 
The findings of this study demonstrate that the second-round fractions of 
M.membrancea demonstrate anti-inflammatory properties when MØ are stimulated 
with the TLR4 ligand, LPS but not with the TLR7 ligand, loxoribine. Numerous 
studies have shown that over activation of macrophages play a major role in 
mediating chronic mucosal inflammation which has been seen in patients with 
ulcerative colitis and Crohn’s disease (Xavier and Podolsky 2007). Additionally, 
aggravated macrophage activation results in extensive tissue damage associated with 
autoimmune diseases such as RA (Feldmann and Maini 2008) and with infection, 
such as schistosmiasis (Wynn, et al. 2004). Therefore, altering macrophage function 
may hold great therapeutic potential. The parameters examined in this study have 
extensive implications and importance in both macrophage activation in inflammatory 
disease and their involvement in the normal immune response to infection. 
Furthermore, this comparative study has revealed that the marine fractions only 
suppress inflammation when cells are activated through certain TLRs.  
 
It has been extensively shown in numerous autoimmune diseases, such as RA, that the 
pro-inflammatory cytokines TNF-α, IL-1 and IL-6 synergistically mediate synovitis 
and destruction of bone cartilage and that IL-1 and TNF-α trigger the secretion of IL-6 
by synovial cells (Szekanecz and Koch 2007). A study by Hata and colleagues 
demonstrated that the synovial fluid of SKG mice contained high amounts of IL-6, 
TNF-α and IL-1 and that genetic deletion in IL-6 completely suppressed the 
development of arthritis in these mice (Hata, et al. 2004). In addition, enhanced IL-1 
production has been implicated in the development and progression of atherosclerosis 
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(Andersson, Libby and Hansson 2010). As a result considerable effort has been placed 
on developing therapeutic targets that can modulate the activities of these cytokines. 
Anti-TNF-α and IL-1 receptor antagonist (IL-1ra) drugs have been shown to 
ameliorate RA. For instance, treatment with anakinra, a recombinant form of human 
IL-1ra has been shown to significantly reduce levels of IL-1 and improve the 
progression of RA (Fleischmann,R.M, 2003). Results from our study provide 
evidence that the second-round fractions of M.membrancea robustly inhibits the 
production of the pro-inflammatory cytokine, IL-6 and a slight reduction in IL-1β 
following stimulation with LPS. Anti-IL-6 receptor antibodies have been developed as 
a therapeutic agent for these diseases, with some efficacy revealed in clinical trials. 
The effects of M.membrancea on the production of these cytokines have not been 
reported to date and suggests that it might be useful in diseases such as RA. 
Interestingly, two marine compounds bolinaquinone and petrosaspongiolide M 
isolated from Dysidea sp and Petrosaspongia nigra, respectively, have been shown to 
significantly reduce the levels of IL-1β in mice with crohns diseases (Busserolles, et 
al. 2005) 
 
IL-12 and IL-23 are closely related cytokines and are heterodimers made up of a 
common p40 subunit complexed to unique p35 (IL-12) or p19 (IL-23) subunits, 
respectively. The primary function of IL-12 and IL-23 is to direct newly activated T 
helper cells to a Th1 and Th17 phenotype, respectively (Bettelli and Kuchroo 2005). 
Marked production of IL-12 and IL-23 by macrophages are largely implicated in 
autoimmune diseases including; MS, IBS and RA and targeting these cytokine may 
hold therapeutic potential (Choy and Panayi 2001, Li, et al. 2007, Uhlig, et al. 2006). 
IL-12 is a potent inducer of IFN-γ which directs the induction of classically activated 
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macrophage by inactivating feedback inhibitory mechanisms, such as those mediated 
by IL-10 (Trinchieri 2003a). Furthermore, a study by Elliott and colleagues 
demonstrated that ustekinumab reduced the severity of plaque psoriasis by inhibiting 
IL-12 and IL-23 mediated cellular responses (Elliott, et al. 2009). Results here provide 
evidence that the second fractions of M.membrancea significantly inhibit IL-12p40 
and IL-23 in macrophages. To the best of our knowledge this is the first report of 
alterations in these cytokines by a marine extract.   
 
The interaction of surface markers CD40, CD80 and CD86 with T cells plays a major 
role in the activation and expansion of all effector and regulatory Th cell subsets (Lu, 
Wang and Linsley 1997). Overexpression of these surface markers has been reported 
in the inflamed tissue of patients with RA and IBD signifying that costimulatory 
markers are potential therapeutic targets for treating inflammatory disorders (Maerten, 
Liu and Ceuppens 2003).  In the present study, we found that culturing macrophages 
with second-round fractions of M.membrancea decreased the surface expression of 
CD80, but more significantly, CD40 expression, following stimulation with the TLR4 
ligands however no alteration was observed following TLR7 simulation.  This 
suggests that they may be useful in inflammatory diseases. The expression of MHCII 
was also markedly down-regulated by M.membrancea after LPS activation.  MHCII is 
essential for antigen processing and presentation which allows macrophages to initiate 
an adaptive immune response by interacting with T cells in the lymph nodes 
(Villadangos 2001). Many viruses have been shown to reduce MHC class II 
expression to avoid protective immune response such as Chlamydia trachomatis 
(Zhong, Fan and Liu 1999). However, abnormal expression of MHCII is linked to the 
development of autoimmune and infectious diseases such as RA (Guardiola and 
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Maffei 1993). A study by Alisky and colleagues demonstrated that the gluccorticoid, 
dexamethasome decreased levels of MHCII on activated microglia and this inhibition 
of class II expression may be one mechanism utilized by glucocorticoids in the 
suppression of neuroinflammatory disease (Alisky 2006). Our results demonstrate that 
M.membrancea significantly downregulate MHCII again indicating their potential in 
the treatment of a range of inflammatory diseases.  
 
Chemokines initiate the recruitment and activation of macrophages leading to 
enhanced inherent protective responses to invading pathogens. Macrophage 
infiltration is of paramount importance during innate host defence. In a model of 
pulmonary pseudomonas aeruginosa infection, inhibition of MIP-2 impaired bacterial 
clearance (Tsai, et al. 2000). In addition, depletion in MIP-1α levels significantly 
decreases clearance of Cryptococcus neoforms (Doyle and Murphy 1997).   The 
interplay between macrophage and bacteria leads to the clearance of infection. This 
highlights the benefits of these chemokines in antibacterial, antifungal and anti-viral 
host defence. Notably, impaired bacterial clearance and increased mortality in mouse 
models of bacterial pneumonia have been reported (Tang, et al. 1996). However, 
dysregulated expression of chemokines causes a mass influx of leukocytes to the site 
of inflammation leading to inflammatory diseases and infections such as RA, MS and 
meningococcal disease (Godessart and Kunkel 2001, Mellergard, et al. 2010, 
Halstensen, et al. 1993). Therefore impeding the production of chemokines and their 
receptors may have therapeutic potential. This study has assessed the modulatory 
effects of M.membrancea on MIP-1α, MIP-2 and MCP-1 following stimulation with 
bacterial and viral TLR ligands. The chemokines, MIP-1α and MCP-1 were 
significantly reduced following treatment with second fractions of M.membrancea 
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post TLR4 activation however no alteration was demonstration in chemokine 
production following stimulation with the viral ligand, loxoribine. MIP-1α production 
is enhanced in mice with pulmonary fibrosis by the secretion of IL-6 and anti-IL-6 
antibodies have been demonstrated to reduce MIP-1α expression thus ameliorating the 
disease (Smith, et al. 1998). Furthermore, MCP-1 mediates the trans-endothelial 
migration of leukocytes across the blood-brain barrier into the CNS initiating 
neuroinflammatory diseases including Alzheimer’s disease and Parkinson disease 
(Reale, Greig and Kamal 2009). Reduced levels of IL-6 in M.membrancea treated 
macrophage following LPS activation reported here may account for the decrease in 
MIP-1α. Similarly, MCP-1 is regulated by IL-1 and TNF-α (Adams and Lloyd 1997) 
therefore M.membrancea reduced IL-1 production may partly be responsible for the 
significant reduction in MCP-1 post LPS stimulation. In addition, the chemotaxis of 
cells have been implicated in the pathogenesis of inflammatory diseases. For instance, 
there is a significant enhancement in the migration of T cells in patients with systemic 
lupus erythematosus (SLE) (Li, et al. 2007).  Therefore the ability of the second-round 
fractions of M.membrancea to inhibit chemotaxis demonstrates that they have great 
anti-inflammatory potential. While the decrease in chemokines and chemotaxis may 
be beneficial in disease, it is also important to note that these chemokines are central 
to cell recruitment during infection and therefore may suppress the normal host 
immune response to infection and thus delay clearance. For instance, genetic deletion 
of MCP-1 in mice significantly reduced the recruitment of monocytes and therefore 
impaired the response to infection by the intracellular bacterium Mycobacterium 
tuberculosis (Lu, et al. 1998) 
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Phagocytosis is a vital role of all macrophages and is fundamental in the ingestion and 
clearing of pathogens (Aderem 2003). To date no studies have investigated the role of 
M.membrancea on phagocytosis activity. Here we report a suppressed ability of LPS-
stimulated macrophage to phagocytose as a result of M.membrancea treatment 
however no alteration in the ability to phagocytosis following loxoribine stimulation 
was observed. Numerous diseases have resulted from a decrease in the ability of 
macrophages to phagocytose (Allen and Aderem 1996). However, phagocytosis is 
crucial in the host in controlling infection and it has been well documented that a 
reduction in phagocytosis can cause increased susceptibility to infection. A study by 
Morran and workers demonstrated that phagocytosis is significantly reduced in 
diabetic NOD mice stimulated with LPS under hyperglycemic conditions causing 
infections to flourish (Morran, et al. 2009).  Results reported in our study suggest that 
M.membrancea can cause increased susceptibility to infection, particularly to those 
pathogens who utilize TLR4 however not to pathogens that utilize the viral receptor, 
TLR7.  Studies have shown that NFκB is involved in the regulation of phagocytosis 
and deletion of the p65 subunit by siRNA inhibited LPS induced phagocytosis 
(Suzuki and Umezawa 2006). A reduction in phosphorylation of NFκB-p65 was 
demonstrated in our study in M.membrancea treated macrophages following 
stimulation with only LPS which may account for the decreased ability of these cells 
to phagocytose. This overall study demonstrates that the second-fractions of 
M.membrancea have the ability to suppress effects downstream of the bacterial 
ligand, TLR4 and not the viral ligand, TLR7 which led us to explore their effects on a 
wider range of TLRs.  
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MECHANISM OF THE 
PURIFIED MARINE 
FRACTION, INV013 
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5.1 INTRODUCTION 
In chapter 3 we described the suppression of cytokine and chemokine production and 
the down-regulation in cell surface marker expression by crude marine extracts, 
A.digitia and M.membranace, and also by the sub-fractions of these extracts following 
stimulation of DCs with LPS. The fractions of M.membrancea, shown to have the 
most potent anti-inflammatory effect were further fractionated and in this chapter we 
set out to elucidate the mechanisms through which the marine extracts exert their anti-
inflammatory effects. Initially we screened the fractions M.membrancea C017, C021, 
C023, C027 to determine which fraction was the most active. Our collaborating 
chemists at UCD then isolated the individual marine compound (INV013) by using 
column chromatography and spectroscopy. INV013 was then used to determine the 
mechanism of action of the marine compound and identify the molecular target. Our 
marine extracts were able to alter the effects of DCs following activation with LPS 
however they did not modulate the function of immature DCs, this finding and the 
fundamental role of TLR4 in signalling in DC activation led us to investigate the 
effects of the marine extracts on TLR signalling pathways. 
 
LPS is the most widely studied and extensively used TLR ligand and it is an effective 
activator of, TLR4 (Sandor and Buc 2005, O'Neill 2007). TLR4 is the only TLR 
capable of activating both the MyD88 dependent and MyD88 independent pathways 
leading to the induction of the transcription factors NF-κB and IRF-3, respectively. 
This leads to the production of pro-inflammatory cytokines, such as IL-6, IL-12 and 
TNF-α, via NFκB activation and type 1 interferons (IFN) via IRF3 activation (Takeda 
and Akira 2007). TLR2 can heterodimerize with TLR1 and respond to triacylated 
lipoproteins such as Pam3CSk4 and peptidoglycan (PGN) or it can dimerize with 
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TLR6 and respond to diacylated lipoproteins such as zymosan (West, Koblansky and 
Ghosh 2006). TLR2 and TLR4 are distinct from other TLRs in that they are the only 
TLR complexes that utilize the adaptor protein Mal in association with MyD88 to 
initiate downstream signalling which leads to NFκB activation and the release of pro-
inflammatory cytokines such as  IL-12, IL-6 and IL-1β (Sheedy and O'Neill 2007).   
 
The remainder of the TLRs do not utilise the adaptor Mal. These include, TLR5 
which is activated by flagellin and activation of this receptor mobilizes the nuclear 
factor NFκB and stimulates pro-inflammatory production (de C Ventura, et al. 2008). 
TLR3 recognizes double stranded RNA (dsRNA), such as Poly:(IC), and the 
stimulation of this receptor induces the activation of IRF-3 through the exclusive 
signalling pathway independent of MyD88 utilizing a sole adaptor, TRIF (Sandor and 
Buc 2005).  TLR7 and TLR8 both detect viral single stranded RNA (ssRNA) such as 
loxoribine and TLR9 detects unmethylated CpG (CpG) motifs from bacterial and viral 
DNA. These TLRs trigger inflammatory cytokine secretion and IFN secretion through 
MyD88.  
 
In this chapter we examined the effects of second-round fractions of M.membrancea 
(C017, C021, C023, and C027) and the individual compound, INV013, on DCs 
activated with a range of TLR ligands. We also investigated their effects on NFκB and 
IRF3 activation which are downstream of TLR activation. Furthermore, we carried 
out advanced mechanistic studies on INV013 by examining its potential to target TLR 
adapter molecules.  
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5.2 RESULTS 
5.2.1 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea MODULATE CYTOKINE PRODUCTION 
BY DENDRITIC CELLS FOLLOWING STIMULATION WITH TLR2 
AND TLR4 LIGANDS ONLY IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), fractions of marine extracts; M. membranacea (C017, C021, 
C023 or C027) at 1:200 dilution for 1 hr prior to stimulation with TLR ligands, 
Pam3CSK4 (5µg/ml), Zymosan (10µg/ml), PGN (10µg/ml), Poly:(IC) (10µg/ml), 
Flagellin (5µg/ml), Loxoribine (5µg/ml) or CpG (2µM). After 24 hrs supernatants 
were removed and assessed for levels of IL-12p40 [Figure 5.1-5.2], IL-12p70 
[Figure 5.3-5.4], IL-23 [Figure 5.5-5.6], IL-6 [Figure 5.7-5.8], IL-1β [Figure 5.9-
5.10], TNF-α [Figure 5.11-5.12], and IL-10 [Figure 5.13] using specific 
immunoassays. 
 
The secretion of the pro-inflammatory cytokines IL-12p40, IL-12p70 and IL-23 were 
significantly suppressed in the second-round fractions of M.membrancea extracts 
(C017, C021, C023 and C027) following stimulation with LPS, Pam3CSK4, Zymosan 
and PGN [Figure 5.1-5.5] compared to the control group (p<0.001). In marine extract 
treated-DCs stimulated with PGN and LPS a significant reduction was also observed 
in the secretion of the pro-inflammatory cytokines IL-6 (p<0.05-p<0.001). In addition, 
a reduction was demonstrated in IL-1β post PGN activation (p<0.001) [Figure 5.7-
5.9] however there was increased levels of IL-1β when DCs were treated with 
fractions, C017 and C027 following activation with zymosan activation [Figure 5.9]. 
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The levels of TNF-α remained relatively unchanged regardless of the marine fraction 
used or the TLR ligand used [Figure 5.11-5.12].   Exposure of DCs to the 
M.membrancea second-fractions (C017, C021, C023, C027) resulted in a small 
increase in IL-10 with LPS (p<0.001) or Pam3CSK4 (p<0.01).  In contrast, the 
fractions decreased IL-10 production when cells were activated with PGN [Figure 
5.13]. Furthermore, no change was observed in any cytokine expression when DCs 
were activated through TLR3, TLR5, TLR7 and TLR9 with Poly:(IC), flagellin, 
loxoribine and CpG, respectively [Figure 5.2-5.14]. 
5.2.2 THE DOSE RESPONSE OF THE PURIFIED MARINE COMPOUND, 
INV013, ISOLATED FROM Membranipora membranacea USED HAVE 
NO SIGNFICIANT EFFECT ON CELL VIABILITY. 
Since the second fractions of M.membrancea C023 and C027 demonstrated the most 
significant anti-inflammatory effects our collaborators at UCD carried out further 
fractionations. From this we received a pure compound which we coded INV013. 
With this pure compound we carried out numerous experiments to determine its 
molecular target [see figure 3.1.1]. Initially we examined the toxicity of INV013 by 
exposing DCs to a range of dilutions. Following INV013 treatment the cell viability 
was assessed using Cell Titer 96 Aqueous One Solution (Promega, WI, USA) 
according to the manufacturer’s instructions. The doses of INV013 (1:100, 1:200, 
1:500, 1:1,000, 1:10,000) chosen for use in future experiments did not have any 
significant cytotoxic effect on DCs in vitro [Figure 5.15]   
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5.2.3 PURIFIED MARINE COMPOUND, INV013, ISOLATED FROM 
Membranipora membranacea MODULATES CYTOKINE 
PRODUCTION BY DENDRITIC CELLS FOLLOWING 
STIMULATION WITH TLR2 AND TLR4 LIGANDS ONLY IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control), purified marine compound, INV013 at 1:200 dilution for 1 
hr prior to stimulation with TLR ligands, LPS (100ng/ml), Zymosan (10µg/ml), PGN 
(10µg/ml), Poly:(IC) (10µg/ml), Flagellin (5µg/ml), Loxoribine (5µg/ml) and CpG 
(2µM). After 24 hrs supernatants were removed and assessed for levels of IL-12p40, 
IL-12p70 [Figure 5.16], IL-23, IL-6 [Figure 5.17], IL-1β, TNF-α [Figure 5.18], IL-
8, Rantes and IFN-β [Figure 5.19] using specific immunoassays. 
 
Treatment with INV013 significantly inhibited the production of the IL-12 family of 
cytokines IL-12p40, IL-12p70 and IL-23 following activation with the TLR4 ligand 
LPS (100ng/ml) and the TLR2 ligands PGN (10µg/ml) and Zymosan (10µg/ml) 
(p<0.001) [Figure 5.16-5.17]. Furthermore INV013-treated DCs were able to decrease 
the secretion of the pro-inflammatory cytokines, IL-6 and IL-1β post stimulation with 
LPS and PGN (p<0.001) and to a lesser extent post activation with zymosan (p<0.05) 
[Figure 5.17-5.18]. The levels of TNF-α, Rantes and IFN-β remained unchanged 
regardless of how cells were activated [Figure 5.18-5.19]. Furthermore, a notable 
decrease was observed in the secretion of the pro-inflammatory cytokine IL-8 in 
INV013-treated DCs post activation with LPS and PGN (p<0.001) [Figure 5.19]. In 
contrast, no alteration in the profile of any cytokine was demonstrated following 
stimulation with the TLR ligands: Poly:(IC), Flagellin, Loxoribine and CpG [Figure 
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5.16-5.19]. Therefore the pure compound, INV013, only exerts its anti-inflammatory 
effects following TLR2 and TLR4 ligation giving us a clear indication that the 
molecular target of INV013 is downstream of these TLR receptors. Furthermore our 
observation that INV013 blocked cytokines downstream of NFκB (IL-8) but not IRF3 
(IFN-β and Rantes) indicates that its target may be involved in the NFκB signalling 
pathway. 
5.2.4 PURIFIED MARINE COMPOUND, INV013, ISOLATED FROM 
Membranipora membranacea MODULATES CELL SURFACE 
MARKER EXPRESSION IN DENDRITIC CELLS IN VITRO 
BMDC isolated from the bone marrow of BALB/c mice were differentiated in the 
presence of GMCSF for 7 days and plated at 1 x 106 cell/ml and pretreated with either 
DMSO (vehicle control) or the purified compound, INV013 at 1:200 dilution for 1 hr 
prior to stimulation with or without 100ng/ml LPS (E.Coli serotype R515), PGN 
(5µg/ml) or flagellin (5µg/ml) for 24 hrs. Control cells and LPS, PGN and flagellin-
stimulated cells were subsequently stained with flourochrome-labelled monoclonal 
antibodies for various cell surface markers (CD11c, CD40, CD80, CD86, MHCII and 
TLR4-MD-2) [see Table 2.7] in preparation for cytometric analysis by flow 
cytometry [Figure 5.20-5.22]. 
 
Stimulation of DCs with LPS, PGN and flagellin enhanced the expression of CD40, 
CD80, CD86, TLR4-MD-2 and MHCII (top row) and the purified compound, 
INV013 was able to inhibit some of these LPS and PGN-induced changes (bottom 
row) [Figure 5.20-5.22]. Following, LPS and PGN stimulation INV013 significantly 
downregulated CD40 and MHCII expression. A small decrease was also observed in 
the expression of surface marker CD86 and there was no change in TLR-4-MD-2. In 
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addition, a significant downregulation in CD80 expression was demonstrated post 
PGN activation [Figure 5.20-5.21]. Contrastingly, INV013 did not change the 
expression of any surface markers following activation with flagellin [Figure 5.22]. 
Furthermore, there was no significant effect of INV013 on expression of these surface 
markers in resting DCs [Figure 5.20-5.22].   
 
5.2.5 SECOND-ROUND FRACTIONS OF MARINE EXTRACT 
Membranipora membranacea INHIBITS THE ACTIVATION OF NFκB 
BUT NOT IRF3 FOLLOWING TLR4 LIGATION 
Given that our extracts were able to block cytokines downstream of NFκB but not 
IRF3 we next examined the effect of M.membrancea second-round fractions on the 
activation of these transcription factors. HEK 293 cells stably expressing TLR4-
CD14-MD-2 (HEK-MTC) were plated at 1 x 105 cell/ml and transiently transfected 
with either an NFκB or ISRE luciferase reporter plasmid as described [see section 
2.8.3]. The IFN-stimulated response element (ISRE) provides a specific readout for 
the induction of IRF3. Following transfection the cells were pretreated with second 
fractionated M.membrancea extracts (C017, C021, C023 or C027) for 1 hr prior to 
stimulation with LPS for 6 hrs and activation of NFκB and IRF3 were assessed. In 
addition supernatants were removed and assessed for levels of downstream readouts, 
IL-8 and Rantes respectively, using specific immunoassays [Figure 5.23].  
 
In cells treated with second-round fractions of M.membrancea (C017, C021, C023 or 
C027) NFκB activation was significantly inhibited and subsequent IL-8 production 
was also reduced following stimulation with LPS (p<0.001) [Figure 5.23]. However, 
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no modulation was observed in IRF3 activation and subsequent Rantes secretion 
compared to control group [Figure 5.23] 
5.2.6 PURIFIED MARINE COMPOUND, INV013, ISOLATED FROM 
Membranipora membranacea DOSE DEPENDENTLY INHIBITS THE 
ACTIVATION OF NFκB BUT NOT IRF3 FOLLOWING TLR4 
LIGATION  
We next examined the effect of the purified compound INV013 on activation of 
NFκB and IRF3. HEK 293 cells stably expressing TLR4-CD14-MD-2 (HEK-MTC) 
were plated at 1 x 105 cell/ml and transiently transfected with either an NFκB or ISRE 
luciferase reporter plasmid as described [see section 2.8.3]. The IFN-stimulated 
response element (ISRE) provides a specific readout for the induction of IRF3. 
Following transfection the cells were pretreated with the purified compound, INV013 
at a range of doses (1:50, 1:100, 1:200, 1:500 1:1000, 1:10,000) for 1 hr prior to 
stimulation with LPS for 6 hrs and activation of NFκB and IRF3 were assessed. In 
addition supernatants were removed and assessed for levels of downstream readouts 
IL-8 and Rantes respectively using specific immunoassays [Figure 5.24].  
 
 As shown in figure 5.24 activation of NFκB was significantly inhibited in a dose 
dependant manner and subsequent IL-8 production was also significantly reduced in 
INV013 treated- HEK-MTC cells (p<0.001) post stimulation with LPS. In contrast, no 
alteration was demonstrated in the activation of IRF-3 or subsequent Rantes secretion 
compared to the control [Figure 5.24].  
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5.2.7 PURIFIED MARINE COMPOUND, INV013, ISOLATED FROM 
Membranipora membranacea INHIBITS MAL-DRIVEN NFKB IN HEK-
MTC CELLS. 
Given that INV013 specifically suppresses the effects of TLR4 and TLR2 ligands and 
the fact that TLR4 and TLR2 utilize Mal, we next examined whether INV013 could 
block Mal-driven NFκB activation. HEK 293 cells stably expressing TLR4-CD14-
MD-2 (HEK-MTC) were plated at 1 x 105 cell/ml and transiently transfected with 
NFκB luciferase reporter plasmid and co-transfected with reporter plasmid encoding 
Mal at different concentrations (20ng and 50ng) or co-transfected with TRIF, which 
served as a control. Following transfection the cells were pretreated with either 
DMSO (vehicle control) or purified compound, INV013 at 1:200 dilutions for 1 hr 
prior to LPS activation. Control cells, which were not transfected with either Mal or 
TRIF, were activated with LPS (100ng/ml) for 6 hrs [Figure 5.25].  
 
As expected, a significant reduction was observed in the activation of NFκB in 
INV013-treated cells following stimulation with LPS (p<0.001) [Figure 5.25].  
Exposure of HEK-MTC cells to INV013 was able to significantly block Mal-induced 
NFκB activation at both of the Mal concentrations employed (p<0.001). Furthermore, 
INV013 treatment exerted no effect on TRIF-driven induction of NFκB as expected 
[Figure 5.25].  
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5.2.8 PURIFIED MARINE COMPOUND, INV013, ISOLATED FROM 
Membranipora membranacea INHIBITS LPS INDUCED 
PHOSPHORYLATION OF NFκB-P65, DEGRADATION OF IκBα AND 
PHOSPHORYLATION OF P38 BUT NOT PHOSPHORYLATION OF 
IRF3 
Given that Mal is essential for the TLR4 activated pathway leading to the 
phosphorylation of NFκB-p65 on serine 536 (Doyle, Jefferies and O'Neill 2005), we 
decided to investigate the effects of INV013 on the phosphorylation of NFκB-p65 
using western blotting techniques.  BMDC isolated from the bone marrow of BALB/c 
mice were differentiated in the presence of GMCSF for 7 days and plated at 1 x 106 
cell/ml and pretreated with either DMSO (vehicle control), and the purified 
compound, INV013 at 1:200 dilution. The cells were then stimulated with LPS over a 
time course (0, 5, 15, 30 and 45 mins) and lysates were generated as described in 
[section 2.6.1].   Lysates were then run on SDS gels, transferred onto nitrocellulose 
membranes and immunoblotted for phospho-NFκB-p65, IκBα, phospho-p38 and 
phospho-IRF3 using specific antibodies. Total NFκB, β-actin and total p38 were used 
a controls [Figure 5.22-5.25].   
 
As shown in figure 5.26 NFκB-p65 was phosphorylated following LPS stimulation 
with maximum phosphorylation occurring at 15 mins in control cells. In cells 
pretreated with the purified marine compound, INV013, this phosphorylation of p65 
was significantly reduced at 0, 5, 15 and 30 mins following activation with LPS 
compared to the control phospho-NFκB-p65 blots. Densitometric analysis of the blots 
revealed that the changes at 5, 15 and 30 mins were statistically significant (p<0.001) 
[Figure 5.26]. 
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Interestingly, when the samples were immunoblotted for IκB degradation, it was 
observed that treatment with INV013 caused a delay in IκB degradation at 0, 5, 15 
and 30 mins when compared with the degradation in the control samples. Again 
densitometric analysis demonstrated this delay in degradation of IκBα be to 
statistically significant (p<0.001) [Figure 5.27]. Furthermore, we decided to examine 
p38, a member of the MAP Kinase family, which is phosphorylated downstream of 
Mal (Piao, et al. 2008). LPS strongly induced p38 phosphorylation where the effect of 
LPS was evident at 15 mins. INV013 was able to inhibit the phosphorylation of p38 in 
response to LPS at all time-points. Densitometric analysis of the blots revealed that 
the changes at 5, 15 and 30 mins were statistically significant (p<0.001) [Figure 
5.28]. In addition, we immunoblotted for phospho-IRF3 and as expected no alteration 
in the phosphorylation of IRF3 was observed in INV013-treated DCs post LPS 
activation. Again densitometric analysis demonstrated there was no significant change 
in phospho-IRF3 [Figure 5.29]. 
5.2.9 PURIFIED MARINE COMPOUND, INV013, ISOLATED FROM 
Membranipora membranacea INTERFERS WITH THE TRYOSINE 
PHOSPHORYLATION OF OVEREXPRESSED MAL IN HEK-MTC 
CELLS. 
Given that Mal undergoes tyrosine phosphorylation during TLR2 and TLR4 
signalling and that this phosphorylation is fundamental for the activation of NFκB we 
next examined whether INV013 could modulate the phosphorylation of Mal. HEK 
293 cells stably expressing TLR4-CD14-MD-2 (HEK-MTC) were plated 1 x 105 
cell/ml and transiently transfected with a reporter plasmid encoding Mal (4µg/dish). 
Following transfection, the cells were pretreated with either DMSO (vehicle control) 
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or purified compound, INV013 at 1:200 dilutions for 1 hr prior to LPS activation. The 
cells were then stimulated with LPS for a number of time-points (5, 15, 30 mins) and 
lysates were generated as described in [section 2.6.1]. Lysates were 
immunoprecipitated (IP) with HA-Mal antibody using A/G sepharose beads as 
described in section [section 2.8]. Lysates were then run on SDS gels, transferred onto 
PVDF membranes and immunoblotted (IB) for α-phospho-tyrosine. To examine total 
levels of Mal proteins, whole cell lysates were immunblotted with HA-Mal antibody.  
 
Figure 5.30 demonstrates that immunopreciptiation of Mal with HA-Mal and 
immunblot analysis with α-phospho-tyrosine-specific antibody showed a constitutive 
Mal tyrosine phosphorylation. In cells pretreated with the purified marine compound, 
INV013, tyrosine phosphorylation of overexpressed Mal was significantly reduced 
[Figure 5.30]. Furthermore, INV013-treated cells downregulated the tyrosine 
phosphorylation of Mal at 5, 15 and 30 mins following activation with LPS compared 
to the control Densitometric analysis showed that these reductions were statistically 
significant (p<0.05 p<0.01-) [Figure 5.30] 
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FIGURE 5.1: Second-round M.membrancea fractions suppress IL-12p40 production in 
DCs following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in 
the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either 
DMSO (vehicle control), second fractions of M.membranacea (C017, C021, C023, C027) for 
1 hr prior to stimulation with either LPS (100ng/ml), PGN (5µg), Pam3CSK4 (5µg) or 
zymosan (10µg). Supernatants were recovered after 24 hrs and assessed for levels of IL-
12p40 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.2: Second-round M.membrancea fractions do not suppress IL-12p40 
production in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. 
BMDCs were differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) 
and then treated with either DMSO (vehicle control), second fractions of M.membranacea 
(C017, C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin 
(5µg), loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and 
assessed for levels of IL-12p40 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.3: Second-round M.membrancea fractions suppress IL-12p70 production in 
DCs following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in 
the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either 
DMSO (vehicle control), second fractions of M.membranacea (C017, C021, C023, C027) for 
1 hr prior to stimulation with either LPS (100ng/ml), PGN (5µg), Pam3CSK4 (5µg) or 
zymosan (10µg). Supernatants were recovered after 24 hrs and assessed for levels of IL-
12p70 using specific immunoassays. Results are ± SEM of quadruplicate assays and represent 
three independent experiments.  ***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-
activated group in the presence/absence of marine fractions as determined by one-way 
ANOVA test  
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FIGURE 5.4: Second-round M.membrancea fractions do not suppress IL-12p70 
production in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. 
BMDCs were differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) 
and then treated with either DMSO (vehicle control), second fractions of M.membranacea 
(C017, C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin 
(5µg), loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and 
assessed for levels of IL-12p70 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.5: Second-round M.membrancea fractions suppress IL-23 production in DCs 
following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in the 
presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO 
(vehicle control), second fractions of M.membranacea (C017, C021, C023, C027) for 1 hr 
prior to stimulation with either LPS (100ng/ml), PGN (5µg), Pam3CSK4 (5µg) or zymosan 
(10µg). Supernatants were recovered after 24 hrs and assessed for levels of IL-23 using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.6: Second-round M.membrancea fractions do not suppress IL-23 production 
in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. BMDCs were 
differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin (5µg), 
loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and assessed for 
levels of IL-23 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.7: Second-round M.membrancea fractions suppress IL-6 production in DCs 
following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in the 
presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO 
(vehicle control), second fractions of M.membranacea (C017, C021, C023, C027) for 1 hr 
prior to stimulation with either LPS (100ng/ml), PGN (5µg), Pam3CSK4 (5µg) or zymosan 
(10µg). Supernatants were recovered after 24 hrs and assessed for levels of IL-6 using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.8: Second-round M.membrancea fractions do not suppress IL-6 production 
in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. BMDCs were 
differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin (5µg), 
loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and assessed for 
levels of IL-6 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.9: Second-round M.membrancea fractions suppress IL-1β production in DCs 
following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in the 
presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO 
(vehicle control), second fractions of M.membranacea (C017, C021, C023, C027) for 1 hr 
prior to stimulation with either LPS (100ng/ml), PGN (5µg), Pam3CSK4 (5µg) or zymosan 
(10µg). Supernatants were recovered after 24 hrs and assessed for levels of IL-1β using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.10: Second-round M.membrancea fractions do not suppress IL-1β production 
in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. BMDCs were 
differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin (5µg), 
loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and assessed for 
levels of IL-1β using specific immunoassays.Results are ± SEM of quadruplicate assays and 
represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.11: Second-round M.membrancea fractions do not suppress TNF-α 
production in DCs following stimulation with TLR2 and TLR4 ligands. BMDCs were 
differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with either LPS (100ng/ml), PGN (5µg), 
Pam3CSK4 (5µg) or zymosan (10µg). Supernatants were recovered after 24 hrs and assessed 
for levels of TNF-α using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.12: Second-round M.membrancea fractions do not suppress TNF-α 
production in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. 
BMDCs were differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) 
and then treated with either DMSO (vehicle control), second fractions of M.membranacea 
(C017, C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin 
(5µg), loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and 
assessed for levels of TNF-α using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.13: Second-round M.membrancea fractions enhance IL-10 production in DCs 
following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in the 
presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either DMSO 
(vehicle control), second fractions of M.membranacea (C017, C021, C023, C027) for 1 hr 
prior to stimulation with either LPS (100ng/ml), PGN (5µg), Pam3CSK4 (5µg) or zymosan 
(10µg). Supernatants were recovered after 24 hrs and assessed for levels of IL-10 using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.14: Seond-round M.membrancea fractions do not enhance IL-10 production 
in DCs following stimulation with TLR3, TLR5, TLR7 and TLR9 ligands. BMDCs were 
differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control), second fractions of M.membranacea (C017, 
C021, C023, C027) for 1 hr prior to stimulation with either poly:(IC) (10µg), flagellin (5µg), 
loxoribine (1mM) or CPG (2mM). Supernatants were recovered after 24 hrs and assessed for 
levels of IL-10 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.15: The concentrations of the purified marine compound, INV013, used do 
not significantly affect the viability of dendritic cells (DCs). 
BMDCs were grown for 7 days and then treated with either a range of dilutions (1:100, 1:200, 
1:500, 1:1000, 1:10000) of DMSO (vehicle control) or purified compound, INV013 for 24 
hrs. Following 24 hr treatment cellular viability was assessed using an MTS assay (Cell Titer 
96 Aqueous One Solution – Promega, WI, USA). Results are expressed as a percentage of 
untreated cells. 
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FIGURE 5.16: The purified marine compound, INV013, suppresses IL-12p40 and IL-
12p70 production in DCs following stimulation with TLR2 and TLR4 ligands. BMDCs 
were differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control) or INV013 for 1 hr prior to stimulation with 
numerous TLR ligands. Supernatants were recovered after 24 hrs and assessed for levels of 
IL-12p40 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.  
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.17: The purified marine compound, INV013, suppresses IL-23 and IL-6 
production in DCs following stimulation with TLR2 and TLR4 ligands. BMDCs were 
differentiated in the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then 
treated with either DMSO (vehicle control) or INV013 for 1 hr prior to stimulation with 
numerous TLR ligands. Supernatants were recovered after 24 hrs and assessed for levels of 
IL-23 and IL-6 using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.  
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.18: The purified marine compound, INV013, suppresses IL-1β production in 
DCs following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in 
the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either 
DMSO (vehicle control) or INV013 for 1 hr prior to stimulation with numerous TLR ligands. 
Supernatants were recovered after 24 hrs and assessed for levels of IL-1β and TNF-α using 
specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.  
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.19: The purified marine compound, INV013, suppresses IL-8 production in 
DCs following stimulation with TLR2 and TLR4 ligands. BMDCs were differentiated in 
the presence of GMCSF for 7 days, plated at (1x106 cells/ml) and then treated with either 
DMSO (vehicle control) or INV013 1 hr prior to stimulation with numerous TLR ligands.. 
Supernatants were recovered after 24 hrs and assessed for levels of IL-8, Rantes and IFN-β 
using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.   
***p<0.001, **p<0.01, *p<0.05 comparing TLR ligand-activated group in the 
presence/absence of marine fractions as determined by one-way ANOVA test  
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FIGURE 5.20: The purified marine compound, INV013, modulates the expression of CD40, CD86 and MHCII on the surface of DCs following 
stimulation with TLR4 ligand. BMDC were differentiated in the presence of GMCSF for 7 days and then treated with DMSO or INV013 for 1 hr prior to 
stimulation with LPS (100ng/ml).Subsequently, cells were washed and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown. Top row: DMSO-treated DCs (filled histogram) and LPS-stimulated DCs (green line). Middle row: DMSO-treated 
DCs vs INV013-treated DCs. Bottom row: LPS-stimulated DCs (filled purple histogram) vs. LPS induced INV013-treated DCs (green line). MFI values for 
INV013-treated cells are also displayed on all histograms for comparison of those of DMSO groups indicated in the top panel.  
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FIGURE 5.21: The purified marine compound, INV013, modulates the expression of CD40, CD80, CD86 and MHCII on the surface of DCs 
following stimulation with TLR2 ligand. BMDC were differentiated in the presence of GMCSF for 7 days and then treated with DMSO or INV013 for 1 hr 
prior to stimulation with PGN (5µg).Subsequently, cells were washed and stained with specific antibodies. Results of flow cytometric analysis and 
corresponding MFI values are shown.  Top row: DMSO-treated DCs (filled histogram) and PGN-stimulated DCs (green line). Middle row: DMSO-treated 
DCs vs INV013-treated DCs. Bottom row: PGN-stimulated DCs (filled purple histogram) vs. PGN induced INV013-treated DCs (green line). MFI values for 
INV013-treated cells are also displayed on all histograms for comparison of those of DMSO groups indicated in the top panel.  
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FIGURE 5.22: The purified marine compound, INV013, does not modulate the expression any of on the surface markers of DCs following TLR5 
stimulation. BMDC were differentiated in the presence of GMCSF for 7 days and then treated with DMSO or INV013 for 1 hr prior to stimulation with 
flagellin (100ng/ml).Subsequently, cells were washed and stained with specific antibodies. Results of flow cytometric analysis and corresponding MFI values 
are shown Top row: DMSO-treated DCs (filled histogram) and flagellin-stimulated DCs (green line). Middle row: DMSO-treated DCs vs INV013-treated 
DCs. Bottom row: flagellin-stimulated DCs (filled purple histogram) vs. flagellin induced INV013-treated DCs (green line).  MFI values for INV013-treated 
cells are also displayed on all histograms for comparison of those of DMSO groups indicated in the top panel.  
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FIGURE 5.23: Second-round M.membrancea fractions suppress activation of NFκB but 
not IRF3 activation downstream of TLR4. HEK-MTC cells were transiently transfected 
with either an NFκB or ISRE luciferase reporter plasmid for 24hrs. Subsequently, HEK-MTC 
cells were treated with either DMSO (vehicle control) or second fractions of M.membrancea 
fractions (C017, C021, C023, C027) for 1hr prior to LPS activation.  Induction of both 
transcription factors was assessed following 6 hr stimulation with LPS (100ng/ml). 
Supernatants were also recovered and levels for IL-8 and Rantes were measured using 
specific immunoassays.  
Results are ± SEM of quadruplicate assays and represent three independent experiments.  
***p<0.001, **p<0.01, *p<0.05 vs DMSO/LPS vs marine extract/LPS control determined by 
one-way ANOVA 
 
 
 
 
 
 
 
 
 
 
 
NFκB IRF3 
 210 
 
 
 
  
Co
ntr
ol 1:5
0
1:1
00
1:2
00
1:5
00
1:1
000
1:1
000
0
0
10
20
30
CTL
LPS (100ng/ml)
INV013/LPS
***
***
***
*** ***
***
R
e
la
tiv
e 
Li
gh
t U
n
its
 
(R
LU
)
Co
ntr
ol 1:5
0
1:1
00
1:2
00
1:5
00
1:1
000
1:1
000
0
0
1
2
3
4
5
CTL
LPS (100ng/ml)
INV013/LPS
R
e
la
tiv
e 
Li
gh
t U
n
its
 
(R
LU
)
Co
ntr
ol
1:2
00
0
200
400
600
800
1000
CTL
LPS (100ng/ml)
INV013/LPS
***
IL-8
IL
-
8 
pg
/m
l
Co
ntr
ol
1:2
00
0
200
400
600
800
CTL
LPS (100ng/ml)
INV013/LPS
Rantes
Ra
n
te
s 
pg
/m
l
 
FIGURE 5.24: The purified marine compound, INV013, suppresses activation of NFκB 
but not IRF3 activation downstream of TLR4 in a dose dependant manner. HEK-MTC 
cells were transiently transfected with either an NFκB, ISRE luciferase reporter plasmid for 
24hrs. Subsequently, HEK-MTC cells were treated with either DMSO (vehicle control) or 
INV013.  Induction of both transcription factors was assessed following 6 hr stimulation with 
LPS (100ng/ml). Supernatants were also recovered and levels for IL-8 and Rantes were 
measured using specific immunoassays. 
Results are ± SEM of quadruplicate assays and represent three independent experiments.  
***p<0.001, **p<0.01, *p<0.05 vs DMSO/LPS vs INV013/LPS control determined by one-
way ANOVA 
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FIGURE 5.25: The purified marine compound, INV013, blocks Mal-driven activation of 
NFκB.  HEK-MTC cells were transiently transfected with either an NFκB, Mal (20ng. 50ng), 
TRIF luciferase reporter plasmid for 24hrs. Cells were then cultured with DMSO (vehicle 
control) or INV013 for 1hr. Activation of NFκB was assessed following 6 hr stimulation with 
LPS (100ng/ml).  
Results are ± SEM of quadruplicate assays and represent three independent experiments.  
***p<0.001, **p<0.01, *p<0.05 vs DMSO/Mal vs marine extract/Mal vehicle control 
determined by one-way ANOVA 
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FIGURE 5.26: The purified marine compound, INV013, suppresses phosphorylation of 
NFκBp65 in DCs. BMDCs were differentiated in the presence of GMCSF for 7 days, plated 
at (1x106 cells/ml) and then treated with either DMSO (vehicle control) or INV013 (1:200 
dilution) 1 hr prior to stimulation with 100ng/ml of LPS over a time-course after which cells 
were lysed and immunoblotted for phospho-NFκBp65. Total cellular levels of total NFκBp65 
were used as a loading control. Densitometric analysis was conducted on immunoblots and 
graphical representation of phosphor-NFκBp65 expression in arbitrary units (AU) is shown. 
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FIGURE 5.27: The purified marine compound, INV013, suppresses the degradation of 
IκBα in DC. BMDCs were differentiated in the presence of GMCSF for 7 days, plated at 
(1x106 cells/ml) and then treated with either DMSO (vehicle control) or INV013 (1:200 
dilution) 1 hr prior to stimulation with 100ng/ml of LPS over a time-course, after which cell 
were lysated and immunoblotted for IκBα. Total cellular levels of βactin were used as a 
loading control. Densitometric analysis was conducted on immunoblots and graphical 
representation of IκBα expression in arbitrary units (AU) is shown. 
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FIGURE 5.28: The purified marine compound, INV013, suppresses phosphorylation of 
p38 in DCs. BMDCs were differentiated in the presence of GMCSF for 7 days, plated at 
(1x106 cells/ml) and then treated with either DMSO (vehicle control) or INV013 (1:200 
dilution) 1 hr prior to stimulation with 100ng/ml of LPS over a time-course, after which cells 
were lysed and immunoblotted for phospho-p38. Total cellular levels of total p38 were used 
as a loading control. Densitometric analysis was conducted on immunoblots and graphical 
representation of phospho-p38 expression in arbitrary units (AU) is shown. 
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FIGURE 5.29: The purified marine compound, INV013, doesn’t suppress 
phosphorylation of IRF3 in DCs. BMDCs were differentiated in the presence of GMCSF for 
7 days, plated at (1x106 cells/ml) and then treated with either DMSO (vehicle control) or 
INV013 (1:200 dilution) 1 hr prior to stimulation with 100ng/ml of LPS over a time-course, 
after which cells were lysed and immunoblotted for phospho-IRF3. Total cellular levels of 
βactin were used as a loading control. Densitometric analysis was conducted on immunoblots 
and graphical representation of phospho-IRF3 expression in arbitrary units (AU) is shown. 
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FIGURE 5.30: The purified marine compound, INV013, suppresses Mal-tyrosine 
phosphorylation in HEK-MTCs. HEK-MTC cells were transiently transfected with HA-Mal 
(4µg) for 24hrs. Subsequently, HEK-MTC cells were cultured with DMSO (vehicle control) 
or INV013 for 1hr prior to stimulation with 100ng/ml of LPS over various time-points as 
indicated, after which cells were lysed, immunoprecipitaed with HA-Mal and immunoblotted 
with α-phospho-tyrosine antibody. Whole cell lysates were immunoblotted with HA-Mal as a 
loading control. Densitometric analysis was conducted on immunoblots and graphical 
representation of α-phospho-tyrosine expression in arbitrary units (AU) is shown. 
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5.3 DISCUSSSION  
 
The focus of this study was to investigate the possible mechanism underlying the anti-
inflammatory effects of M.membrancea on DCs reported in chapter 3. The ability of 
these fractions to suppress macrophage function following activation through TLR4 
and not through TLR7 led our study to examine the possible mechanisms underlying 
the M.membrancea extracts by activating DCs with a panel of TLR ligands. In this 
study we have demonstrated that the pure compound of M.membrancea (INV013) 
exerts its anti-inflammatory effects by suppressing the phosphorylation of Mal, the 
downstream adaptor which is unique to the TLR2 and TLR4 signalling pathways.  
 
TLRs sense invasion of pathogens by detecting microbial components that are 
conserved among micro-organisms thus triggering the activation of innate immunity. 
They are considered a link between innate and adaptive immunity due to their 
promotion of pro-inflammatory cytokine production, surface maker expression and 
activation of T cells. On engagement with ligands, TLRs recruit specific adaptor 
molecules that propagate downstream signalling (McCoy, et al. 2008). Two 
predominant TLR signalling pathways have been identified, the MyD88 dependant 
and the MyD88 independent pathways. Although different TLRs share the same 
pathways, there are dissimilarities in patterns of the inflammatory response to TLR 
ligands (Akashi-Takamura and Miyake 2008).  Roles for TLRs have emerged in 
sepsis (Lorenz, et al. 2002), RA (Seibl, et al. 2003), asthma (Eder, et al. 2004) and 
atherosclerosis (Kiechl, Wiedermann and Willeit 2003). Numerous studies have 
reported that interfering with TLR signalling can improve inflammatory diseases 
(O'Neill, Bryant and Doyle 2009) . For example, a study by Posadas and colleagues 
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demonstrated that mannoproteins protects intestinal tissue against Salmonella 
triphymorium infection in rats by impeding TLR5 expression (Posadas, et al. 2010) 
 
Results here demonstrate that treatment of DCs with second-round fractions of 
M.membracea (C017,C021,C023,C027) significantly suppresses the production of the 
IL-12 family of cytokines (IL-12p40, IL-12p70 and IL-23) following activation with 
ligands for TLR4 (LPS),  TLR2/1 (PGN, Pam3CSK4) and ligands for TLR2/6 
(zymosan). In contrast, the M.membranea fractions had no effect when cells were 
activated with ligands for TLR5 (flagellin), TLR3 (Poly:(IC)), TLR7 (loxoribine) and 
TLR9 (CpG). This result demonstrated that our compound is exerting its anti-
inflammatory properties downstream of TLR2 and TLR4 pathway but does not affect 
TLR signalling downstream of any other TLR. TLR2 and TLR4 are highly expressed 
in the synovial tissue of patients with RA and are associated with high levels IL-12 
(Radstake, et al. 2004). Additionally, a study by Gomariz and workers demonstrated 
an up-regulation of TLR2 and TLR4 in a mouse model of Crohn’s disease and 
treatment with Vasoactive intestinal peptide (VIP) induced a decrease in these 
receptors ameliorating the disease (Gomariz, et al. 2005). We found C023 and C027 
to have the most potent anti-inflammatory effects so we therefore chose these 
fractions to be further fractionated in order to carry out advanced mechanistic studies. 
We received a purified compound from our collaborators in UCD termed INV013. 
This pure compound demonstrated similar properties to the second fractions of 
M.membrancea, downregulating the production of pro-inflammatory cytokines IL-
12p40, IL-12p70, IL-23, IL-6 and IL-1β following stimulation with TLR4 and TLR2 
ligands however not with the other TLR ligands. A number of studies have reported 
molecules that specifically suppress TLR2 and TLR4, activation. For instance, the 
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compound rabeximod has been shown to suppress arthritis severity in mice by 
exerting its anti-inflammatory effects downstream of TLR2 and TLR4 however it’s 
molecular target has not been identified (Hultqvist, et al. 2010). Therefore we decided 
to examine the effects of INV013 on the pathways downstream of these TLRs. 
 
TLR2 signalling activates the MyD88 dependant pathway leading to activation of 
NFκB however TLR4 signalling is unique in its ability to activate both NFκB and 
IRF3 via MyD88 dependent and independent pathways, respectively (Akira and 
Takeda 2004a, Akashi-Takamura and Miyake 2008). The data generated in this study 
demonstrates that second-round fractions of M.membrancea and the purified 
compound, INV013 all suppress NFκB activation and subsequent IL-8 production. 
This wasn’t surprising as many of the cytokines that M.membrancea fractions had 
suppressed are know to be NFκB dependant such as IL-12, IL-1β and IL-6 (Atreya, 
Atreya and Neurath 2008).  Furthermore, our data demonstrates that INV013 has no 
effect on IRF-3 activation post LPS stimulation. The activation of IRF-3 leads to the 
secretion of IFN-β and Rantes (Yoneyama, Suhara and Fujita 2002). Our results also 
demonstrate no alteration in the production of these cytokines in INV013-treated cells 
following TLR4 stimulation indicating further that this compound mediates its affects 
through the MyD88 dependant pathway.  
 
Upon activation, NFκB is released from its inhibitory protein IκBα, leading to the 
phosphorylation of NFκB on serine residues. This phosphorylation is required for 
transactivation of gene expression because mutating these serine residues greatly 
impairs NFκB-dependant gene transcription (Schmitz, Bacher and Kracht 2001).  Our 
data demonstrates that culturing DCs in the presence of INV013 inhibits this 
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phosphorylation of p65 post LPS stimulation. A report by (Moussaieff, et al. 2007)  
demonstrated that the compound incensole acetate isolated from Boswellia resin, 
inhibited inflammation in the inflamed paw model in mice by suppressing the 
phosphorylation of NFκBp65. Furthermore, numerous marine compounds have been 
reported to date as NFκB inhibitors (Folmer, et al. 2008). For example, 
hymenialdisine, a compound isolated from the marine sponges Axinella verrucosa and 
Acanthella aurantiaca, inhibited IL-8 production in U937 cells by blocking DNA 
binding of NFκB following stimulation with LPS (Breton and Chabot-Fletcher 1997). 
Similarly, Cycloprodigiosin hydrochloride (cPrG·HCl) obtained from a marine 
bacterium Pseudoalteromonas denitrificans suppresses NFκB-dependent gene 
expression through the inhibition of transcriptional activation (Kamata, et al. 2001). 
We also examined the signalling molecule IκBα that leads to NFκB activation. Our 
data demonstrates that the degradation of IκBα was interrupted in INV013-treated 
DCs post LPS activation. A number of marine compounds have been shown to 
interfere with this signalling molecule. For example, Scytonemin a marine natural 
product isolated from cyanobacteria inhibits IκBα degradation (Shah, et al. 2002). Of 
significant note is that the phosphorylation of the p65 subunit of NFκB at serine 536 
in response to LPS requires the adaptor Mal (Gray, et al. 2006). We next examined 
the effect of INV013 on Mal driven NFκB activation and showed that it is inhibited 
indicating that our extract is mediating its anti-inflammatory effects through Mal.  A 
study by Medvedev and colleagues demonstrated that overexpression of Mal in 
human embryonic kidney 293T cells led to activation of p38, NFκB and IL-8 
expression and mutations in the phosphorylation of Mal reduces the ability to mediate 
IκBα degradation, p38 phosphorylation and NFκB reporter activation (Piao, et al. 
2008).  Given that p38 is phosphorylated downstream of Mal we examined the effects 
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of INV013 on p38 phosphorylation. Our findings support our hypothesis that INV013 
targets Mal. Numerous reports showed a significant reduction in the phosphorylation 
of p38 in Mal deficient cells (Yamamoto, et al. 2003b). Additionally, activation of the 
p38 pathway has been shown to be involved in IL-12p40 promoter activity and 
cytokine release in DCs. Our study demonstrated that treatment of DCs with INV013 
significantly reduced the phosphorylation of p38.  
 
It has been well documented that inhibiting Mal impedes the production of pro-
inflammatory cytokine following stimulation with TLR2 and TLR4 ligands 
(Yamamoto,M. 2010). The reduced levels (Kikuchi, et al. 2003) of pro-inflammatory 
cytokines in M.membrancea treated DCs following TLR4 and TLR2 activation 
reported here may be due to inhibition of Mal, given that the marine extract only 
exerts there effects when DCs are activated by TLR2 or TLR4 ligand. Additionally, it 
has been shown that inhibition of Mal alters the expression of cell surface markers. A 
study by Akira and workers demonstrated that enhancement of MHCII following LPS 
activation was severely impaired in Mal-deficient splenocytes (Yamamoto, et al. 
2002). Interestingly we showed a significant reduction in MHCII expression in 
INV013-treated DCs post TLR2 and TLR4 activation however there was no alteration 
following TLR5 stimulation.  
 
To date no specific compounds inhibiting Mal have been identified. However, a Mal 
inhibitory peptide that specifically interferes with Mal signalling by blocking TIR-
TIR domain interactions has been described and is commonly used in experiments to 
examine the effects of Mal on TLR signalling (Horng, et al. 2002a, Doyle, et al. 
2003). 
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The final question of this study concerns how INV013 inhibits Mal signalling. A 
study by Gray and workers demonstrated that upon LPS stimulation of macrophages, 
Mal is tyrosine phosphorylated by Bruton’s tyrosine kinase (Btk) at residues 86 and 
187 following TLR2 and TLR4 activation (Gray, et al. 2006).  It has been reported in 
numerous studies that tyrosine phosphorylation of Mal is essential in TLR2 and TLR4 
signalling (Piao, et al. 2008). Furthermore, it was shown that this tyrosine 
phosphorylation of Mal is important for the translocation of NFκB into the nucleus 
via the phosphorlaytion of the p65 subunit (Doyle, Jefferies and O'Neill 2005).  To 
confirm that INV013 exerts its effect on Mal, we carried out immunoprecipitation 
with HEK-MTC cells over expressing Mal. Our findings demonstrated a significant 
reduction in the tyrosine phosphorylation of Mal in INV013-cultured DCs post LPS 
stimulation. Numerous diseases such as diabetes, RA and cardiovascular disease are 
linked to both TLR2 and TLR4 therefore interfering with the tyrosine phosphorylation 
of Mal is an attractive target for these diseases (Underhill, et al. 1999, Park, et al. 
2004, Frantz, Ertl and Bauersachs 2007).  In addition, a mutation in Mal where the 
serine at position 180 is mutated to leucine, conferred protection against disease 
including pneumonia, malaria and bacteraemia (Khor, et al. 2007). 
 
Results presented in this chapter confirm that our purified marine compound, INV013, 
exerts its anti-inflammatory effects on the TLR adaptor, Mal, specifically by 
inhibiting its tyrosine phosphorylation. A schematic illustrating our proposed model 
for INV013-mediated effects on TLR2 and TLR4 signalling is presented in figure 
5.30 
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FIGURE 5.30: Illustration of our proposed model of INV013-mediated effects on TLR4 and 
TLR2 signalling. INV013 inhibits MAP kinase and NFκB activation by suppressing the 
phosphorylation of the adaptor MAL following TLR2 and TLR4 stimulation.  
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6.1 GENERAL DISCUSSION 
 
Inflammation is a crucial process initiated by the innate cells of the immune system 
and dysregulation at any stage of cellular activation can have detrimental effects.  
Inflammation is part of the normal host response that protects us from invading 
pathogens and infectious micro-organisms in general circumstances (Calder 2006). 
However, excessive and prolonged inflammation is harmful to the host and in some 
cases fatal, leading to extensive tissue damage, uncontrolled infection and acute and 
chronic diseases (O'Neill, Bryant and Doyle 2009). Numerous inflammatory diseases 
have been associated with this sustained inflammatory response such as, IBD, MS, 
RA and atherosclerosis (Andreakos, Foxwell and Feldmann 2004). Biological agents 
such as steroids have been developed to treat these diseases however a large 
proportion of patients are unresponsive to treatments and can have severe side effects 
(Hultqvist, et al. 2010). Therefore, novel compounds with better therapeutic efficacy 
are required. Within many inflammatory cascades or pathways there are often pivotal 
molecular targets that, when antagonized or neutralized, block the output of the 
pathway. For instance, resveratrol, a polyphenol found in grapes, has been shown to 
exert its anti-inflammatory effects by interacting with the adaptor TBK-1 which is 
downstream of TLR3 and TLR4 (Youn, et al. 2005). Furthermore, advances in our 
understanding of the inflammatory process have led to the development of therapies 
which selectively inhibit pro-inflammatory mediators, such as cytokines, chemokines 
and cell surface markers. The ocean represents a rich resource for the development of 
therapeutic drugs and a lot of pharmacologically important substances have been 
isolated with novel anti-microbial, anti-tumour and anti-inflammatory properties 
(Bhadury and Wright 2004).  
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The main strategy for this study involved screening numerous marine species in order 
to identify a compound that can be used as a therapeutic drug for the treatment of 
inflammatory diseases. A range of marine species were harvested from the Irish Sea 
by National University of Ireland, Galway (NUIG) and subsequently given to our 
collaborating chemists at UCD where they generated the crude marine extracts 
isolated from marine algae, Alcyonium digitia and the marine sponge, Membranipora 
membrancea. These crude marine extracts were examined to see if they had any anti-
inflammatory properties and those that were active were sent to UCD were they were 
fractionated. A.digitia and M.membrancea first-round fractions were then screened 
and M.membrancea fractions were chosen to be further fractionated (second-round 
fractions) as they demonstrated to have the most potent anti-inflammatory properties. 
This overall process allowed for the isolation of a novel purified marine compound 
from M.membrancea (INV013) that has demonstrated to have potent anti-
inflammatory capabilities [see figure 3.1.1]. In order to examine the activity of these 
marine extracts we used parameters that were relevant to the pathogenesis of 
inflammatory diseases. For instance we examined their effects of the production of the 
pro-inflammatory cytokines IL-12 and IL-23 as numerous studies have demonstrated 
their detrimental effect in inflammatory disease such as IBD and MS (Gee, et al. 
2009, Wakashin, et al. 2009). Additionally, we focused on examining their effects on 
dendritic cells and macrophages as they are the main immune cells implicated in 
inflammatory disease. Given the success of the fractionation and the identification of 
the anti-inflammatory compound (INV013) we also undertook to identify the 
molecular target.  
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The anti-inflammatory activity of the compounds was evident in a number of cell 
types. DCs are considered to be the most potent antigen presenting cells possessing 
the unique ability to activate naïve T cells.  In this study we found that DCs exposed 
to the marine extracts produced significantly less IL-12 and IL-23 following LPS 
stimulation. Since IL-12 and IL-23 have such significant roles in initiating and 
maintaining inflammation in EAE, RA and IBD (Bettelli and Kuchroo 2005, 
Stockinger, Veldhoen and Martin 2007), their inhibition has proved beneficial in 
treating these inflammatory disorders (Zhang, et al. 2007). For instance, in several 
rodent models of IBD, treatment with anti-IL-12 antibody prevents the development of 
colitis (Blumberg, Saubermann and Strober 1999). As well as suppressing pro-
inflammatory IL-12 and IL-23 production, treatment with the marine extracts 
enhanced the production of IL-10 from DCs in vitro.  IL-10 is known for its 
regulatory and anti-inflammatory properties and administration of IL-10 to patients 
with Crohn’s disease has been reported to reduce bowel inflammation (Mocellin, et al. 
2004).  
 
Since IL-12 and IL-23 are involved in initiating Th1 and Th17 cell development 
respectively, and because IL-10 promotes the differentiation of T regulatory cells, the 
marine-induced suppression of IL-12 and IL-23 and enhancement of IL-10 suggests 
that the marine extracts may have consequential effects for T cell responses, therefore 
we investigated the down-stream effects of M.membrancea on adaptive immunity. 
Numerous autoimmune diseases such as IBD have been documented as 
predominantly Th1 mediated disorders associated with high levels of IFN-γ 
production. Our data demonstrates a significant reduction in IFN-γ production from a 
DC-T cell co-culture model following treatment with M.membrancea. Given the 
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widely accepted pro-inflammatory role of IFN-γ, inhibition of this cytokine may have 
tremendous therapeutic potential in inflammatory diseases. The compound Bosweilla 
carterii isolated from the plant Burseraceae, has shown some efficacy in treating 
patients with arthritis by inhibiting IFN-γ (Chevrier, et al. 2005). Furthermore, 
fontolizumab, a monoclonal antibody directed against human IFN-γ, has been 
demonstrated to have tremendous therapeutic effects in patients with Chron’s disease 
(Hommes, et al. 2006).  
 
Th17 cells are another subset of T cells that have been implicated in a number of 
inflammatory disorders and their presence has been linked to some of the pathology 
previously attributed to a disproportionate Th1 response (Wong, et al. 2008, 
Komiyama, et al. 2006, Paradowska, et al. 2007). We found that IL-17 was 
significantly reduced by M.membrancea in a DC-T cell co-culture model. Numerous 
studies have evaluated the benefit of neutralising IL-17 to alleviate inflammation. For 
instance the active form of vitamin D3 (1,25-dihydroxyvitamin D3) suppresses the 
production of IL-17 from Th17 cells and ameliorates the onset of the EAE (Chang, et 
al. 2010).   This overall result from the DC-T cell co-culture demonstrates that the 
inhibition of the cytokines from DCs by our marine extracts has a subsequent effect 
on T helper cell responses. The significant decrease in cytokine production by DCs 
and T cell response reported in the study demonstrates the potential for the marine 
compound as a therapeutic drug for a range of inflammatory diseases.  
 
Furthermore our results indicated that the marine compounds may have an overall 
effect on T helper cell responses by inhibiting key surface markers found on DCs. In 
order to activate a naïve T cell, dendritic cells present antigen coupled to MHCII and 
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express co-stimulatory markers CD40, CD80 and CD86 that interact with 
corresponding receptors on T cells (Lu, Wang and Linsley 1997). Enhanced 
expression of these surface markers has been implicated in disease. The over-
expression of CD80 molecules has been reported in the inflamed tissues of patients 
suffering from MS and IBD (Kobata, et al. 2000) and numerous researchers have also 
reported increased expression of CD40 and CD40L in the inflamed ileum of CD 
sufferers (Battaglia, et al. 1999), therefore targeting co-stimulatory molecules can 
have therapeutic potential in inflammatory diseases. Examination of surface marker 
profiles in marine-treated DC showed a collective decrease in CD80, CD40 and 
MHCII expression. The reduction in T cell cytokines observed in our study may be 
due to the decreases in these markers as it would impair the ability of DCs to present 
antigen to T cells and activate them. Inhibiting the expression of CD80 using a CD80-
CAP (competitive antagonist peptide) has been shown to suppress established 
inflammation in TNBS-induced colitis (Eri, et al. 2008). Furthermore, a study by 
Danese and workers demonstrated that the use of anti-CD40L antibodies in TNBS-
induced colitis effectively prevented mucosal inflammation and decreased IFN-γ 
production by lamina propria T helper cells (Danese, Sans and Fiocchi 2004). The 
significant down-regulation of these surface markers in our study further demonstrates 
the potential for the marine compound as a therapeutic drug in a range of 
inflammatory diseases.  
 
Macrophages, MØ are highly sophisticated phagocytes and one of the many 
leukocytes recruited to sites of inflammation in order to neutralise and eliminate 
potentially harmful stimuli. TNF-α, IL-6 and IL-1β are the principle cytokines 
produced by these cells and are highly implicated in the pathogenesis of numerous 
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inflammatory diseases, in particular RA (Kinne, et al. 2000). In RA, TNF-α is mainly 
produced by MØ in the synovial membrane and is the proximal cytokine in the 
inflammatory response (Feldmann and Maini 1999). In addition, IL-1 gene expression 
is found predominantly in CD14+ MØ and acts in sequence after TNF-α and mediates 
articular damage in arthritis (Kinne, et al. 2000). Furthermore, IL-6 is highly elevated 
in the synovial fluid of patients with RA and is implicated in the promotion of 
osteoclasts (Kinne, et al. 2000). Numerous drugs that target these specific cytokines 
have been developed and have demonstrated great effects in ameliorating diseases. 
For example, Golimua is a human monoclonal antibody directed against TNF-α and is 
widely used in the treatment of patients with RA (Smolen, et al. 2009). Our results, 
demonstrate a significant reduction in IL-6 but there is no alteration in the levels of 
TNF-α in macrophages following LPS stimulation. Given that blockade of TNF-α has 
been shown to effectively treat RA, this may suggest that our marine extract would 
not be very effective in this disease. However, MØ do secrete IL-12 which plays a 
major role in interacting with activated Th1 cells enhancing the production of IFN-γ. 
Largely on the basis of animal studies, RA has been considered a Th1 cell-mediated 
disease as the synovial fluid contains high levels of IFN-γ (Adorini 1999a). Retinoids 
are used in the treatment of patients with RA and in MØ they have shown a 
significant reduction in IL-12 secretion (Nozaki, et al. 2005). Therefore, the inhibition 
of IL-12 by MØ in our study demonstrates that M.membrancea can still have great 
effects on a wide range of diseases including RA. Regardless of the effects of the 
marine extracts on MØ, their effect on DCs is so potent and specific for the generation 
of Th1 and Th17 cells which are known to mediate a range of inflammatory diseases, 
that the effects of M.membrancea on DCs alone may be sufficient to treat the 
diseases.  
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If the effect of M.membrancea on MØ is less important than DCs then is it beneficial 
to turn off a wide range of MØ functions? In this study we have found distinct effects 
of our marine extracts on macrophage function. We have demonstrated that the effects 
of the second-round fractions of M.membrancea on MØ may modulate parameters 
which suggest increased susceptibility to infection. The ability of macrophage to 
phagocytose, a fundamental event in bacterial clearance and homeostasis was 
decreased following treatment with marine fractions of M.membrancea. Furthermore, 
we found M.membrancea fractions also significantly reduced chemotaxis and the 
production of the chemokines MIP-1α and MCP-1. The infiltration of leukocytes to 
the site of infection is crucial in mounting an immune response. Furthermore, depleted 
levels of MCP-1 have been broadly implicated in impaired bacterial clearance 
(Matsukawa, et al. 1999). In addition chemokines have a crucial anti-viral role 
(Melchjorsen, Sorensen and Paludan 2003). Numerous studies have reported that 
MIP-1α knockout mice have a reduced ability to clear virus infections such as 
influenza (Cook, et al. 1995). Although phagocytosis, migration and the production of 
chemokines by macrophages are essential in the host in controlling infections they 
have also been implicated in the pathogenesis of numerous inflammatory diseases 
including IBD and MS (Murdoch and Finn 2000, Reale, Greig and Kamal 2009, 
Adams and Lloyd 1997). It has been well documented that enhanced levels of MIP-1α 
and MCP-1 are greatly involved in the promotion of MS by mediating an influx of 
macrophages and T cells into the CNS (Simpson, et al. 1998). Furthermore, enhanced 
levels of MCP-1 and MIP-1α have been shown in patients with active lupus nephritis, 
idiopathic pulmonary fibrosis, atherosclerosis, ischemia and RA (Adams and Lloyd 
1997). Although inhibiting these chemokines can have great therapeutic potential they 
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can also cause increased susceptibility to infection. Numerous studies have 
demonstrated that MIP-1 knockout mice are resistance to EAE however have 
increased susceptibility to T. gondii infection compared to wild type mice (Power 
2003). Our study shows that second-fractions of M.membrancea may only increase 
susceptibility to infection to bacterial pathogens via TLR4 but not to viral pathogens 
via TLR7.  
 
Since the fractions of M.membrancea and the purified marine compound 
demonstrated significant anti-inflammatory effects we therefore decided to elucidate 
the mechanism underlying their actions. TLRs are important at initiating innate 
immunity and recognising diverse microbial products. Upon recognition of a ligand, 
TLRs recruit specific adaptor molecules that initiate downstream signalling. Although 
TLRs induce common signalling pathways, there is specificity in recruitment of TLR 
adaptors. Therefore the first step in our mechanistic study was to examine if the 
marine extracts of M.membrancea had any specific effects on these TLR pathways by 
activating DCs with a panel of TLR ligands. Our data demonstrated that the fractions 
of M.membrancea and its purified compound demonstrate significant anti-
inflammatory effects by downregulating pro-inflammatory cytokines and surface 
marker expression following stimulation with TLR2 and TLR4 ligands but not when 
cells were activated with other TLR ligands. The TLR2 and TLR4 signalling 
pathways are unique as they are the only TLRs capable of recruiting the TIR adaptor, 
Mal. Numerous studies have shown that Mal signals exclusively through the MyD88- 
dependant pathway leading to the activation of MAP kinases and the transcription 
factor NFκB (Verstak, et al. 2009, Horng, et al. 2002b). Firstly we showed that 
INV013 decreased NFκB activation but not IRF3 activation, indicating that the 
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marine extract is exerting its effect through the MyD88-dependant pathway. We then 
showed that it significantly reduced Mal driven NFκB activation in HEK-MTC cells. 
Furthermore, the phosphorylation of p38 and NFκBp65 was greatly impaired in 
INV013-treated DCs following LPS stimulation. Finally, we showed that INV013 
significantly reduced the tyrosine phosphorylation of Mal, demonstrating that our 
marine extract exerts its anti-inflammatory abilities by targeting this specific adaptor.  
It has been reported that Mal-deficient mice are resistant to the toxic effects of LPS, 
with defective induction of IL-6, IL-1β and IL-12, decreased activation of NFκB and 
MAP kinases (Horng, Barton and Medzhitov 2001a). The recruitment of neutrophils 
to the lungs is also abrogated in Mal-deficient mice reducing the severity of LPS-
induced lung inflammation in this model (Togbe, et al. 2006). This also correlates 
with our study as we saw a significant reduction in chemokines and migration in LPS-
induced DCs following treatment with INV013. It has been well documented that Mal 
plays a major role in diseases such as RA, IBD and acute lung injury. A study by 
Sacre and workers demonstrated that RA synovial cell cultures release a TLR ligand 
that stimulates human macrophages in a Mal-dependent manner, contributing to the 
destructive processes of RA (Sacre, et al. 2007). Furthermore, a variant in Mal 
(S180L) showed to be protective against diseases such as systemic lupus 
erythematosus (Castiblanco, et al. 2008). Since our purified marine compound, 
INV013 has the ability to target this specific adaptor it may have therapeutic 
advantage in a wide range of diseases. To date numerous anti-inflammatory drugs 
have been identified that have specific targets allowing them to have major benefits in 
specific inflammatory diseases (Simmons 2006). For instance, the anti-inflammatory 
drug, Celebrax, specifically targets the enzyme COX-2 and is widely used in the 
treatment of patients with RA. Furthermore, the drug canakinumab specifically blocks 
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the production of IL-1β and is currently being tested in clinical trials for treating 
patients with type 1 and type 2 diabetes (Dinarello 2010). The compound, TAK-242 
(resatorvid) has been shown to selectively bind to TLR4 and subsequently disrupt the 
interaction of TLR4 with adaptor molecules Mal and TRAM thereby inhibiting TLR4 
signal transduction (Matsunaga, et al. 2011).  A wide range of molecules have been 
shown to interfere with TLR2 and TLR4 signalling. The oxidised 1-palmitoyl-2-
arachidonyl-sn-glycero-3-phosphorylcholine (OxPAPC), has been demonstrated to 
inhibit LPS (TLR4) and Pam3CSK4 (TLR2) signalling but not other TLRs which can 
be used in the treatment of TLR-mediated inflammatory diseases such as RA (Erridge, 
et al. 2008a). However only one drug to date has been identified to specifically 
interact with Mal and has been used in numerous studies (Radin, et al. 2008).  
 
Steroids such as glucocorticoids are currently being used to treat inflammatory 
diseases but have demonstrated serious side effects, one of which is decreased ability 
to mount an immune response to infection-immunosuppressant. Therefore by finding 
a drug that has a specific target that has fewer side effects may be more beneficial 
(McCoy, et al. 2008). The major advantage of our marine compound is that it is 
specific and may only suppress the ability to mount a normal immune response to 
gram-positive and gram-negative bacteria whereas the ability to mount a normal 
immune response to most other pathogens would not be affected.  
 
As the novel compound has demonstrated tremendous potential for the development 
of an anti-inflammatory drug, an invention disclosure has been filed. The 
identification of the structure is currently being carried out by our collaborators at 
UCD.  
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Future Work  
• Given that we have already generated a significant amount of data in vitro, 
future work will concentrate on examining the effects of INV013 in in vivo 
models. Firstly we will assess the effects of INV013 on Th1 and Th17 
responses in vivo using an adoptive transfer model. Following this we will 
undertake a study using two murine models of IBD to determine whether 
administration of INV013 results in suppression of Th1 and Th17 response 
and thus inhibition of disease. If INV013 demonstrates significant anti-
inflammatory effects in both these studies it will allow the translation of this 
research into a therapeutic, therefore permitting us to patent this compound.  
• The mRNA expression of cytokines following treatment with INV013 will be 
assessed by real time-PCR to support the decreased cytokine production 
presented in chapter 3, 4 and 5.  
• Exam alternative effects that INV013 may have on the adadptor Mal; does it 
interfere with caspase-1 binding? What effect does it have on PKC-δ activity? 
• Examine the effects on INV013 on the promoter regions of cytokines in the 
nucleus such as IL-12p40, IL-12p70, TNF-α by chromatin 
immunoprecipitation (CHIP).  
• Once the structure has been identified future work will concentrate on 
developing analogues of the structure and screening them to see if potency can 
be improved.  
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7.1 APPENDIX 
 
CELL CULTURE MEDIA 
 
COMPLETE RPMI 1640     500ml 
5% Heat inactivated Foetal Calf Serum (FCS)  25ml 
Penicillin/streptomycin/L-glutamine Culture Cocktail 10 ml 
(Gives a final concentration of 2 mM L-glutamine,  
100 µg/ml penicillin and 100 U/ml streptomycin) 
 
COMPLETE DMEM      500 ml 
5% Heat inactivated Foetal Calf Serum (FCS)  25ml 
Penicillin/streptomycin/L-glutamine Culture Cocktail 10 ml 
(Gives a final concentration of 2 mM L-glutamine,  
100 µg/ml penicillin and 100 U/ml streptomycin) 
 
10X PHOSPHATE BUFFERED SALINE (PBS) 
Na2HPO4.2H2O (8 mM)    23.2 g 
KH2PO4 (1.5 mM)     4 g 
NaCl (137 mM)     160 g 
KCl (2.7 mM)      4 g 
Make up to 2 L pH to 7.4  
 
10 X TRIS BUFFERED SALINE (TBS) pH 7.6 
NaCl       48.4 g 
Trizma Base      160 g     
Dissolve in 2 L dH2O pH to 7.6 
 
2N H2SO4 
H2SO4 (36 N)      11.1 ml 
dH2O       88.9 ml 
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FACS BUFFER  
2%FCS 
0.05% NaN3 
PBS 
 
LOW STRINGENCY LYSIS BUFFER: 
1M HEPES (pH 7.9)      11.92g into 50ml 
1M MgCl2       74.55g into 50ml 
1M KCl       3.73g into 50ml 
1M NaCl       2.92g into 50ml 
0.5M PMSF       0.3484g into 4ml acetone 
0.5M EDTA       9.306g into 50ml 
Glycerol       25% = 12.5ml into 50ml 
        20% = 10ml into 50ml 
 
5X SAMPLE BUFFER 
125 mM Tris       6.25 ml 1M Tris HCl pH 6.8 
10 % Glycerol      5 ml 
2 % Sodium dodecyl sulphate (SDS)   10 ml (10 % (w/v) SDS) 
0.05 % (w/v) Bromophenol Blue   0.01 g 
dH2O       28.75 ml 
 0.25 M Dithiothreitol (DTT)*   250 µl 1 M DTT S 
* Added to 1 ml 5X Sample Buffer just before use 
 
SEPARATING GEL (10 % (v/v)) 
33% w/v Bisacrylamide (30% stock) 
1.5M Tris-HCl pH8.8 
1% w/v SDS 
0.5% w/v Ammonium persulpate 
dH2O 
0.1% v/v TEMED 
 
STACKING GEL 
6.5% v/v Acrylamide/Bisacrylamide (30% stock) 
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0.5M Tris-HCl pH6.8 
1% w/v SDS 
0.5% w/v Ammonium persulphate 
dH2O 
0.1% v/v TEMED 
 
ELECTRODE RUNNING BUFFER 
25mM Tris base 
200mM Glycine 
17mM SDS 
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